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PREFACE 
Co-trimoxazole, a combination of a 5-to-l ratio of 
Sulphamethoxazole (SMZ) and Trimethoprim (TMP) , is a 
highly effective, broad-spectrum antibacterial agent. 
Since its introduction in 1968, it has been extensively 
used in infections of the respiratory and urinary tracts l • 
Co-trimoxazole was developed by the systematic investig?tion 
of a series of compounds whose mechanism of action was 
already known 2 • As early as 1950 synergy between sulphon= 
amides and 2,4-diaminopyrimidines was reported. This was 
to be expected as both groups of drugs exert their anti= 
bacterial activity by interfering with the same biochemical 
pathway in bacteria. TMP was chosen from among many 
2,4-diaminopyrimidines tested 3 because of its good anti= 
bacterial activity and low toxicity. SMZ was chosen from 
the sulphonamides available for combination with TMP because 
of similarity of their biological half-lives. 
The widespread use of the combination coupled with the fact 
that monitoring of the levels of all drugs in the body is 
becoming increasingly important has stimulated research into 
rapid and efficient methods for the analysis of TMP and SMZ 
in biological fluids. Another consequence of the immense 
popularity of the combination is the appearance on the market 
of several generic preparations of Co-trimoxazole. It is 
now generally recognized that drug products from different 
manufacturers which are chemically equivalent may not be 
therapeutically equivalent'. This is due to the fact that 
••••• - 2 -/ 
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the absorption rate and/or bioavailability (extent of 
absorption) of a poorly soluble drug may be markedly 
affected by its release rate from the product and by its 
subsequent dissolution rate in gastrointestinal fluids. 
Hence bioequivalence of these various products should be 
established. 
• ••.. - 3 -/ 
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CHAPTER 1 
INTRODUCTION 
1.1 PHYSICO-CHEMICAL PROPERTIES OF TMP AND SMZ: 
A. Trimethoprim: 
Chemically trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxy= 
benzyl)pyrimidine. Its structural formula is indicated in 
Fig. 1.1. 
Figure 1.1 Trimethoprim 
It appears as a white, odourless, bitter powder. The 
molecular weight of TMP is 290,3 and it has a melting point 
of 199-200 0 C5 • TMP is a weak difunctional base with both 
basic groups titrating almost simultaneously with a pKa of 
7,2 6 , and is lipid soluble. It forms stable salts with a 
variety of acids. 
TMP is very slightly soluble in water, soluble in 550 parts 
of 0,01 N HC1, in 300 parts of alcohol (95%), in 55 parts 
of chloroform, ~n 80 parts of methanol and in 640 parts of 
methylene chloride. It is practically insoluble in solvent 
. • • •• - 4 - / 
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The ultraviolet absorption spectrum of TMP in methanol shows a 
maximum at 289 nm (E 1 %, 1 cm 223)8. 
B. 8ulphamethoxazole: 
Chemically sulphamethoxazole is 3-(4-aminobenzenesulphonamido)-
5-methylisoxazole (Fig. 1.2). 
Figure 1.2 8ulphamethoxazole 
It is a white or yellowish-white, crystalline powder, odourless 
and slightly bitter. The molecular weight is 253,28 and the 
melting point 169 - 170°C 5 • 8MZ is a weak acid with a pKa 
value of 5,6 9 • 
8MZ is very slightly soluble in water, soluble in 50 parts of 
alcohol (95%) and in 3 parts of acetone and is soluble in 
solutions of the alkali hydroxides 7b • 
in ether and in chloroform 1o • 
It is almost insoluble 
The ultraviolet absorption spectrum of 8MZ in sodium hydroxide 
solution (1 in 250) exhibits a maximum at about 257 nm lO • 
It has been shown that a physico-chemical interaction occurs 
• • . •• - 5 - / 
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between TMP and 5MZ s • This report indicates that TMP and 
5MZ will , in aqueous solution or suspension, interact to 
form a 1:1 molecular compound. Linkage may be due to the 
amino group in position 2 or 4 of the TMP pyrimidine ring 
and to the - 50, - grouping of the sulphonamide. 
The effec t of such interactions on solubility, dissolution, 
methods of analysis, membrane transport and pharmacological 
response is not known. Thin-layer chromatography (TLC) was 
found to readily separate the TMP-5MZ compound into its 
components so that its formation is unlikely to interfere 
with chromatographic methods of analysis. These methods 
could possibly be useful in studying the unknown effects of 
this interaction. 
1.2 MODE OF ACTION: 
TMP and 5MZ sequentially interfere with the biosynthesis of 
tetrahydrofolic acid in bacteria. 5MZ, like all sulphon= 
amides, produces its antibacterial effect by competing with 
the tiatural precursor para-aminobenzoic acid in the synthesis 
of dihydrofolic acid. In man the folate pathway requires 
exogenous folate as its initial substrate so the step 
blocked by the iulphonamides is absent, thus forming the 
basis for their selective toxicity for bacteria. The next 
step in the folate pathway is the conversion of dihydrofolic 
acid to tetrahydrofolic acid by the enzyme dihydrofolate 
reductase. In bacteria TMP b inds strongly to this enzyme 
and blocks this reduction. The TMP is bound at least 10 000 
• • • •• - 6 - / 
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times more strongly by the bacterial than by the mammalian 
enzyme ll . The blocking at two sequential stages in the 
folate pathway leads to a halt in the synthesis of DNA, RNA 
and protein and, therefore the death of the bacterium 9 ,12-l4. 
It is this sequential blockade in the synthesis of tetra= 
hydrofolic acid that generally has been held responsible for 
the high degree of synergy observed when these two drugs are 
administered together. The combination TMP - SMZ is more 
rapidly bactericidal and is less susceptible to the develop= 
ment of resistance than either of the component drugs 2 . 
That the antibacterial potentiation of TMP by SMZ can be 
explained by sequential blockade has been doubted by Poe iS • 
He has found SMZ to be a moderately potent inhibitor of 
E. coli dihydrofolate reductase and suggests that potentiation 
may occur by inhibition of this single enzyme. 
As may be expected from its mode of action, trimethoprim 
potentiates and is potentiated by all of the sulphonamides 3 • 
SMZ was chosen for combination with trimethoprim because of 
the similarity of their biological half-lives. Other 
sulphonamides, however, have been proposed and utilized as 
partners for TMP because of improved concentrations under 
certain conditions and similar pharmacokinetic behaviour, 
e.g. sulphadiazine l6 , sulphamoxole l7 , Ie, sulphamethoxypyraz inel9. 
The sulphadiazine-trimethoprim combi nation (Co-trimazine) 
has only recently been marketed. Sulphadiazine may have 
certain advantages over SMZ, viz., lower protein-binding 
..... - 7 -/ 
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and a lower degree of metabolism 20 and may potentially be 
more suitable for administration to patients with reduced 
renal function 2l . The minimum inhibitory concentrations 
of the two sulphonamides are identical l6 . 
1.3 ANTIMICROBIAL ACTIVITY: 
The ultimate effect of TMP and SMZ on bacteria is to deprive 
them of folate coenzymes. The spectra of in vitro activity 
of both drugs are therefore similar although TMP is usually 
20-100 times more active than SMZ22. Multiple studies have 
confirmed that the combination, TMP-SMZ, has a wide spectrum 
of activity against both Gram-positive and Gram-negative 
The only outstanding exceptions are 
Pseudomonas aeruginosa, Mycobacterium species, Treponema 
pallidum and Mycoplasma species l4 . 
The mutual potentiation of TMP and SMZ when used in 
combination, as measured by a reduction in the minimum 
inhibitory concentration (MIC) of each individual drug, 
has been demonstrated both in vivo and in vitro',22,25,26. 
Examples of the increased in vitro activity are shown in 
in Table 1. 1. An important point is that the degree of 
potentiation which occurs depends on the ratio of the 
concentrations of SMZ and TMP used and tends to be maximal 
when this ratio is similar to that of their respective MIC's 
when acting alone 22 . Thus for a range of organisms 
sensitive to both drugs the ratio would be about 20 parts 
of SMZ (MIC's 5-50 ~g/ml) to one part of TMP (MIC's 
. . • .. - 8 - / 
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TABLE 1.1 
EFFECT ON MIC OF COMBINING ONE PART TRIMETHOPRIM WITH 
TWENTY PARTS SULPHAMETHOXAZOLE . a 
MIC (].Ig/ml) 
Sulphamethoxazole Trimethop rim 
Organism Alone Mixture Alone Mixture 
Streptococcus 
pyogenes >100 1 1 0,05 
Streptococcus 
pneumoniae 30 2 2 0,1 
Staphylococcus 
aureus 3 0,3 1 0,015 
Haemophilus 
influenzae 10 0,3 1 0,015 
Bordetella 
pertussis 50 4 3 0,2 
Klebsiella 
pneumoniae >100 4 1 0,2 
Klebsiella 
aerogenes >100 4 1 0,2 
Escherichia 
coli 3 1 0,3 0,05 
Salmonella 
typhimurium 10 1 0,3 0,05 
Shigella 
sonnei 10 1 0,3 0,05 
Proteus 
vulgaris 30 3 3 0,15 
a from Bushby22 . 
• • • • • - 9 -I 
- 9 -
0,25 - 2 ~g/ml), although it may vary widely with individual 
species. Significant potentiation does, however, occur 
over a fairly wide range of ratios on either side of the 
optimum!4. Neisseria gonorrhoeae is an exception in which 
the ratios of the MIC's of SMZ and TMP are completely 
reversed, the organism being more sensitive to sulphonamides 
than to TMP2 2 . 
Administration of TMP and SMZ in combination allows for a 
high degree of synergy and enables the conversion of the 
bacteriostatic activity of both drugs when administered 
individually to a bactericidal action in the combination'. 
It also makes possible the administration of a lower dose 
of both drugs, thus reducing the incidence of side-effects. 
Resistance to one of the drugs does not abolish synergy; 
synergy is maximal however, when the organism is susceptible 
to both drugs 22 . Administration of the drugs in combination 
plays a role in preventing the acquisition of resistance to 
TMp 27 . 
Great care must be taken in the selection of media and 
conditions for sensitivity testing and for microbiological 
assay methods for TMP and SMZ. The presence of even small 
amounts of thymidine can reverse the an t imicrobial action 
of t he combinati o n in vitro!!. Often discrepancies in 
susceptibility data in the literature are due to a lack of 
standardization of these parameters!4, !7 . 
..... - 10 -/ 
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1.4 CLINICAL PHARMACOLOGY OF CO-TRIMOXAZOLE: 
Due to the sequential blockade achieved by 8MZ and TMP a 
quantitatively fixed combination has become available. A 
5:1 ratio of 8MZ to TMP has been found most suitable in 
patients with normal organ functions and this has, besides 
a bacteriological explanation, also pharmacokinetic reasons. 
In many cases, however, the fixed ratio may not provide 
ideal therapy. Hence, monitoring of drug levels in patients 
with serious and difficult infections could playa valuable 
role in optimizing therapy. 
1.4.1 Absorption: 
Most pharmacokinetic studies have indicated that both TMP 
and 8MZ are rapidly and completely absorbed following oral 
administration 6 ,9,2s. Invasion phase kinetics of both 
compounds are of the same order 29 • More important, up-
take of both drugs in patients under treatment'O arid in 
non-fasting volunteers'l is also satisfactory. 
After absorption TMP is metabolized only to a small extent 
and most of these metabolites are antibacterial, whereas 
8MZ is metabolized to inactive products l4 . Thus 8MZ 
levels are usually expressed as "active" 8MZ which refers 
to the unchanged drug, both free and protein-bound, and as 
total 8MZ which is the sum of the active drug and its 
inactive biotransformation products. Of these inactive 
metabolites, the N4-acetylated derivative of 8MZ predominates . 
..... - 11 -/ 
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Peak blood levels occur for TMP, active 8MZ and for total 
5MZ between 1 and 4 hours following administration of all 
dose levels studied 29 , 32 ,33. 
There have been some reports however that suggest incomplete 
or delayed intestinal absorption of 5MZ. Baethke et al.,3' 
have postulated that approximately 85% of ingested 5MZ is 
absorbed. Kaplan et al.,32 found that the absorption of 
8MZ was somewhat slower when the drug was administered in 
combination tablets than when it was administered in a 
separate tablet. It was also found 32 that the mean peak 
concentrations of TMP from combination tablets were slightly 
lower than those after administration of separate tablets. 
These absorption problems may indicate non-ideal formulations. 
1.4.2 Protein Binding: 
Trimethoprim has been shown to be 42-46 % bound to plasma 
proteins 21 ,33, 35. About 66% of unchanged 8MZ is bound to 
proteins 21 ,33. Of the total sulphonamide present in the 
plasma, about 70% is in the active form 36 . About 84% of 
the metabolized 5MZ is bound to plasma proteins 2 7 . 
The addition of 10 mg % 8MZ to plasma, the concentration 
expected after a single therapeutic dose, decreased the 
binding of TMP by only 3-4 %. TMP does not influence the 
protein binding of 8MZ at the range of concentrations 
usually encountered in therapy35. 
. .... - 12 - / 
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Hence 34% 5MZ and 55% TMP (i.e. the non-protein-bound 
portions) will remain in a diffusible state and equilibrate 
with the interstitial fluids 33 . In addition, only these 
unbound portions will be available for chemotherapeutic 
activity. Thus, protein binding should be accounted for 
when quoting plasma drug levels. 
In the evaluation of drug concentrations in biological fluids 
it is important to consider whether the assay method utilized 
will measure the protein bound or unbound portions of the 
drug. Microbiological methods of analysis will measure 
the non-protein-bound part37. If ultrafiltration is 
utilized for the removal of proteins during sample 
preparation 38a this will also give a measure of unbound, 
rather than total, drug. In contrast most chemical methods 
involving extractions and protein precipitation always 
measure the sum of the bound and unbound drug. Good 
coincidence has, however, been found between chemical and 
microbiological results 34 ,39,4o especially in the case of 
5MZ4l. This coincidence may be explained by the high dose 
of this drug used in these studies which would be clearly 
above the protein-binding capacity saturation level of this 
drug 4l . 
Protein binding figures may, however, be altered under 
certain conditions. Certain disease states affect the 
protein binding of sulphonamides and will influence the 
amount of protein present in plasma 42 ,4 3 . Binding also 
..... - 13 -/ 
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depends on renal function (see Section 1.4.6). Displace= 
ment of protein-bound sulphonamides can occur by compounds 
such as phenylbutazone, sulfinpyrazone, salicylate, etc.'2,"" 
and these may also influence binding of TMP. If the non-
protein bound fraction is required with great accuracy, it 
must be evaluated in each patient. Monitoring of drug 
levels could also playa role here in ensuring optimum 
levels. Ultrafiltration of the sample will yield the non-
protein bound fraction which is bacteriostatically active. 
1.4.3 Distribution: 
The distribution of TMP and SMZ in the body can, to a large 
extent, be explained on the basis of their physicochemical 
properties. TMP is a base with a pKa of 7,2 and hence in 
plasma constitutes nearly an equilibrium mixture of uncharged 
molecules of free TMP base and cations. The uncharged base 
is lipid soluble and seems to diffuse throughout the tissues 
of the body. TMP will concentrate in areas where the pH 
is lower than that in the plasma, e.g. prostatic fluid"5,"G, 
urine 33 , vaginal fluid"7. There also appears to be an 
active localization of the drug in certain tissues, e.g. 
kidney and liver 9. In general, TMP levels in serum are 
lower than those found simultaneously in other biological 
fluids and tissues. The relative concentrations of TMP in 
most body tissues has been described by Hansen"" and 
Wormser'". 
SMZ, on the other hand, has a pKa of 5,6 and hence is 
• . . .. - 14 - / 
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essentially ionized at plasma pH. Less of this drug also 
is unbound to plasma proteins and hence free to diffuse. 
The volume of distribution of 8MZ is thus much smaller than 
that of TMP9. Concentrations of active 8MZ in all tissues 
and fluids except urine are always lower than those in the 
plasma". Detailed reviews have appeared concerning 8MZ 
distribution throughout the bodyl4,4B. 
Bergan and Brodwal1 29 found the mean distribution coefficient 
to be 1,75 £/kg for TMP but only 0,2 for total and 0,28 for 
active 8MZ. Data for concentrations of TMP and 8MZ in 
some body fluids and tissues are shown in Table 1.2. 
This difference in relative distribution volumes between 
8MZ and TMP will influence the ratios between the two drugs 
in the blood and various tissues of the body. After 
administration of the standard preparation which provides 
a fixed 5:1 ratio of 8MZ to TMP there will be a gradual 
rise of the 8MZ : TMP ratio during the absorption phase 
in plasma". After such a dose, the mean ratio in the 
plasma between non-protein bound non-metabolized 8MZ to active 
non-protein bound TMP is approximately 20:1; a range 
of values between 10:1 and 30~40:1 can be encountered",'6. 
Thus therapeutic doses of a combination containing 5 parts 
8MZ and 1 part TMP will yield, in the plasma, a concentration 
ratio that is practically optimal for their reciprocal 
potentiation for a large spectrum of bacterial species 
(see 8ection 1.3). 
. .... - 15 -/ 
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TABLE 1. 2. 
TRIMETHOPRIM AND SULPHAMETHOXAZOLE CONCENTRATIONS IN 
BODY FLUIDS AND TISSUES RELATIVE TO SERUM LEVEL. a 
Cerebrospinal fluid 
Aqueous humour 
Breast milk 
Prostatic fluid 
Vaginal fluid 
Bile fluid 
Saliva 
Urine 
Amniotic fluid 
Foetal tissues 
Erythrocytes 
Lung tissue 
Liver tissue 
Spleen 
Skin 
Kidney 
TMP 
Concentration 
0,3-0,5:1 
0,1-1,0:1 
1,25:1 
2,0-2,3:1 
1,0-3,0:1 
2,0:1 
1,13:1 
100: 1 (approx.) 
0,75:1 
0,5:1 
1, 0: 1 
2-6:1 
6-7:1 
2:1 
2:1 
7:1 
Active SMZ 
Concentration 
0,2:1 
0,25:1 
0,1:1 
0,3-0,5:1 
very low 
0,4-0,7:1 
0,02:1 
1: 1 (approx.) 
0,45:1 
0,04:1 
0,25-0,5:1 
0,3:1 
0,2-0,5:1 
0,2-0,5:1 
0,2-0,5:1 
0,2-0,5:1 
a Data from Hansen"s, Stamey and Condy"7 and Eatman et al."9 . 
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This optimal ratio, however, will certainly not be present 
in the tissues and since organisms are more usually in other 
tissues or body fluids may present a serious problem. 
Thus in the treatment of individual tissue infections it 
may be necessary to supplement the sulphonamide dosage if 
a satisfactory ratio between the two drugs is to be 
maintained. However some sources doubt whether this 
argument has any relevance to the chemotherapeutic efficacy 
of the drug, since the concentrations in interstitial fluid 
should equal those in plasma water 3 It. 
TMP was found to be equally distributed between plasma 
and erythrocytes but the concentration of SMZ was 2-4 times 
higher in plasma 30 • Thus TMP concentrations will be 
similar in serum and whole blood but whole blood concentra= 
tions of SMZ will therefore be lower than equivalent serum 
concentrations so • Thus care must be taken when quoting 
"blood" or "serum" levels of the drugs which are often used 
interchangeably in the literature. In addition care must 
be taken in the assay methodology utilized. Some methods, 
e.g. a colorimetric method for sulphonamides s1 and a 
differential pulse polarographic method for TMP analysis S2 
use whole blood, whereas most other analyses determine 
levels in plasma or serum. 
1.4.4 Serum levels: 
Peak serum levels after a single oral dose of 160 mg TMP 
and 800 mg SMZ, the usual adult dose, are 1-2 ~g ml- 1 for 
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TMP, 40-60 ~g ml- 1 for total SMZ and 30-50 ~g ml- 1 for 
Nolte and BUttner 28 encountered wide 
variations in the peak concentrations of TMP and in the 
time in which they are reached. These are thought to be 
due to different dissolution and absorption conditions 
among the individuals. Plasma levels 1 hour after dosage 
are especially variable 33 • Mean levels at 8 hours after 
a single oral dose of 160 mg TMP and 800 mg SMZ are still 
higher than the MI C's for the majority of bacteria3o ,4". Of 
the total SMZ, an average of 70 % is in the active form 36 • 
The mean peak serum concentration is proportional to the 
dose administered so • Each drug has no appreciable effect 
on the concentrations achieved in the blood by the other 3s • 
Steady state blood levels for TMP, active SMZ and total SMZ 
are reached within 2-3 days after chronic administration of 
160 mg TMP and 800 mg SM2 every 12 hours 6 ,32,36. These 
levels are approximately 1,5-2 fold greater than the levels 
observed following the first dose. These steady state 
levels are pharmacokinetically predictable based on the 
blood level data obtained following a single dose 6 ,32. 
Steady state levels further substantiate the constancy of 
absorption, distribution, metabolism and excretion with 
each administration of the TMP-SM2 combination 9 • The 
steady state profile precludes unpredicted drug cumulation 
and suggests no enzyme induction by either drug. Since 
one can successfully predict plateau levels in blood for 
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each drug after multiple dosing, based on pharmacokinetic 
data following a single dose, a patient may be titrated for 
an individual dosing regimen. The mean ratio of active 
SMZ:TMP in serum is approximately 20:1 at steady state 36 • 
The slow build-up to steady state levels could be obviated 
by using an initial double dose'. 
The pharmacokinetic profile of both drugs remains the same 
whether the drugs are administered separately or in combina= 
tion in single or in multiple dosing regimens 28 ,3 2 . Both 
TMP and SMZ exhibit physiologic-disposition characteristics 
which follow first order kinetics 28 ,32. 
TMP and SMZ blood levels appear earlier and are higher after 
intra-muscular administration than after oral administration. 
After intra-muscular administration to humans peak serum 
concentrations are reached, in the case of TMP, about 40 
minutes after injection and in that of SMZ, about 2 hours 
after injection". After such administration blood levels 
of both drugs are regular and have a constancy that is not 
observed after oral administration. The optimum 20:1 ratio 
is for the most part maintained, although it has been 
suggested that reducing the SMZ:TMP ratio to 4:1 in intra-
muscular preparations will improve the serum ratio". 
1.4.5 Metabolism and Excretion: 
The metabolic pathways of TMP and 8MZ are shown in Figures 
1.3 and 1.4 respectively. 
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Fig. 1.3. Metabolism of trimethoprim. (Reproduced from 
Rieder'l). In pooled human urine, collected during the first 
24 hr after an oral dose of 2 mg I"e-labelled TMP per kg of 
body weight, Schwartz et al.,s3 found 77,5 % of the total 
radioactivity in the form-of the unaltered drug, 5 , 8% as 
free extractable metabolites, 5,5% as conjugates, a nd 11,2% 
as o ther water solubl e metabolites. 
¢L, 0 0y--. ,/--. V V 
~(L, "CHQ1 Q ... coo 0 0 
OCH1 Io4etcbot It. !II Metabotil. y TrWn!thcpr.m (TMP I Mt\9bOUt' U 
al,'-00anwI0-5- jo( -11y<rOIC Y - T MPl (TMP-I-o<i<M1 ... _ CQlbonyI - TMPI 
-13',(5 ·-Inme4hO< ybtnZyIl- V 
-pyn- .x '"~ I.d cu IUdl 0 \I'lCOf\jUgO l.d 
. A .A . 0 <; V- V- act,led par1Iy cu a.cn, but CHZ 9 (L Q rnc1Iriy COtIMI- 1 o.fuc. ·~ alad with gIuc-~add 
()1 glue . QC . 
.... Qbn' •• tv Mtlabot~. 1 ~14boIi11 ~:iIL ~boIil. 1:iI! 
11-~-TMPI (,'- dtmtlhyl- TI4'I 1 glucuronide of IV 1 (g1ucllOnidt of I 1 
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Fiq. 1.4. Metabolism of sUlphamethoxazole . (Reproduced 
from Riede r 37 ). About 20 % of all renal excretion o f 8MZ 
occurs in the unaltered form . The N'-acetyl derivative and 
t he different N-glucu r onides account for about 60-65 % and 1 5% 
respectively of the tot al urina r y excretion . Other metabolites 
a r e p r esent only in mi nor amount s'7. 
• Su1tometholo:uolt (S~Z) 
• 3- sulfanilamido-S-mtlhyl - isolOlzoi 
( major fruction) 
>oso-~-o 2 N... CH OH o 2 
• 5 - hy!ttIoIymethr\- SMZ 
( minor mtlclld 
unknown nan acttylaltd, unconjugaltd 
mttabolitt 4 b I minor m.lab. ) 
unknown octtytattd, unconjugalt d 
m.tabohlt 40 (minor mt lab . ) 
H.u'~so -NH-O ocfV 2 ~ CH 3 
• N'-actlyl-SIo4Z (major mtlab .1 
conjugatu 
.. 
H2NOS02 -NH,.--. 
. . l'O>·CH 3 -
glucutooic acid 
: ring -N- glucurooid. I minor m.lab .) 
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TMP is more slowly metabolized than 8MZ 33 • In the serum, 
metabolites account for approximately 10-15% of the·total 
TMP concentration 4S and most have antibacterial activity 
similar to TMP14. In contrast 8MZ undergoes rapid bio= 
transformation to inactive products. 25-35% of total 
plasma SMZ consists of various transformation products, 
among which the inactive N4-acetylsulphamethoxazole 
(N4-acetyl-SMZ) predomina tes 37 • 
SMZ and TMP are completely eliminated from the body of 
humans with unimpaired liver and kidney functions 33 • Both 
are excreted for the most part in the urine with mean 
recoveries after 96 hours of 80-100% of the administered 
dose excreted as total SMZ and 65-75% as intact TMp 32 ,33,36. 
20-30% of the total sulphonamide is excreted as intact 
8MZ '4 ,32,36 with the remainder of the dose excreted for 
the most part as N4-acetylated SMZ. The approximate 
proport ions of other metabolites of TMP and SMZ found in 
the urine are indicated in Figures 1.3 and 1.4 respectively. 
Thus it can be seen that the N4-acetyl derivative constitutes 
the major metabolite for SMZ (and for most other sulphon= 
amides) . The difference between the total and active SMZ 
values is cons idered to represent the quantity of N4- ace tyl-
SMZ present in assay methods based on the Bratton-Marshall s1 
reaction, which has been utilized for the majority of 
pharmacokinetic studies on Co-trimoxazole (see Section 2.2). 
This is of course an oversimplification as it disregards the 
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fact that acetylation is not the only metabolic pathway 
and that it is unlikely to be an irreversible reaction". 
Because of this relatively extensive metabolism of active 
8MZ to the inactive N~acetylated metabolite, differences in 
the rate at which this acetylation occurs is bound to affect 
blood levels of active 8MZ. 80me drugs are polymorphically 
acetylated in man, some persons being genetically constituted 
as slow acetylators (Mendelian recessives) and others as 
rapid acetylators (dominants). Examples of drugs 
acetylated by this enzymatic system are isoniazid, sulpha= 
dimidine, hydrallazine, dapsone, sulphapyridine 55 , sulpha= 
methazine, sulphamethoxypyridazine 5G ,57 and procainamide 58 • 
The determination of the acetylator phenotype may be of 
importance in establishing a suitable dosage regimen for a 
particular drug. It is not known whether this will apply 
to 8MZ but it should be borne in mind that this could 
influence blood levels of active 8MZ and N'-acetyl-8MZ. 
Certainly a wide inter-subject variation of active and 
total 8MZ levels has been repor ted 29, _, 0 which may poss ibly 
be due to differences in acetylator status. Vree et al. ,59,GO 
however, suggest that no such acety lation differences occur 
in the case of 8MZ and that the extent of acetylation depends 
on the amount of 8MZ available for acetylation. Inter-
subject variability may be due to differences in urinary pH 
and flow which will affect 8MZ excretion (see below). 
The mean elimination half-lives of 8MZ and TMP have been 
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calculated following single dose administrations. In 
adults with normal renal functions, these values have been 
reported to be 6-17 hours for TMP, 7-11 hours fo r active 
SMZ and 12-14 hours for total SMZ I4 ,2S,29,36. In all these 
studies the mean values of the half-lives for each drug are 
similar. This was a prime reason for choosing SMZ as a 
companion sulphonamide for TMP in the marketed preparations. 
The half-life corresponds closely with the dosing interval 
which is 12 hours. 
The half-life of both drugs is u s ually shorter in children, 
but will vary greatly according to the age of the child 4s • 
Monitoring of drug levels in children would be an inv aluable 
aid in optimizing therapy. 
Concen trati ons of intact SMZ and TMP in the urine of subjects 
receiving the combination are high. The concentration of 
TMP in the urine parallels that in the blood but is 10-100 
times greater 30 • Concentrations of active SMZ in plasma 
and urine are approximately equa1 4s • The ratio of the 
concentrations of active SMZ to TMP in urine is variable 
but in general it approximates 1:1 14 ,30 after both single 
and multiple dosing. This ratio is far from ideal. 
However, due to the high concentrations present in the 
urine, the overall antibacterial activity is usually more 
than adequate to deal with urinary pathogens. 
The renal handling of SMZ and TMP differs. TMP is subjected 
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to passive non-ionic tubular diffusion in the kidneys 6!. 
Being a weak base, TMP dissociates increasingly by a 
reduction in pH and thus this tubular transport will be 
dependent on urinary pH. With urinary pH values below 
6,2 there is generally net tubular secretion, whereas there 
is net reabsorption above this point 2 !,6!. Salvesen and 
Fr¢num 62 have suggested that the recovery of unchanged TMP 
in urine is dependent not only on urine pH but also on 
urine flow. Thus when doing bioavailability studies with 
TMP formulations, they have stressed the need for acidic 
urine and high urinary output. 
In a similar manner, acidic urine causes a reduction in 
the excretion of SMZ which is an acidic drug whereas 
alkalinization of the urine increases the renal clearance 
and cumulative renal excretion of this compounds,. There 
is also a linear relationship between urine flow and renal 
clearance of SMZ S ,,6!. The renal clearance of the 
metabolite N'-acetyl-SMZ is not influenced by urine pH 
or urine flow s ,,6o. However, if renal excretion of SMZ 
is suppressed, e.g. acidic urine, the concentration of the 
metabolite in the plasma is higher and the half-life is 
slightly longer s ,. 
Thus the ratio of urinary concentration of SMZ to TMP is 
dependent on urine pH and flow 6 3 , i.e. alkalinization 
results in higher active SMZ:TMP ratios and acidification 
results in lower ratios. Care should be taken when 
..... - 25 -j 
- 25 -
acidic urines are encountered due to increased risk of 
precipitation of N'-acetyl-SMZ in the tubules under these 
conditions. 
Urinary pH also has some influence on the absorption rate 
of SMZ. Under alkaline urine conditions the compound was 
absorbed faster than under acidic conditions 59 • Differences 
in the plasma half-life of SMZ under acid and alkaline 
urinary conditions were small. 
Uncontrolled urinary conditions have led to certain 
discrepancies in the literature in pharmacokinetic para= 
meters, e.g. Schwartz and Ziegler 35 found 80-90 % unchanged 
TMP excreted within 48 hours, but Kaplan et al. 6 could only 
find 30-60% excreted unchanged in the same interval. 
This variation in the urinary levels will influence serum 
levels and may result in non-ideal values in some instances. 
Closer monitoring of body levels may provide more information 
about the extent of this variation. 
1.4.6 Impaired Renal Function: 
SMZ-TMP has found extensive application in the treatment of 
urinary tract infections, especially for the long-term 
therapy of recurrent bacteriuria. Inevitably patients with 
widely different degrees of kidney function will receive 
this combination. The effect of impaired renal function 
on pharmacokinetic characteristics has been well 
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All patients with creatinine clearance 
values above 60 ml min- l are considered, from a pharmaco= 
kinetic point of view, to have normal renal functions 29 , 61 
The clearance of TMP decreases markedly in renal 
insufficiency (see Figure 1.5a). A marked rise in the 
elimination half-life (tl)of TMP is seen at a creatinine 
29 
c learance value of about 20 ml min-l For creatinine 
clearances of less than 10 ml per minute, the tl of TMP 
rises to 1,5 to 3 times normal '4 . However the urine 
concentration of TMP remains at therapeutic levels 
irrespective of the renal function 61 . Even in chronic 
haemodialysis patients, unmetabolized TMP will be effectively 
eliminated and urine levels will be in the therapeutic range 14. 
The fate of TMP metabolites in renal failure has not yet 
been determined. 
The mean tl for active SMZ is practically uninfluenced by 
alterations in kidney function (see Fig. 1.5.a - the slope 
of the unchanged sulphonamide fraction is not significantly 
different from zero ). Renal insufficiency, howeve r, 
entails a larger variation in the tl of active SMZ'4. Thus 
th e rapeutic concentrations of unchanged SMZ may be ach ieved in 
the ur ine even in severe r ena l insuffici e ncy '4 . The active 
SMZ:TMP ratio in urine remains constant for all practical 
purposes, even in dialysis patients'4. 
For total SMZ however, there is a precipitous increase in tl 
as creatinine clearances become successively reduced below 
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Fig. 1.5. The effect of impaired renal function on the 
pharmacokinetic characteristics of trimethoprim and 
sulphamethoxazole. (Reproduced from Baethke et al. 34 ) 
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approximately 30 ml min- l (see Fig. 1.S.b). Thus, in 
renal insufficiency, accumulation of SMZ metabolites 
especially N4-acetyl-SMZ occurs. Accumulation of these 
metabolites increases hyperbolically and their elimination 
half-life approaches infinity in severe renal failure. The 
N4-acetyl derivative of SMZ has been implicated in renal 
damage associated with Co-trimoxazole therapy64 and thus 
levels of this metabolite should be closely monitored in 
patients with reduced renal function. 
Renal insufficiency is reflected by delayed excretion but 
does not affect the cumulative amount of total sulphonamides 
eliminated by the kidneys 34. 
The plasma concentration of TMP rises with a deterioration 
in renal function 34 . Active SMZ concentrations also 
increase slightly due to displacement from protein binding 
sites caused by rising metabolite levels 34 ,6l. These 
metabolites have a higher affinity for serum proteins. 
It is possible that they may also interfere with binding 
of TMP although this has not been determined. The ratio 
of the chemotherapeutically active components in plasma 
remains almost unchanged unless renal insufficiency becomes 
very severe 34 ; at low creatinine clearance values (e.g. 
dialysis patients) the ratio between active SMZ and TMP is 
reduced 29, 34,6 1 • The volume of distribution of TMP is 
unaffected by renal impairment but that of active SMZ 
increases with reduction in renal function 34 . 
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It is apparent that the limitations in the use of TMP-SMZ 
in renal insufficiency are due primarily to the kinetic 
behaviour and potentially toxic effects of their metabolites. 
Since the retention of SMZ metabolites becomes marked at 
creatinine clearance values of less than 30 ml min-I, it is 
this range of renal failure at which routine prescription 
should be abandoned. In cases of drug overdosage, 
conditions also arise which favour metabolism to inactive 
and possibly toxic compounds. 
The recommended dosage must be altered for patients with 
renal insufficiency to guard against toxic accumulation 65 . 
The most probable half-life for each drug component can be 
estimated from creatinine clearance values to allow selection 
of appropriate dosage intervals although prediction of the 
half-life value is made more difficult because greater 
variations are found in patients with reduced renal function 29 • 
Lower maintenance doses are required for subjects with 
marked renal impairment; dosage schedules have been 
postulated,e,66. It would be advisable here to monitor 
levels of drugs, especially the SMZ metabolites, and 
possibly one should refrain from using the fixed combination 
altogether. The half-lives become so unpredictable and 
dissimilar that the two components cannot be given with 
equal time intervals. The use of the fixed combination, 
Co-trimoxazole, is not recommended in patients where the 
creatinine clearance is below 15 ml/minute 65 . However, 
with careful monitoring of blood levels, it could be used 
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~n such cases because active drugs remain within the 
therapeu tic range. 
The use of the full recommended dose in the elderly, who 
often have diminished renal function, could lead to excessively 
high blood concentrations, which might in turn account in part 
for the higher incidence of adverse haematological r eactions 
in this group of patients'. 
From the above it can be seen that SMZ metabolites are 
excreted almost exclusively through the urine. Since the 
half-life for active SMZ is largely uninfluenced by the renal 
function, the elimination of this compound must therefore 
depend largely on non-renal mechanisms 29 • Thus one would 
expect that malfuncton of other vital organs, e.g. liver, 
would change the half-life for active SMZ. At impaired 
hepatic function the peak levels of active SMZ and TMP in 
plasma were lower by an average factor of 1,5 - 2,0 48 • 
The effect of other organ malfunctions on the pharmacoKinetic 
profile of TMP-SMZ is unknown. 
1.5 THERAPEUTIC USES OF CO-TRIMOXAZOLE: 
Lower respiratory and urinary tract infections are the 
commonest indications for Co-trimoxazole. Other recognized 
uses are the treatment of Gonorrhoea, brucellosis, enteric 
fevers, some types of endocarditis and septicaemia, coliform 
meningitis, pneumocystis pneumonitis and febrile episodes in 
patients with l eucopenia , ,6 5. 
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There are some aspects of Co-trimoxazole dosage and duration 
of therapy that need careful re-assessment 65 • Some authorities 
have questioned whether TMP alone would not be equally 
satisfactory treatment in urinary tract infections. The 
latter has been used successfully in Finland for some timel. 
Different ratios of TMP-SMZ could be useful for treating 
infections caused by some bacteria (for example gonococci) 
or infections in certain sites, but this is impractical. A 
useful method for determining serum and urine levels of these 
drugs would be an invaluable aid in the re-examination of 
dosages. 
1.6 DOSAGE: 
TMP-SMZ is supplied as a standard tablet containing 80 mg 
TMP and 400 mg SMZ; as a double-strength tablet containing 
160 mg TMP and 800 mg SMZ; as an oral suspension containing 
the equivalent of 40 mg TMP and 200 mg SMZ per teaspoonful 
and as an ampoule for intravenous administration containing 
80 mg TMP and 400 mg SMZ per 5 ml. The usual adult dosage 
is two standard tablets twice a day. 
1.7 ADVERSE EFFECTS: 
In the recommended dosage, Co-trimoxazole is well tolerated. 
Nausea, vomiting and drug rash may occur; the latter is due 
to hypersensitivity to the sulphonamide component l . 
Haematological changes (mainly leucopenia and thrombocytopenia) 
have been reported in isolated cases but are generally re= 
versible. TMP may induce folate deficiency especially in 
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patients with pre-existing deficiency and this may be 
implicated in blood dysc rasias 27 • 5ulphonamides are 
nephrotoxic 64 , and crystalluria has been considered a 
potential hazard related to N4 -acetyl-5MZ insolubility 67. 
Current evidence suggests that creatinine clearance is 
diminished by Co- t rimoxazole, probably bytheTMP component 6S • 
1.8 THE ROLE OF DRUG MONITORING IN CO-TRIMOXAZOLE THERAPY: 
Fixed combinations of chemotherapeutic agents should usually 
be avoided. However it can be seen that TMP-5MZ is a drug 
combination with reproducible and predictable drug levels 
under normal c ircumstances that can be maintained at fixed 
dose-levels and intervals. Thus the fixed combination has 
become available for general therapeutic use. 
There are , however, certain instances, as has been shown above, 
where close moni t oring of leve l s in the body and supplementa= 
tion of either drug if necessary could play a great rol e in 
optimizing and providing for more effective therapy. This 
could be invaluable where a serious infection is encountered; 
in these cases optimization of 5MZ and TMP ratios and 
concentrations according to the particular organism and the 
s ite of i nfection could provide maximum therapeutic activity. 
Observations on concentrations in numerous tissues and 
secretions strongly suggest that physico-chemical factors 
alone, e.g. pKa , pH, protein-bind i ng, generally govern the 
disposit i on of TMP and 5MZ' 6 ,'7,'9 , 6" . Thus it may be 
possible to predict, from serum or urine data , or from 
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available distribution data, the amounts of each drug in 
certain tissues and hence one could theoretically calculate 
the dosage regimen necessary to create an optimum ratio and 
concentration in that tissue with respect to the particular 
invading organism. 
There are many factors, e.g. volume of distribution, acetylator 
status, urine pH, etc. , that will affect blood and tis sue levels 
of both drugs and will result in inter- and intra-individual 
differences. In many cases, patients t o whom t he combination 
is administered may have pharmacokinetic parameters deviating 
from normal as a result of certain organ malfunctions. 
Monitoring of drug levels will improve therapy in these cases 
and may also playa part in delaying the development of 
resistance. Non-ideal ratios and concentrations for a 
certain organism may promote the development of resistance. 
It is also theoretically possible that use of the drug could 
be extended to patients with severe renal failure (creatinine 
clearance less than 15 ml/minute) provided that close contro l 
is kept over drug levels, especially of N'-acetyl-SMZ. 
Monitoring of the levels of this metabolite especially is 
important as it constitutes by far the major amount of any 
of the metabolites and it has been implicated in kidney damage 
and crystalluri a especially in cases where renal function is 
impaired. 
Thus monitoring of drug levels can po t entially playa greater 
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role. Hence a quick and accurate method for the assay of 
these drugs in biological fluids is desirable. Care must 
be taken in the chemical or biological method utilized in the 
assessment of drug concentrations. Many reports have been 
based on analytical methods which did not permit unequivocal 
determination of the chemotherapeutically active substances. 
Problems of specificity and speed of assays are becoming 
increasingly predominant with the advent of bioavailability 
determinations and the large numbers of samples requiring 
processing. 
In addition, since Co-trimoxazole is marketed under several 
trade names, it is essential to ensure bioequivalence of all 
these products and ensure adequate absorption of both 
components to yield the optimum ratios required. In the 
assessment of bioavailability in human volunteers, many 
parameters would have to be strictly controlled, e.g. urine 
pH, urine flow, etc. A more specific determination of SMZ 
and N'-acetyl-SMZ would be useful to discriminate poor 
biological availability from fast metabolic degradation in 
cases of low blood levels. 
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CHAPTER 2 
ANALYTICAL METHODS FOR THE DETERMINATION OF TMP AND SMZ 
IN BIOLOGICAL FLUIDS 
Several methods are available for the quantitative determination 
of TMP and SMZ in biological fluids69~ 96 . The majority of 
these methods involve a separate analysis of these two 
compounds. This is effected, in microbiological assays, 
by the use of certain antagonists or organisms to nullify the 
effect of one component or, as in the more commonly used 
chemical methods, by separation of the two drugs through an 
extraction procedure. In most cases, determination of the 
major metabolite of SMZ, N4-acetyl-SMZ, and of other meta: 
bolites of these drugs, requires additiona l analytical steps. 
Many of the earlier, long-established methods available 
suffer from one or mo r e limitations. They are either non-
specific, invo lve lengthy sample preparation and/or analysis 
time or are not amenable to simultaneous determination. 
Attempts to improve specificity and speed have in recent 
years led to a ·'.growth in chromatographic methods of analys is. 
High pressure liquid chromatography (HPLC) has become recognized 
as an invaluable tool for the routine analysis of drugs in 
physiological samples 97 ,98. Over the past two or three years 
and during the course of this present investigation, several 
methods have appeared where the application of HPLC to the 
determination of TMP and SMZ, both separately and in 
combination, in pharmaceuticals and in biological fluids, has 
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been investigated 90 - 96 ,99. The HPLC determination of 
N'-acetyl-SMZ has also been reported 59 ,9'-96. 
The present investigation was undertaken in the attempt to 
develop a method for the simultaneous extraction and 
determination of TMP, SMZ and also N4-acetyl-SMZ in 
biological fluids by HPLC. 
2.1 EXTRACTION OF TMP AND SMZ FROM BIOLOGICAL FLUIDS: 
The vast majority of literature methods available for the 
determination of TMP and SMZ depend upon a separate analysis 
of these two compounds. Hence emphasis has been placed on 
extraction methodology that will enable their separation. 
Because of their diverse characteristics, TMP and SMZ can, 
in fact, be extracted selectively from aqueous samples 
using water-immiscible solvents following the classical 
approach of Brodie et al.,loo i.e. basic drugs are made 
alkaline before extraction into water immiscible organic 
solvents and acidic drugs are made acidic, the principle 
being that the unionized form is more lipophilic than the 
ionized form. 
Thus, TMP, a basic drug with a pKa of 7,2, is extracted at 
alkaline pH into a variety of water-immiscible solvents. 
Most published methods involve the addition of sodium 
carbonate or occasionally sodium hydroxide to the biological 
fluid or tissue in order to adjust the pH to 11, followed by 
extraction into chloroform 3 ,7o,so . Isopropanol - dichloro= 
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methane (1:4)81, chloroform - isopropanol (95:5)92 and 
dichloromethane 87 have also been utilized as solvents for 
the extraction of TMP. It has been found that a pH of 11 
is satisfactory with regard to the selectivity and effic iency 
of extraction into chloroform 91 • Under these conditions 
fairly good recoveries of TMP are obtained even if a very 
small amount of chloroform is used to extract a larger 
volume of aqueous phase 8s • One serious disadvantage, however, 
associated with the use of chloroform is emulsification when 
extracting from biologica l fluids, especially urine at alkaline 
pH. Thus care must be taken when samples are shaken. 
Unconjugated metabolites will be extracted together with 
unchanged TMP when these methods are utilized 1ol • 
The extraction methodology described above that is commonly 
utilized for TMP will not extract SMZ which is an acid i c 
drug (pKa 5,6) and hence will be ionized under these 
conditions. Often SMZ is analysed directly in the remaining 
aqueous layer si • Extraction of SMZ from plasma or urine is 
usually effected by adjusting each fluid to an acidic pH, 
making the SMZ essential ly non-ionized and hence lipophilic. 
SMZ can be extracted into several water-immiscible solvents, 
e.g. chloroform 94 , ethyl acetate 78 , ether 84b • Addition of 
acetone to the aqueous phase prior to extraction with 
chloroforms 1 or ether 84b greatly increases the yield. The 
choice of pH of extraction is important. An extreme pH 
offers little selectivity in extraction and also may result 
in ionization of secondary groups thus producing water-
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soluble species. The appropriate pH which would allow an 
almost quantitative extraction was found to be pH 3 for SMZ 91 . 
However, pH values of 5,5 78 and 4,1 81 have also been used. 
The N4-acetyl derivative of SMZ and other non-co njugated 
metabolites will also be extracted under these conditions 78 . 
SMZ, like most sulphonamides i s highly protein-bound35 ~ The 
a bove extraction methodology is likely to be effective in 
r eleasing all the bound drug for analysis 79 . The procedure 
utilized for the extraction of TMP will also remove protein-
bound and unbound drug 102 . 
These methods of extraction are unsuitable for the 
simultaneous determination of SMZ and TMP. A sample 
preparation system was required which wbuld quantitatively 
extract both drugs in a single operation. No methods for 
the simultaneous extraction of TMP and SMZ were available 
at the time of this investigation. Vree et al.,96 have 
since, however, emp l oyed a perchloric acid protein 
precipitation procedure for biological samples in order to 
determine both SMZ and TMP, and also N4-acetyl- SMZ. In 
addition , Bury and Mashford 93 have recently utilized tri= 
chloroacetic acid t o prepare plasma samples for both SMZ 
and TMP analyses. 
Thus various solvent systems and protein-precip i tation 
methods were evaluated for their extraction efficiencies and 
ability to separate the relevant compounds from impurities . 
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A simple and rapid method of extraction is preferable since 
simplicity of the method reduces manipulative errors and hence 
enhances reproducibility and precision. A rapid method is 
highly desirable especially if the method is to be applied to 
a bioav ailability or pharmacokinetic study of Co-trimoxazole 
where large numbers of samples require analysis. It is very 
often the extraction that takes the longest time in an analysis. 
Simultaneous extraction of TMP and SMZ would save time as both 
drugs would be extracted in one procedure. 
The extraction of SMZ and TMP simultaneously poses certain 
problems because of their widely differing characters. The 
pH of extraction would have to be closely controlled as 
changes in pH will affect r e coveries of both drugs. In this 
particular case a neutral or near-neutral pH is the most 
logical choice. Several reviews dealing with sample 
preparation techniques have appeared 3 .,91,102. 
It must also be bo rne in mind that TMP presents a problem 
in that assays must be extremely sensitive to determine the 
very low levels (0,1-2 ~g/ml) found in serum during treatment 
with the drug. Urine levels are higher (10-100 times) and 
hence less of a problem in this respect . TMP has a low 
absorptivity· and hence for HPLC analysis where UV detection 
is most commonly employed the low TMP levels will not be 
detected unless large volumes of biological fluid or 
adequate concentration of extracts is done. Thus the 
ability to readily concentrate the sample extract is an 
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important factor that must be considered. For SMZ, plasma 
and urine levels are high, so little concentration of the 
original plasma or urine level is needed. 
2 . 2 METHODS AVAILABLE FOR THE DETERMINATION OF TMP, SMZ AND 
THEIR METABOLITES IN BODY FLUIDS: 
Methods for the analy sis of TMP were first outlined by Bushby 
and Hitchings in 1968 3 • They utilized a micro biological 
procedure with Ba c illus pumilus as the test organism. A 
second microbiological a s say method for TMP appeared in 1970 G9 , 
in this method para-aminobenzoic acid was added to the medium 
to neutralize any sulphonamide present. For the microbio= 
logical assay of SMZ a TMP-resistant strain is us e d 4G • The 
microbiological techniques are reproducible and sensitive but 
not specific. Active meta bolites and other antibacterial 
agents, if present, will interfere. These methods will 
measure only the immediately active, i.e. non- p rotein-bound 
portion of the drug (see Section 1.4.2). Microbiological 
procedures, however, have been shown to correlate well with 
chemical determinations 24 ,4o and have even been used recently 
for many pharmacokinetic studies 4G • 
Bushby and Hitchings 3 also outlined a spectrophotometric method 
f o r the determination of TMP in biological fluids. This 
method is not sufficiently sensitive to determine the very 
low concentrations encountered in the serum. In addition 
it is not very specific although metabolites interfering here 
are only formed in very small amounts . 
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In 1969 a spectrofluorimetric method 70 was developed which 
was sufficiently sensitive for biological samples (sensitivity 
0,1 ~g/ml TMP). The method was later modified to enable semi-
automa tion 71. Despite being rather intricate and time-
consuming, this method has become the most commonly used 
analytical technique for the routine determination of intact 
TMP in biological fluids. The majority of pharmacokinetic 
studies, even recently'9, carried out on TMP or TMP-SMZ have 
utilized this technique. The method is not absolutely 
specific for the unaltered drug. Small amounts of metabolites 
are also extracted and contribute slightly to the fluorescence 
measured, but they do not affect the determination to any 
considerable extent 37 • (More interference from metabolites 
may, however, be encountered in animal species who metabolize 
TMP to a far greater extent than man 35 ,lOl. 
Urinary concentrations of unchanged TMP can be measured by 
a simple and specific method based on the native fluorescence 
of the drug 72 • This method is not, however, sufficiently 
sensitive to allow for the determination of serum levels. 
TMP and its metabolites have also been determined by 
scintillation spectrometry of "e labelled TMp 53 and by 
diffe rential pulse polarography 52,73. The latter method 
is considerably less sensitive but more strictly specific 
for unaltered TMP than the spectrofluorimetric procedure 7o • 
The most widely used method for the determination of SMZ and 
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other sulphonamides is a colorimetric procedure based upon 
the Bratton-Marshall sl reaction which was originally described 
in 1939. This method consists of diazotizing the aromatic 
amino group of the sulphonamide followed by coupling to form 
a coloured azo compound. It gives a measure of the formerly 
incorrectly called "free sulphonamide", i.e. the sulphonamide 
fraction reacting directly with Bratton-Marshall reagents, 
but includes, together with unaltered SMZ, several metabolites 
which possess a free amino group37. The quantitatively 
important metabolite of SMZ, N'-acetyl-SMZ, can be assayed 
by repeating the analysis after hydrolysis so that "total" 
sulphonamide is measured. The difference between "total" 
and "free" SMZ gives a measure of the N'-acetyl-SMZ present. 
Despite its lack of specificity, the Bratton-Marshall method 
has been widely used for pharmacokinetic studies and is still 
being used". It has been adapted to automated systems to 
Rieder 7 s ,79 modified the procedure 
to include an extraction step and hence improved specificity. 
His modification is generally applicable to the routine 
determination of sulphonamides and their metabolites in body 
fluids and potentially could be automated. 
Recently the use of various chromatographic techniques for 
the determination of drugs in biological fluids has increased. 
The major advantage of these methods is that specificity is 
increased, particularly for tissue level studies where other 
drugs, metabolites or endogenous materials may interfere . 
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Various thin-layer chromatographic (TLC) methods were 
developed for the determination of TMP in biological fluids. 
A fluorescence TLC method developed in 1973 80 enabled 
quantitative determination of TMP in plasma and urine and 
its metabolites in urine. Other TLC methods for the 
determination of TMP in plasma 81 and in both plasma and 
urine 82 followed. 
Chromatographic techniques have also been used to improve 
specificity for the determination of SMZ and N"-acetyl-SMZ 
in both pharmaceutical preparations and biological samples. 
TLC has been used for the determination of SMZ in plasma 81 , 
both plasma and urine 82 , and for the simultaneous 
determination of SMZ and N"-acetyl-SMZ in urine 83 • These 
TLC methods provide a rapid, sensitive, accurate and specific 
means for quantitative determinations. 
TMP has been determined by gas chromatography (GC). A GC 
method for the analysis of TMP was first outlined by Clark,"a. 
Recently a number of GC methods for the determination of TMP 
in biological fluids have appeared 62 ,8s-87. These methods 
are sensitive, selective and rapid. 
Various attempts have been made to develop GC methods for 
the determination of sulphonamides 88 ,89. They are not, 
however, readily determined by GC and extensive derivatization 
is required which is too time consuming for routine analyses . 
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The advent of HPLC has led to increased speed, specificity 
and accuracy in the quantitative determination of drugs in 
biological fluids. HPLC has been used for the simultaneous 
determination of vancomycin, anisomycin and TMP lactate in 
antibiotic mixtures 9o • Bye and Brown 91 carried out 
preliminary studies in an attempt to devise an HPLC assay 
for TMP in biological fluids but experienced difficulty in 
quantitating results. A recent sensitive method describing 
the determination of TMP in biological fluids using HPLC and 
fluorescence detection has appeared 92 • Bury and Mashford 93 
have also described an HPLC analysis of TMP in plasma employing 
ultraviolet (254 nm) detection. These two methods do not 
utilize an internal standard for the quantitation nor do they 
allow for the simultaneous determination of SMZ. 
Sulphonamides are well suited to assay by HPLC. HPLC has 
been used for the determination of pure sulphonamides'03-'06 
and for the determination of sulphonamides in biological 
The determination of SMZ alone 93 as well 
as the simultaneous determination of SMZ and its N4 -acetylated 
metabolite 59 ,94,95 in biological fluids by HPLC have been 
reported. 
It must be of great value to be able to determine simultaneously, 
in a single operation, the concentration of each component from 
a small volume of sample. Various methods have been reported 
where a simultaneous determination of TMP and SMZ is described. 
TMP and SMZ have been determined from a single volume of 
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biological fluid using a microbiological procedure following 
separation of the two drugs by electrophoresis'o. NMR has 
also been used for the simultaneous determination of TMP and 
8MZ in pharmaceuticals 1 10, 111 but this technique is not 
sensitive enough to determine the low concentrations found 
in biological fluids. 
Helboe and Thomsen 99 used HPLC for the simultaneous 
determination of TMP and 8MZ in pharmaceuticals, but did 
not adapt the system to biological fluids. Vree et al. ,96 
have recently reported the simultaneous determination of 
TMP, 8MZ and N'-acetyl-8MZ in biological fluids by HPLC. 
However, this method is only sensitive down to 0,75 ~gjml 
of TMP and hence is unsatisfactory for clinical pharmacokinetic 
studies. In addition, it does not incorporate the use of an 
internal standard for the quantitation. 
The value of simultaneously determining TMP, 8MZ and 
N'-acetyl-8MZ is clearly apparent. HPLC seems to be the 
ideal technique to use for this purpose. Hence this study 
was undertaken to develop an HPLC method for the simultaneous 
determination of all three compounds. The method described 
by Vree et al . ,9 6 appeared during the course of the present 
investigation and will be compared and discussed in relation 
to the present studies. 
2.3 CHOICE OF HPLC A8 A TECHNIQUE FOR THE DETERMINATION: 
Of the techniques discussed above, the only specific ones 
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are those including a chromatographic separation. In 
addition, since a mixture of compounds is to be determined, 
a chromatographic procedure would facilitate the 
simultaneous analysis of the relevant compounds. As a 
technique, HPLC offers superior resolving power to TLC 
combined with the quantitative precision similar to that 
obtained with GC. GC, however, requires prior derivatization 
of the sulphonamides with its attendant disadvantages. A 
great advantage of HPLC is that low concentrations of drugs 
may be analysed without any necessity to deriva ti ze the 
compounds. 
For this particular analysis HPLC seems the most logical 
choice. The technique itself provides specificity, speed, 
good accuracy and precision. It is versatile and can be 
applied to drugs of diverse characteristics as in this case. 
In addition it offers the possibility of a simplified method 
of sample preparation 3Ba as compared with other analytical 
techniques, since extraction is fol10wed by another separation. 
Often removal of proteins from biological fluids before 
injection will suffice so that speed and accuracy are 
incr e ased. 
Ultra-violet (UV) detection is the most widely used technique 
in HPLC and was utilized for the present studies. However, 
the use of this detector has an associated disadvantage since 
it is totally dependent upon the absorptivity of the relevant 
compounds being analysed. Thus, it has limited sensitivity 
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in the case of TMP which has a low absorptivity. It was 
necessary, therefore, to develop methods of extraction that 
will enable concentration of the sample to be effected. 
2.4 OBJECTIVES IN THE DEVELOPMENT OF AN HPLC ASSAY FOR THE 
SIMULTANEOUS DETERMINATION OF TMP AND SMZ IN BIOLOGICAL 
FLUIDS: 
The objectives were as follows: 
(i) The selection of suitable conditions, i.e. column, 
mobile phase, etc., for the separation of TMP and SMZ. 
(ii) The choice of a suitable detection system for both 
drugs and a method of ensuring relatively similar responses 
from both drugs present in widely differing proportions. 
(iii) The development of a su itable extraction procedure 
from biological fluids where these drugs, of differing 
chemical nature, may be simultaneously extracted and where 
reproducibility and extraction efficiency are satisfactory. 
(iv) Suitable concentration of the sample extract to enable 
det ection of low concentrations of drugs, especially TMP. 
(v) The choice of a suitable internal standard if possible. 
(vi) The simultaneous quantitation of the major metabolite 
of SMZ, N4-acetyl-SMZ. 
\vii) The application of the method to the analysis of samples 
of dissolution medium taken during dissolution rate studies of 
various Co-trimoxa~ole dosage forms . 
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CHAPTER 3 . 
PREPARATION OF N4 -ACETYLSULPHAMETHOXAZOLE 
The N4 -acetyl derivative of sulphamethoxazole was prepared 
by acetylation with acetic anhydride in acetic acid. The 
method employed is outlined by Sharma, et al. ' 07 
3.1 REAGENTS: 
Sulphamethoxazole (Lot No. 3262) was obtained from Wellcome 
(Pty) Ltd., S.A., and was used without further purification. 
It complied with BP standards. Other reagents used were 
all of analytical grade and included acetic anhydride 
(E. Merck), extra pure glacial acetic acid (E. Merck), 
diox ane (E. Merck) and ethyl acetate (Hopkin and Williams) . 
The water used was deionized and then glass distilled. 
3.2 APPARATUS: 
Infrared spectra were obtained using a Beckman AccuLab 4 
Infrared spectrophotometer. Pre-coated silica gel 60F-254 
plates (20 x 20 cm, 0,25 mm; E. Merck) were used for the 
thin-layer chromatography. Melting points were obtained 
using the apparatus specified in the British Pharmacopoeia 7 c • 
3.3 METHOD : 
To 2 g SMZ was added 20 ml of acetic anhydride. The SMZ 
dissolves almost immediately and a fine precipitate of the 
product, N4-acetyl-SMZ, appears after a few minutes. 8 ml 
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of glacial acetic acid was then added; this increases the 
yield of the product. The reaction mixture was then allowed 
to stand overnight at room temperature . 
The product was filtered off by suction, washed t horoughly 
with cold distilled water and then recrystallized from 
dioxane-water (1:1 vol/vol). Finally it was dried in an 
oven at 50 0 C. 
3.4 TESTS FOR PURITY: 
The following tests were performed to confirm the identity 
and purity of the N4 -acetyl-SMZ formed: 
(i) Carbon, Hydrogen, Nitrogen Analys isa : 
The results of this analysis are shown in table 3.1 
TABLE 3.1 
RESULTS FOUND EXPECTED VALUES 
% C 48,75 48,81 
% H 4,50 4,44 
% N 14,25 14,23 
a This analysis was performed by the Microanalytical Section, 
Department of Organic Chemistry, University of Cape Town by 
the courtesy of Dr. G. Cragg . 
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(ii) Infrared Absorption Spectra: 
The infrared (i.r.) spectra of both SMZ and its N4 -acetyl 
derivative were obtained (see Figures 3.1 and 3.2). Both 
compounds were examined as nujol mulls . 
(iii) Thin-layer Chromatography: 
Solutions of SMZ and N4 -acetyl-SMZ in methanol were applied 
to a pre-coated fluorescent silica gel plate (Merck). The 
plate was developed in a solvent system consisting of 
ethylacetat~dioxane-glacial acetic acid (8:2:0,1)83 to a 
height of 13 cm. Once dry, the plate was viewed under an 
ultraviolet lamp (254 nm) and the Rf values of each compound 
determined. 
(iv) HPLC: 
An aliquot of a solution of the product in methanol was 
injected into a high-pressure liquid chromatograph under 
the conditions described in Section 4.3.2, and the retention · 
time was no t ed. 
(v) Melting Point Determination: 
The melting point of a finely powdered sample of the product 
was determined using the method specified in the British 
Pharmacopoeia'c . 
3 . 5 RESULTS AND DISCUSSION: 
The previously described method was found to give a high 
yield (> 90%) of N4 -acetyl-sulphamethoxazole. The product 
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Fig . 3.1. Infrared spectrum of sulphamethoxazole. 
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Fig. 3.2. Infrared spectrum of N4 -acetylsulphamethoxazole. 
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appeared as white crystals which melted at 224 - 22 5 °C. 
The reaction goes to completion without any application of 
heat; heating, in fact, causes decomposition of the product. 
The structure of N4-acetyl-SMZ is shown in Figure 3.3. 
Figure 3.3. N4-acetylsulphamethoxazole 
The C, H, N analysis on the product agreed very closely 
with values expected on the basis of the molecular formula 
of N4-acetyl-SMZ. 
Two important features are apparent when comparing the i.r. 
spectra of SMZ and N4-acetyl-SMZ. The first is the 
significance reduction in the intensity of absorptions in 
the region 3600 - 3200 cm- I seen in the spectrum of N4-acetyl-
SMZ. These absorptions correspond to stretching frequencies 
of N-H bonds. The reduction in their intensity is due to 
the monosubstitution of the primary -NH, group in SMZ that 
has occurred. The second feature of interest is the strong 
carbonyl group absorption at ca. 1700 cm -I that is seen only 
in the spectrum of N4-acetyl-SMZ and is due to the acety l 
group at the N4 position. These features further confirm 
the identity of the product formed. 
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Chromatographic methods were used to check the purity of 
the product. Both SMZ and N4-acetyl-SMZ appeared as single 
spots on th e thin-layer chromatogram. There was no trace 
of the parent compound, SMZ, nor of any other impurity in 
the sample of N4-acetyl-SMZ. 
The Rf-value of SMZ was found to be 0,815 and that of 
N4-acetyl-SMZ was 0,662. No positive i dentification can 
be made on the basis of this TLC separation as an authentic 
specimen was not available; the product was, however, shown 
to be apparently pure. 
Under the HPLC conditions described in Section 4.3.2, the 
N4-acetyl-SMZ produced was found to have a retention time 
of 16,7 minutes. A single well-defined peak was obse rved 
indicating a pure sample. No SMZ was observed in the 
chromatogram. HPLC analysis of serum and urine extracts 
from patients after ingestion of Co-trimoxa z ole show a 
peak at the same retention time which can only correspond 
with the N4-acetylated metabolite of SMZ. 
These tests confirm the identity and purity of the synthesized 
N4-acetyl-SMZ. This product was thus used as a standard to 
allow for quantitative analysis of N4-acetyl-SMZ in serum 
and urine. 
The identity and purity of further batches of N4-acetyl-SMZ 
synthesized were confirmed by i.r., melting point, mixed 
melt ing point and retention time when injected under the 
specified HPLC conditions. 
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CHAPTER 4 
CHROMATOGRAPHIC ANALYSIS 
4.1 MATERIALS AND APPARATUS: 
4.1.1 Reagents: 
Trimethoprim (Lot No. 3156) and Sulphamethoxazole (Lot No. 
3262) were supplied by Wellcome (Pty) Ltd., S.A. 
Sulphafurazole (Lot No. RFA 2258) was obtained from Maybaker 
(pty) Ltd., S.A. and Sulphasomidine (Batch No. 81/10) from 
Noristan Laboratories (Pty) Ltd., S.A. All of these drugs 
complied with B.P . standards and were used without further 
purification. The N'-acetylsulphamethoxazole was prepared 
by acetylation of SMZ (see Chapter 3). 
All other solvents and materials used were of analytical 
grade and were purchased from E. Merck, Darmstadt, with the 
exception of acetonitrile which was "synthesis" grade (E. 
Merck), whereas chloroform (A.R.) and ethyl acetate (A.R.) 
were obtained from Hopkin and Williams (Searle Co., S.A.). 
The water used was deionized and then glass-distilled. 
4.1.2 Source of Biological Samples: 
Drug-free serum was obtained from polycythaemia patients. 
Whole blood without anticoagulants was centrifuged at 3000 
rpm for 10 minutes and the serum removed and stored frozen 
at -20 0 C. The serum was thawed at room temperature before 
use. Human urine was obtained daily from a volunteer . 
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4.1.3 Apparatus: 
4.1.3.1 ~i9b=~E~~~~E~_~!9~!9_~bE2~~!29E~pbi~_§Y~!~~~: 
System A. 
A Perkin-Elmer Model 601 liquid chromatograph was used, 
equipped with a Perkin-Elmer Model LC-55 variable wavelength 
ultraviolet absorption detector and a Model 123 strip-chart 
recorder. A temperature controlled column oven was also 
included. Samples were injected using a Rheodyne Model 
70-10 Sample Injection Valve equipped with a 20 ~l loop. 
System B. 
A Spectra-Physics Model 3500B liquid chromatograph was used. 
Two detectors were included for monitoring the column 
effluent, a Model 770 spectrophotometric detector (Schoeffel 
Detector) and a Spectra-Physics dual channel U.V. absorbance 
detector Model 230. Recording and integration were performed 
using a Hewlett-Packard Automation System 3385A. A Pantos 
Unicorder U-125 M strip-chart recorder was also included. 
Samples were injected using a Valco CV-6-UHPa sample 
injection valve equipped with a 10 ~l loop. 
System C. 
A Varian Aerograph 8500 liquid chromatograph was used, 
equipped with a stop-flow septumless injector, a Vari-chrom 
variable wavelength U.V. detector and a CDS III electronic 
integrator. A Perkin-Elmer Model 56 recorder was also used . 
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4.1.3.2 Columns: 
(i) Amino-bonded Column. 
An Aerograph(R) Micropak(R) NH2 - 10 bonded phase column 
(25 em x 2 mm x ~ inch 0.0.; varian Associates) was used. 
(ii) C 1B Reverse-phase Column. 
A 30 em x 3,9 mm (i.d.) ~Bondapak C1B reserve-phase column 
(Waters Associates) was employed. 
4.1.3.3 Other Instruments Used: 
(i) Bransonic 220 ultrasonic bath. 
(ii) Whirlimixer(R), Fisons. 
(iii) Roto-Uni II, BHG, centrifuge. 
(iv) Techne Dri-Block DB-3. 
(v) Sartorius Precision 5-figure Analytical Balance, 
Type 2474. 
(vi) Edwards "Modulyo" Freeze Drier. 
(vii) Orion Research Model BOlA digital ionalyzer. 
(viii) A Hewlett-Packard Model 9810A desk-top calculator 
was used for the linear least squares regression 
analysis. 
Finely tapered 15 ml conical Pyrex centrifuge tubes were 
used as well as vacutainer(R) tubes (Becton-Dickinson, U.S.A.). 
Tubes were sealed with parafilm(R) M (American can company). 
Grade A volumetric glassware was used . 
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All glassware was cleaned in chromic acid, thoroughly rinsed 
with distilled water and dried, before use. 
Millipore type HA(0,45 ~m) and type FH(0,5 ~m) membrane 
filters (Millipore Corp., Bedford, Mass . , U.S.A.) were also 
employed. 
4.2 PRELIMINARY TESTS USING AMINO-BONDED COLUMN: 
During the development of a high-pressure liquid chromatographic 
method for the determination of TMP and SMZ two types of 
columns were used. The first column employed was an amino-
bonded column (see Section 4.1.3.2). This column has a 
high polarity, strongly basic surface functionality created 
by chemically bonding a monomolecular layer of 3-aminopropyl 
silane to 10 ~m silica particles. This phase is bonded 
through the stable siloxane bond (Si-O-Si) and is claimed 
to be thermally and hydrolytically stable " 2 • During the 
present studies, however, a lack of stability was observed 
(see later). This type of column can be used for normal 
phase, reverse phase or ion-exchange chromatography. 
The use of an amino-bonded reverse phase column has been 
reported for the HPLC determination of sulphamethazine, 
sulphamerazine, sulphathiazole and their N4 -acetylated 
metabolites in cattle urine , 0 7 • 
A preliminary method for th e determination of TMP and SMZ 
in urine was developed using this column and recovery 
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studies were carried out to evaluate a few sample 
preparation techniques that were of possible use in 
simultaneously extracting these drugs. 
A. Experimental: 
(i) Standard solutions: 
Trimethoprim Stock Solution: 125 mg TMP per 100 ml water, 
dissolved with the aid of 20 ml 0,1 N HC1. 
Sulphamethoxazole Stock Solution: 125 mg SMZ per 100 ml 
water, dissolved with the aid of 20 ml 0,1 N NaOH . 
Internal Standard Solution: This solution consisted of 0,5 mg 
ml -1 sulphasomidine in methanol. 
All standard solutions were freshly prepared. 
(ii) Preparation of "spiked" urine samples: 
The method utilized for fortifying urine with known quantities 
of TMP and SMZ consisted of adding suitable small aliquots of 
the aqueous stock solutions (see above) to larger volumes of 
urine in order to obtain the required urine concentration. 
For each urine sample equal volumes of the acidic TMP and 
alkaline SMZ solutions were added so that, in effect, the 
resulting solution had a neutral pH. 
(i i i) Chromatographic conditions and quantitation: 
The following chromatographic conditions were utilized: 
Column: Amino-bonded (Micropak(R) NH, - 10) 
HPLC system: C (see section 4.1.3.1) 
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Detection wavelength: 290 nm 
Sensitivity: Vari-chrom 0,1 A 
CDS III 4 
Recorder inpu t 5 mV 
Chart speed: 5 mm min-1 
Flow rate: 40 ml hr-1 
Pressure: 1000 p.s.i. 
Temperature: Ambient (20 - 24° C) 
Mobile phase: Acetonitrile - methanol 80:20 (vol/vol) 
Preparation of mobile phase: 
The mobile phase was prepared by mixing 80 parts by volume 
of acetonitrile with 20 parts by volume of methanol. No 
correction was made for volume changes as a result of mixing. 
The mobile phase was recycled twice and then discarded. 
Quantitation: 
The areas of all peaks were r ecorded on the electronic 
integrator. The ratios of the peak areas of TMP and SMZ to 
that of the internal standard were determined. These ratios 
were quantitated by comparison with the ratios obtained from 
the analysis of standards of known concentration. 
(iv) Extraction procedure: 
To a 5 ml urine sample in a separating funnel was added 
approximately 7 ml of chloroform-ethyl acetate 85:15 (vol/vol). 
The funnel was carefully shaken by continuously inverting 
gently for 15 minutes. This usually avoided emulsification 
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and allowed easy separation of the phases without 
centrifugation. Occasional emulsions which formed were 
broken by centrifuging at 2000 rpm for 10 minutes. The 
extraction was repeated twice and the organic layers 
combined. The aqueous phase was discarded. 
To the combined organic phases was added 1 ml sulphasomidine 
internal standard (see above) and this was then made up to a 
volume of 25 ml. Aliquots of 1 to 5 ~l were injected into 
the liquid chromatograph. 
(v) Calibration curves: 
Control urine was fortified with TMP and 8M2 to yield six 
different concentration levels varying between 25,0 and 
250,0 ~g ml-1 of both drugs. Each urine pool was assayed as 
described above. Calibration curves were then constructed 
by plotting the ratios of the peak areas of each drug to 
that of the internal standard, sulphasomidine, versus their 
respective concentrations. Each sample was assayed in 
triplicate and the mean value obtained. 
(vi) Extraction efficiency: 
Recoveries of TMP and 8M2 from urine were assessed at five 
different concentration levels. Drug-free urine samples, 
spiked with known quantities of TMP and 8M2, were taken 
through the extraction procedure, the internal standard 
was added and peak area ratios were computed. Results 
were expressed as percentages of the peak area ratios 
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obtained by the injection of equivalent concentrations of 
pure drugs in chloroform-ethyl acetate (85:15) solution. 
Since the internal standard, which was added to both 
standards and urine extracts, was not carried through the 
extraction procedure it was used to correct for volumetric 
error in sample injection. 
B. Results and Discussion: 
Chromatograms of a blank urine extract and an extract of a 
urine sample containing TMP, SMZ and the internal standard, 
sulphasomidine, are shown in Figures 4.1(a) and (b) 
respectively. Under these conditions the retention times 
were as follows: 
TMP 
SMZ 
Sulphasomidine 
2,3 minutes 
4,0 minutes 
8,0 minutes 
No interfering peaks were evident in the urine control. 
In addition, a urine sample obtained from a volunteer, who 
had ingested 160 mg TMP and 800 mg SMZ (two tablets 
septran(R)) four hours before sampling, showed no interfering 
peaks when subjected to the above analysis. 
(i) Linearity: 
Calibration curves obtained were linear over the entire 
range of concentrations tested. Table 4.1 lists the linear 
regression data for the calibration curves . 
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Pia. 4.1. Chromatograms o~ (a) a blank urine extract and 
(b) anextract of urine containing 98,2 \.Ig ml -1 TMP and 
99,3 \.I g ml-1 SMZ. Chromatographic conditions as in Section 
4.2. The arrows denote times of sample injection (2,5 \.11 
inj e cted) . 
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TABLE 4.1: 
LINEAR REGRESSION DATA FOR CALIBRATION CURVES a 
DRUG CONCENTRATION SLOPE Y-INTERCEPT b CORRELATION RANGE, ]lg ml-1 COEFFICIENT 
TMP 25,0 - 250,0 0,0035 -0,0342 0,9952 
5MZ 25,0 - 250,0 0,0066 -0,0339 0,9998 
aAnalysis using NH, - bonded column. 
bpeak-area ratios are plotted on the y-axis and urinary drug 
concentrations in ]lg ml -Ion the x-axis. 
Drug concentrations normally encountered in the urine during 
therapy will fall within the linear range of the calibration 
curves. 
(ii) Extraction Efficiency: 
The results of the analytical recovery of TMP and SMZ from 
urine are listed in Table 4.2. 
TABLE 4.2; 
ANALYTICAL RECOVERY OF TMP AND SMZ FROM URINE a 
DRUG CONCENTRATION, ]lg ml-
1 
RECOVERY % ADDED FOUND 
SMZ 24,8 24,4 98 ,4 
49,6 49,2 99,1 
99,3 98,2 98,9 
148,9 148,3 99,6 
248,2 249,2 100,4 
TMP 24,5 20,0 81,8 
49,1 40,6 82,6 
98,2 79,8 81,3 
147,2 120,6 81,9 
245,4 202 ,0 82,3 
aAnalysis using NHz -bonded column. 
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Recoveries of both drugs are fairly consistent over a la-fold 
range in concentration and the values obtained are sufficiently 
high for analytical work 38c , 1 0 2 
(iii) Sensitivity and de tect ion limit: 
Under the conditions of this assay, the detection limits for 
TMP and SMZ were established as 10,0 and 5,0 ].Ig ml-I 
respectively. The method i s adequately sensitive for all 
clinical applications. The detection limits may, however, 
be improved by increasing the injected sample volume and 
also by employing a lower wavelength for the detection 
(see Figure 4.2). However, it must be borne in mind 
that background absorbance also increases at lower wavelengths. 
(iv) Extraction procedure: 
various solvent extraction techniques were investigated in 
the search for a suitable system which would quantitatively 
extract both TMP and SMZ fr om urine. The development of 
an appropriate technique is largely empirical although 
general guidelines on the methodology and requirements 
of extrac t ion procedures have appeared 38c ,lo2. Jones 38C 
has listed the properties of the ideal solvent. The 
preferred solvent i s usually the least polar one which 
will efficiently extract the required substance 102 as thi s 
will also extract minimal amounts of impurities. 
Several liquid-liquid ex traction methods were tested and 
the suitability of a range of solvents of varying polarity 
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was assessed. Preliminary studies were carried out by 
extracting aqueous solutions (neutral pH) containing known 
amounts of 8MZ and TMP with various organic solvents in a 
similar manner to that described above for urine samples. 
In order to ascertain the efficiency of extraction, aliquots 
of both the organic and remaining aqueous phase were injected 
into the liquid chromatograph. 
It was found that non-polar solvents, i.e. iso-octane, 
cyclohexane and benzene, extract very little of either drug. 
Ether extracts approximately 56% of the 8MZ from an aqueous 
solution but very little TMP. 8MZ is completely and 
efficently extracted by both ethyl acetate and methyl= 
isobuty l ketone but these solvents remove very little TMP. 
Use of chloroform results in total extraction of TMP and 
about 72% extraction of the 8MZ from an aqueous solution. 
Addition of acetone to chloroform in the proportion 1:481 
yielded a solvent mixture which improved 8MZ recovery but 
not to a significant ex tent. Various chloroform-ethyl 
acetate combinations were then tested for suitability. A 
mixture of 85 parts by volume of chloroform and 15 parts by 
volume of ethyl acetate was found to be optimal with r espect 
to efficiency and completeness of extraction of both 8MZ and 
TMP from an aqueous solution. A reduction of the ethyl acetate 
proport ion in this mixture results in lower 8MZ recoveries 
whilst increased proportions yield lower TMP recoveries. 
When applied to urine samples, extraction with the chloroform-
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ethyl acetate 85:15 solvent system was found to give 
adequate recoveries of both drugs. This was the final 
sample preparation method chosen for use. The extract 
was found to be analytically 'clean', permitting high 
detector sensitivity, and it could be injected directly 
since solvent and drug peaks were well resolved. 
Concentration of the extract is not required for the 
determination of urine levels of TMP and SMZ. However, 
should this be necessary, e.g. for the evaluation of lower 
concentrations found in serum, it is possible to evaporate 
the extract to dryness and reconstitute the residue in a 
small quantity of a suitable solvent or mobile phase. 
Incorporation of ethyl acetate reduces the liklihood of 
emulsion formation compared to chloroform when used alone. 
Possibly the presence of a high concentration of an 
inorganic salt would be beneficial for the extraction 3Bc • 
This further lowers the incidence of emulsification by 
reducing the solubility of the organic solvent in the 
aqueous phase. It may also aid the transfer of TMP and 
SMZ from aqueous to solvent phase and may thus obviate the 
need for repeated extraction of a single sample. A single 
extraction step is optimal for a solvent extraction process· 02 • 
Simplified techniques for sample preparation, e.g. removal of 
proteins by precipitation, will often suffice for HPLC 
analysis 3Ba • For the determination of sulphonamides in 
urine using an amino-bonded packing, Sharma et al."o7 
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pretreated urine samples with methanol before injection. 
Precipitation of urine components with organic solvents, 
e.g. acetonitrile and methanoI 38a ,91, was investigated as 
a possible approach to the TMP-SMZ analysis. Four parts 
of methanol or acetonitrile were added to I part urine. 
The gelatinous precipitate formed was removed by 
centrifugation and the supernate was injected. However, 
in this case organic solvent precipitation of urine samples 
was found to be inadequate as endogenous urinary constituents 
interfered with the TMP and SMZ peaks and could not be 
separated without very large increases in analysis times. 
These components may also be detrimental to column life. 
Liquid-solid extraction methods were also considered for 
this assay since these are often particularly suitable for 
compounds which are not easily extracted from aqueous 
solutions 38c • Biological samples can be freeze-dried before 
extraction as used, for example, by Dell 113 for the determin= 
ation of cephalosporins. Potentially, freeze-drying of 
samples has several advantages for this type of assay where 
drugs of differing character are required to be efficiently 
and selectively extracted. In addition, emulsification 
would be avoided, no control of pH would be necessary, 
storage of samples would be facilitated and samples may be 
easier to handle. 
In this case, urine samples fortified with TMP and SMZ were 
freeze-dried and the solid residue was then extracted with 
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chloroform-ethyl acetate 85:15. The solvent was filtered, 
sulphasomidine was added as internal standard and an aliquot 
of the resulting solution was chromatographed . However, 
extraction was found to be non-quantitative by this method 
since the recoveries of both drugs decreased with increasing 
concentrations. 
Several factors may have contributed towards this non-
quantitative recovery. The drugs may have been volatile 
or unstable and thus the conditions utilized for freeze-
drying may require more careful control. In addition, the 
suitability of a range of solvent extractants should be ' 
assessed since chloroform-ethyl acetate may not be ideal 
in this case. Possibly the use of polar solvents miscible 
with water, e.g. methanol, as used by Dell l 1 3 who did not 
encounter these variations, may prove advantageous. Soxhlet 
extraction may be necessary to dissolve the drugs fully as 
proposed by Bye and Brown 91 • Filtration of samples after 
extraction could have been a source of drug loss; 
centrifugation may be a better method for the removal of 
unwanted solid material. Jones 38C has suggested that when 
urine is to be freeze-dried it is convenient to add a 
quantity of a cellulose filtering aid so that a fine dried 
powder results and this may also improve extraction 
efficiency. Incomplete recovery may be due to adherence 
of the drugs to urinary constituents. The use of an 
internal standard is probably essential if a freeze-drying 
technique were to be employed. 
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(v) Chromatographic conditions: 
Mobile Phase 
No restrictions are imposed on solvents which may be used 
with this column provided the pH does not go below two or 
above nine l12 • Several solvent combinations, containing 
varying proportions of each component, were investigated 
in the search for a mobile phase suitable for the analysis. 
Water/methanol, dilute acetic acid/methanol, chloroform/ 
methanol and chloroform/acetonitrile mixtures were tested 
as mobile phases but were found to be unsuitable as TMP 
eluted within the void volume. Improved separation was 
obtained using acetonitrile/methanol mixtures. A mobile 
phase consisting of acetonitrile-methanol 80:20 with a flow 
rate of 40 ml hr -1 was found to be optimal and was finally 
selected for use. When applied to urine assaYSi there 
was no interference from urinary constituents or metabolites. 
The mobile phase was recycled twice before being discarded. 
Trace amounts of TMP and SMZ present in the recycled solvent 
did not affect the quantitative aspects of the analysis. 
Detection 
The ultraviolet absorption spectra of TMP and SMZ measured 
under the conditions of this assay (acetonitrile-methanol 
80:20 solvent mixture) are shown in Figure 4 . 2. Since 
the mean ratio of TMP to SMZ in urine is approximately 1:1, 
it would be advantageous to select a wavelength where 
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Fig. 4.2. Ultraviolet absorption spectra of 5 ~g ml~ 
TMP and 8MZ in acetonitrile-methanol 80:20 (vol/vol). 
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similar absorption occurs for both drugs at the same 
concentration. 
A wavelength of 290 nm was utilized for these preliminary 
studies. This wavelength is less than optimal since 
responses for SMZ exceeded those of TMP. However, despite 
this discrepancy in relative peak heights, both drugs were 
easily quantitated at this wav elength, especially since 
peak areas were being employed. In addition, use of this 
wavelength resulted in low background noise and enabled 
adequate sensitivity for both drugs at the levels encountered 
in urine. 
The use of lower wavelengths may be more ideal in terms of 
relative responses but problems of increased background 
noise and greater absorbance of injected solvents were 
encountered at these wavelengths. 
(vi) Column deterioration: 
Deterioration and alteration of column characteristics were 
apparent within a short space of time. The separations and 
retention times were found to be non-reproducible under the 
experimental conditions previously described . Progressive 
migration of the TMP and SMZ peaks occurr e d until these 
finally reversed in position. The gradual changes that 
took place are depicted by the chromatograms in Figures 
4.3 (a) - (i) . These were all run under identical 
chromatographic conditions. The numbers of samples 
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Fig. 4.3(a)-(i): Stages in the deterioration of the amino-
bonded c olumn. Chromatographic conditions as in Section 4.2. 
Peaks: 1 = solvent (chloroform-ethyl acetate 85:15); 2 = TMP; 
3 = SMZ. The arrows denote times of sample injection. 
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Fig. 4.3 (continued): 
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Fig. 4.3 (continued): 
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injected during the course of this deterioration were 
approximately 50 during the initial stages (a) and (b), 
approximately 300 during stages (c) and (d) and approximately 
40 during stages (e) to (i). Thus changes were apparent 
when the column was initially used, although it seemed to 
have stabilized somewhat during stages (c) and (d). 
During the latter stages, all the previously described 
quantitation, recovery, etc., determinations were undertaken. 
In the final stages ((e) to (i)) the alterations in the 
chromatogram were apparent in successive injections. The 
retention time of TMP continued to increase until it reached 
a value of 12,1 minutes, whereas that of SMZ gradually 
decreased until this compound eluted within the void 
volume. 
The efficiency of the column at each stage ((a) to (i)) was 
assessed by c~lculation of the height equivalent to a 
theoretical plate (HETP) for the SMZ peak in several 
chromatograms. The HETP was fairly constant at all stages 
and was found to have a value of 0,04078 ± 0,00530 cm 
(Mean ± S.D., n = 12). Thus, there was no apparent decrease 
in column efficiency but possibly a change in the actual 
nature and polarity of the bonded phase itself. 
Initially it was thought that a weak acid may have become 
permanently bound to the NH, groups in the column. This 
would result in increased retention times for a basic 
compound, e.g. TMP, and decreased retention times for 
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acidic compounds, e.g. sulphonamides. A number of 
sulphonamides had been injected under the same chromatographic 
conditions (see Chapter 6). Whilst changes in column 
characteristics had resulted in a reversal in the relative 
positions of the TMP and 5MZ peaks, there was no alteration 
in the elution sequence of the various sulphonamides tested 
although their retention times had shortened considerably. 
Thus the fact that an acid may have become bound to the NH, 
groups seemed to be possible. 
Hence, in an attempt to regenerate the column, it was rinsed 
with 100 ml triethylamine (0,1% vOl/vol) in chloroform and 
then with pure chloroform. This appeared to reverse the 
change to a limited extent in that the TMP retention time 
was shortened to 7,8 minutes and 5MZ was retained slightly 
longer although it remained incompletely resolved from the 
solvent (methanol) peak. A repeat of this treatment failed 
to improve these conditions. 
irreversible at this stage. 
Possibly the change was 
A complete explanation for t he sudden column deterioration 
is not however known. It appeared that a chemical change 
occurred resulting in an alteration of the chemical nature 
of the bonded NH, groups. These groups are highly reactive 
and hence this type of column tends to be rather unstable 
and must be treated with extreme caution. With this in 
mind, recycling of the mobile phase may have been a 
contributory factor towards the instability found when 
using this column. 
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It may be possible also that trace amounts of water were 
p resent in the solvent system and caused a r e duction in 
se parating efficiency. Water has been found to produce 
changes in the characteristics of amino-bonded columns lO ? 
The NH, group, because of its high reactivity, will react 
with compounds containing aldehyde or ketone groups to form 
Schiff bases l l '. In addition, the group is readily oxidized 
and therefore the use of peroxides should also be avoided 
with this packing material lls • Thus, great caution should 
be exercised, i n the selection of solvents and these should 
possibly have been further purified and redistilled before 
use. 
Failure of the sample preparation method utilized to 
sufficiently purify the biological samples and remove 
endogenous constituents may have contributed towards 
column degradation. Nonabsorbing inorganic ions in ur1ne 
may have been inadvertantly extracted and the gradual 
accumulation of these ions on the column could influence 
column characteristics and lead to a change in retention 
times iO ?,ll3. An NH,-bonded phase column was employed by 
Sharma et al., for sulphonamide analyses lO ? They found 
retention times to be r eproducible with the column but a 3 
hour column regeneration step was required after only 15 to 
30 urine samples were injected (samples pretreated with 
methanol to precipitate unwanted urine components). Thus 
the NH, column is clearly very sensitive to impurities in 
biological samples. Possibly, a pre-column should always 
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be included to safeguard this type of column when biological 
samples are injected so that t he above effects are minimized. 
Regeneration of the column was attempted by utilizing the 
method employed by Sharma et al.,lo7 and also by rinsing 
with a variety of solvents covering the range from low to 
high polarity. These were, however, unsuccessful. 
Attempts were made to restore some column performance and 
enable separation of TMP and SMZ by alteration of the mobile 
phase. A three-component mobile phase comprising chloroform-
acetonitrile-methanol 45:50:5 (parts by volume) at a flow rate 
of 60 ml hr-l was found to adequately separate TMP and SMZ. 
Sulphasomidine could be used as internal standard (see Figure 
4. 4) . The addition of a less polar third component to the 
mobile phase is a useful means of adjusting retention and 
selecti vi ty 1 1 6 • 
However, no further use was made of this column. In all 
liklihood further changes would have occurred. In addition, 
it is doubtful whether the analysis could ever be reproduced 
if another, simi l ar column were utilized. 
A second, unused amino-bonded column (obtained from the same 
manufacturer) was tested under similar conditions as 
described for the first column. Separation of TMP and SMZ 
was achieved using an acetonitrile-methanol 40:60 (vol/vol) 
mobile phase at a flow rate of 80 ml hr-l. Sulphamoxole 
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Fig. 4.4. Separation of TMP, SMZ and the internal standard, 
sulphasomidine, on the amino-bonded column using chloroform-
acetonitrile-methanol 45:50:5 as the mobile phase at a flow 
rate of 60 ml hr -'. The arrow denotes the time of sample 
injection. 
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could be employed as internal standard. However, once 
again, the separation changed drastically during the course 
of approximately 50 injections. Large increases in the 
retention times of all components were observed. The 
mobile phase was not recycled in this case so this seems 
an unlikely reason for rapid column deterioration. Rinsing 
with triethylamine (0,1%) in chloroform worsened the 
situation further. 
C. General Conclusions: 
A method was devised for the simultaneous extraction and 
determination of TMP and SMZ in human urine which, at first, 
seemed potentially useful insofar as recovery, linearity of 
calibration curves and sensitivity were concerned. However, 
the amino-bonded column employed for the analysis was found 
to be non-reproducible and unstable under the conditions 
used and eventually was abandoned, before any attempt was 
made to assess precision or to adapt the assay to serum or 
to the determination of the sulphonamide metabolite, 
N'-ace tyl-SMZ. Thus, extreme caution must be exercised 
when utilizing this type of column for the purposes of 
analysing biological samples and possibly its use for these 
samples should be avoided altogether. Solvents must be 
carefully selected and purified, strict attention should 
be paid to sample preparation methods and back-extractions 
may be required. Pre-columns should also be considered 
for inclusion to safeguard the main column . 
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4.3 SIMULTANEOUS DETERMINATION OF TRIMETHOPRIM, 
SULPHAMETHOXAZOLE AND N4-ACETYLSULPHAMETHOXAZOLE 
IN SERUM AND URINE USING AN OCTADECYLSILANE REVERSE-
PHASE COLUMN: 
The possibility of employing reverse phase chromatography 
for the Co-trimoxazole analysis was investigated. In its 
most commonly practiced form, this mode of chromatography 
utilizes a hydrophobic bonded phase packing, usually 
possessing an octadecyl or octyl functional group, and 
a polar mobile phase. In general, polar substances have 
a higher affinity for the mobile phase and elute first . 
As the hydrophobic character of the solute increases 
retention becomes longer'17. For these determinations, 
the column packing consisted of a monomolecular layer of 
octadecylsilane chemically bonded to fully porous 10 ~m 
silica particles. A pre-packed column was obtained 
commercially (see Section 4.1.3.2). 
The reverse phase technique is presently the most widely 
used mode in HPLC '17 . The majority of the currently 
available HPLC methods for the analysis of TMP, SMZ and 
N4-acety l-SMZ both separately and in combination, in 
pharmaceuticals and in biological fluids, have utilized 
either Cs reverse-phase columns· 2,.s,.6," or C's reverse-
phase column~o,'3. Several advantages are associated 
with this technique which account for its high degree of 
popularityl17. Efficient separation of a wide variety 
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of compounds can be accomplished, solvents commonly utilized 
are relatively cheap and, in addition, these columns are 
known to be stable provided certain precautions are taken. 
When applied to biological fluids, reverse-phase micro= 
particulate columns offer the possibility of minimum sample 
preparation prior to actual injection into the chromatograph 3Ba • 
This mode of HPLC is preferred because endogenous compounds 
in biological samples are predominantly hydrophilic and hence 
it would be advantageous to have these components eluting 
first. This would avoid excessively long retention of 
polar constituents associated with normal phase silica 
columns (polar stationary phase-nonpolar mobile phase). 
Thus, for routine clinical applications, the use of reverse-
phase HPLC is preferable. 
The C1B bonded reverse-phase column was successfully employed 
for the determination of TMP, 8MZ and N4-acetyl-SMZ in human 
serum and urine. This was the final method chosen for the 
analysis. A number of additional methods of sample 
preparation were evaluated using this column since a wide 
range of procedures can potentially be utilized . 
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4.3.1 Development of Methods for the Simultaneous Extraction 
of TMP and SMZ from Serum Samples: 
A. Experimental: 
(i) Standard solutions: 
TMP stock solution. 
per 100 ml methanol. 
SMZ stock solution. 
methanol. 
This solution contained 10,00 mg TMP 
This contained 20,00 mg SMZ per 100 ml 
Internal Standard solution. This contained 20,0 pg ml~ 
sulphafurazole (SFZ) in methanol . 
All standard solutions were freshly prepared. 
(ii) Preparation of 'spiked' serum samples: 
A bulk quantity of serum (40 ml) was fortified with 5,0 pg ml~ 
TMP and 3,0 ug ml-I SMZ. This was prepared by transfering 
2,0 ml of the TMP stock solution and 600 pI of the SMZ stock 
solution to a ground-glass stoppered flask and evaporating 
to dryness at 50° C under a gentle stream of nitrogen. 
Once dry, 40,0 ml serum was added and the flask was then 
gently shaken for 4-5 hours to ensure complete dissolution 
of the drugs in the serum. This bulk spiked serum was 
utilized for all extraction procedures, 
(iii) Chromatographic conditions : 
The following chromatographic conditions were utilized: 
Column: C's reverse-phase (uBondapak C's) . 
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HPLC system: B (see Section 4.1.3.1) 
Detection wavelength: 270 nm (Schoeffel detector) and 280 nm 
(Spectra Physics Model 230 detector). 
Sensitivity: 0,040 Absorbance Units Full Scale (A . U. F.S . ) 
Char t speed: 5 mm min-1 
Flow rate: 2,2 ml min-1 
Pressure : 1950 p. s. i. 
Temperature: Ambient (_20° C) 
Mobile Phase : 1% Acetic acid-methanol 80:20 (vol/vol). 
Preparation of mobile phase: 
The mobile phase was prepared by mixing 20 parts by volume 
of methanol with 80 parts by volume of a 1% vol/VOl acetic 
acid solution, the latter solution being prepared from glacial 
acetic acid and water. The solvent mixture (pH 2,9) was 
simultaneously filtered and degassed before use by vacuum 
filtration through a Millipore type HA (0,45 ~m) membrane 
filter. 
(iv) Extraction Procedures: 
Generally for each method, 1,0 ml of the bulk spiked serum 
was extracted. Unless otherwise indicated, vacutainer(R) 
tubes were employed for the extractions . These were sealed 
with parafilm(R) after each addition of reagent and, in 
addition, solutions were mixed for approximately 30 second 
intervals on a vortex mixer . Centrifugation was performed 
at 3000 r. p . m. for 15 minutes . 
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In all extraction procedures investigated, a specified 
aliquot of the final extract was placed in a tapered 
centrifuge tube. Subsequent treatment was identical for 
each and was carried out as follows: 
The extract was evaporated to dryness at 50° C under a 
gentle stream of nitrogen. The sides of all tubes were 
carefully washed down with methanol during drying. Each 
dry extract was then reconstituted in 100 ~l of the internal 
standard solution, and the tube was sealed. The reconstituted 
extracts were mixed thoroughly on a vortex mixer and were then 
centrifuged at 3000 r.p.m. for 15 minutes. An 8 ~l sample of 
each was injected into the liquid chromatograph. 
The following extraction procedures were assessed. 
I. Acetonitrile/NaCl. To the serum sample was added 3 ml 
ace t onitrile. The solution was thoroughly mixed and left 
to stand for 15 minutes to ensure complete protein 
precipitation. Sufficient sodium chloride (0,36 g) was 
added to saturate the aqueous phase, and the sample was 
re-mixed thoroughly. It was then centrifuged and 2 ml of 
the clear upper layer was transferred to a tapered centrifuge 
tube. 
II .. Acetoni tr ile/ (NH,) 250,. The serum sample was treated 
as in extraction I except that, in place of sodium chloride, 
ammonium sulphate (0,6 g) was utilized to saturate the 
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aqueous phase. 
III. Acetonitrile/Na,C0 3 • The serum sample was treated 
as in extraction I except that, in place of sodium chloride, 
sodium carbonate (0,36 g) was utilized to saturate the 
aqueous phase. 
IV. Acetonitrile/Na2S0,. The serum sample was treated as 
in extraction I except that, in place of sodium chloride, 
anhydrous sodium sulphate (0,36 g) was utilized to saturate 
the aqueous phase. 
V. Dilute/acetonitrile/NaCl. The serum sample was initially 
diluted by the addition of an equal volume of pH 7 buffer. 
It was then treated as in extraction I with the exception 
tha t 0,72 g sodium chloride was required to saturate the 
aqueous phase. 
VI. NaC l /acetonitrile. In this case, solid sodium chloride 
(0,36 g) was added to the serum sample initially and dissolved 
wi t h the aid of thorough mixing. 3 ml acetonitrile was 
subsequently added, the mixture was vortexed briefly and it 
was then allowed to stand for 15 minutes. It was finally 
re-mixed and centrifuged. 2 ml of the clear upper layer 
was transferred to a tapered centrifuge tube. 
VII. Pentane sulphonate sodium (0,005 M)/acetonitrile/NaCl. 
To the serum was added 1 ml aqueous pentane sulphonate 
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sodium solution (0,005 M). The sample was subsequently 
treated as in extraction I with the exception that it was 
necessary to add 0,72 9 sodium chloride to saturate the 
aqueous phase. 
VIII. Pentane sulphonate sodium (1 g)/acetonitrile/NaCl. 
Preliminary treatment of the serum sample involved the 
addition of 1 9 solid pentane sulphonate sodium. 
Subsequently the sample was treated exactly as described 
in extraction I. 
IX. Isopropanol/NaCl. The sample was treated as in 
extraction I, except that 3 ml isopropanol was utilized in 
place of acetonitrile as the protein precipitating agent. 
X. Ethanol/NaCl. In this case, 3 ml ethanol was used 
to replace the acetonitrile employed in extraction I. 
Subsequent treatment of the sample was performed as described 
in extraction I. 
XI. Acetone/NaCl. The method utilized was similar to 
extraction I with the exception that 3 ml acetone was employed 
in place of acetonitrile. 
XII. Acetone-Ethanol (l:l)/NaCl. The sample was treated 
as in extraction I, except that 3 ml of an acetone-ethanol 
1:1 (vol/vol) mixture was utilized in place of acetonitrile 
to precipitate proteins. 
. .... - 88 -/ 
- 88 -
XIII. Trichloroacetic acid (14%)/acetonitrile/NaCl. 
To the serum sample was added 0,5 ml of a 14 % (wt./vol.) 
aqueous solution of trichloroacetic acid. The tube was 
mixed and left to stand for 15 minutes. 3 ml acetonitrile 
was added, the sample re-mixed thoroughly and finally 0,54 g 
sodium chloride was transferred to the tube . The whole was 
then vortexed briefly, centrifuged and a 2 ml portion of the 
clear supernatant was transferred to a tapered centrifuge 
tube. 
XIV. Perchloric acid (2%)/acetonitrile/NaCl. The sample 
was treated as in extraction XIII but with the following 
modifications: (a) in place of 0,5 ml 14 % trichloroacetic 
acid solution, 1 ml of a 2% (wt./vol.) aqueous solution of 
perchloric acid was added, and (b) 0,72 g sodium chloride 
was required to saturate the aqueous phase. 
XV. Perchloric acid (5%)/acetonitrile/NaCl. The serum 
sample was treated as in extraction XIII but with the 
following modifications: (a) 1 ml of a 5% (wt./vol.) 
aqueous perchloric acid solution was utilized in place 
of the trichloroacetic acid solution, and (b) 0,72 g sodium 
chloride was required to saturate the aqueous phase. 
XVI. NazSO, /sodium tungstate (lO %)/sulphu ric acid (0,1 N)/ 
acetonitrile. To the serum sample was added sodium sulphate 
(0,9 g) and 1 ml of 10 % (wt./vol.) aqueous sodium tungstate. 
The mixture was thoroughly shaken, 1 ml 0,1 N sulphuric acid 
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was added, and, after further shaking the mixture was 
allowed to stand for 15 minutes. The aqueous layer was 
then extracted by shaking with 3 ml acetonitrile. After 
centrifugation, 2 ml of the organic layer was transferred 
to a finely tapered centrifuge tube . 
XVII. NaCl/Chloroform-ethyl acetate (85:15). To the serum 
sample in a glass-stoppered, round-bottom centrifuge tube 
was added 1 ml pH 7 buffer, 0,72 g sodium chloride and 6 ml 
of an 85:15 (vol/vol) mixture of chloroform and ethyl acetate. 
The mixture was extracted by shaking slowly for 30 minutes 
on a mechanical reciprocating shaker. The samples were 
centrifuged and the upper aqueous layer and most of the 
protein interface were aspirated . 4 ml of the organic 
layer was then removed and transferred to a tapered 
centrifuge tube. 
XVIII. NaCl/Chloroform-ethyl acetate-methanol (6:2:2). 
The sample was treated as in extraction XVII except that 
6 ml of an organic solvent mixture composed of chloroform-
ethyl acetate-methanol 6:2:2 (parts by volume) was utilized 
as the extractant in place of chloroform-ethyl acetate 
(85:15). 
XIX. Acetonitrile/ethyl acetate (l:l)/NaCl. To the sample 
was added 3 ml of acetonitrile, the solution was thoroughly 
mixed and it was then allowed to stand for 15 minutes. 
3 ml ethyl acetate was transferred to the tube and it was 
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again shaken thoroughly. To the mixture was added 0,36 g 
sodium chloride. The sample was shaken and then centrifuged. 
4 ml of the clear supernatant was transferred to a tapered 
centrifuge tube. 
xx. Acetonitrile/ethyl acetate (l:l)/Na,CO,. The serum 
sample was treated as in extraction XIX except that, in 
place of sodium chloride, sodium carbonate (0,36 g) was 
utilized to saturate the aqueous phase. 
XXI. Acetonitrile/ethyl acetate (l:l)(NazSO,. The serum 
sample was treated as in extraction XIX except that 0,36 g 
sodium sUlphate was employed in place of sodium chloride to 
saturate the aqueous phase. 
XXII. Isopropanol/ethyl acetate (l:l)/NaCl. The sample 
was treated as in extraction XIX except that 3 ml isopropanol 
was utilized in place of acetonitrile. 
XXIII. Ethanol/ethyl acetate (l:l)/NaCl. The method 
utilized was similar to extraction XIX with the exception 
that 3 ml ethanol was employed in place of acetonitrile. 
XXIV. NaCl/methylene chloride/ethanol. To the serum 
sample was added 1 ml pH 7 buffer, 0,72 g sodium chloride 
and 3 ml methylene chloride. The tubes were shaken, 
centrifuged and then the aqueous phase was removed by suction. 
3 ml ethanol was added and the tubes were well mixed. They 
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were then centrifuged and 4 ml of the supernatant was 
transferred to a tapered centrifuge tube. 
(v) Quantitation and assessment of recovery: 
The ratios of the peak heights of TMP and SMZ to that of the 
internal standard, sulphafurazole, were calculated for each 
sample injected. In order to calculate percentage recovery, 
these ratios were compared with those obtained from the 
injection of a standard solution in methanol which was 
prepared so as to contain pure drugs in concentrations 
corresponding to those expected if 100 % recovery were to 
have occurred during the extraction procedure. Since 
identical dilution and concentration steps were applied to 
all extracts, these could be compared to a single standard 
solution. The same amount of internal standard was added 
to both extracted samples and the standard solution. Since 
the internal standard was not carried through the extraction 
procedure it was used to correct for volumetric errors in 
sample injection. 
(vi) Background: 
The nature and relative size of peaks appearing in the 
chromatogram which were due to serum components extracted 
by each of the procedures employed were investigated . 
This was carried out by applying these extractions to 
samples of serum known to be drug-free. The final extracts 
were reconstituted in 100 ~l methanol before injection . 
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The appearance of t he extracts in the tubes before and 
after reconstitution was also noted. 
B. Results: 
Typical chromatograms obta ined after the injection of an 
extract of serum spiked with TMP and SM2 and of blank serum 
using extraction procedure I (acetonitrile/NaCl - see p.85) 
and a detector wavelength of 280 nm are shown in Figures 
4.5 (a) and (b) respectively. The retention times under 
these conditions were found to be 5,8 minutes for TMP, 
8,4 minutes for SM2 and 11,0 minutes for the internal 
standard, sulphafurazole. 
It was found that, for all extraction procedures investigated, 
chromatograms of blank sera showed peaks at retention times 
similar to those depicted in Figure 4.5 (b). Thus, in all 
cases the majority of endogenous serum constituents or 
extraneous substances in the extracts elute at retention 
times of between 1, 5 and 4,8 minutes and an additional small 
peak appears at 7,9 minutes. The relative sizes of these 
background peaks were, however, found to vary depending upon 
the extraction methodology used and variations were also 
encountered among sera obtained from different patients. 
Table 4.3 lists the results obtained for the various 
extraction procedures carried out on serum samples spik ed 
with TMP and SM2. 
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injection (8 ul injected) . 
1 
o 
Peaks: 
1 = TMP 
2 = SMZ 
3 = internal standard, 
sulphafurazole 
3 
1 
2 
4 8 12 
RETENTION TIME, min. 
(a) 
fiI 
Ul 
Z 
0 p., 
Ul 
fiI 
~ 
~ 
0 
E-< 
U 
fiI 
E-< 
fiI 
Q 
1 
o 4 8 
RETENTION TIME, min. 
(b) 
12 
"-I 
'<l' 
0"\ 
94 -
TABLE 4.3: 
EXTRAC'l'ION PROCEDURES CARRIED OUT ON SERUM SAMPLES II 
REmVERY % 
EXTRACTlool> s-lZ 1M!' 
I Acetonitrile/NaCl 55 ll5 
II Acetonitrile/(NH~)lSO~ 60 104 
III Acetonitrile/Na 3 COJ 85 100 
IV Acebonitrile/NazSO~ 80 95 
V Oilute/acetonitrile/NaCl 60 ll2 
VI NaCliacetonitrile SO 105 
VII Pentane sulphonate 35 112 
sodium (0,005 M)/ 
acetonitrile~ 
VIII Pentane sulphonate 43 102 
sodium (1 g) / 
acetonitrile/NaCl 
IX lsopropanol/NaCl 80 102 
X EthanoljNaCl 88 100 
Xl Acetone/NaCl 60 98 
XII Acetone-ethanol(l:l)/ 90 93 
NaCl · 
XIII Trichloroacetic acid 88 104 
(14%)/acetonitrile/ 
NaC] . 
XIV Perchloric acid (2%)/ 75 85 
acetonitrile/NaCl 
'IN Perchloric acid. (5%)/ 95 67 
acetonitrile/NaCl 
XVI Na2SO,.!scXl.iLm tungstate 87 114 
(l0%)/sulphuric acid 
(0,1 N)/acetronitrile 
XVII NaCl/chloroforrn-ethyl 70 101 
. acet.at.e (85:15) 
~II NaCl/chloroforrn- SO 109 
ethyl acetate-
methanol (6:2:2) 
XIX Acetonitrile/ethyl 85 ll4 
acet.ate(l:l)/Nacl 
XX Acetonitrile/ethyl 70 110 
acet.ate (l:l)/Na,OO. 
XXI Acetonitrile/ethyl 60 100 
acetate {1:l)/Na2SOIt 
XXII lsopropancl/ethyl 85 ll3 
acet.ate (l:l)/NaCl 
XXIII Ethanol/ethyl 92 113 
acet.ate (1: l)/NaCl 
XXIV Nacl/me thy lene 90 ll5 
chloride/ethanol 
-Analysis using CII revers~phase collJm. 
bFor details of these extracticns see text. 
APPFAlWO OF EX'rnACT 
DRY EXTRACr EXTAACl' AFTER 
REOJNSTIIDrION 
Small salt defX>si t. Clear, slightly yellow 
solution. 
Slightly less salts Clear, very slightly 
deposited than after yellow solution. 
extraction I. 
Small salt deposit. Clear, slightly yellow 
solution. 
Snal.l salt deposit. Clear, slightly yellow 
solution 
Snal.l salt deposit. Clear, slightly yellow 
solution. 
Small salt deposit. Clear, slightly yellow 
solution. 
Snal.l salt. deposit. Clear, slightly yellow 
solution. 
Large salt depoei t . Clear extract but 
contained deposit of 
undissolved salts. 
Large salt deposit. Slightly cloudy extract 
- deposit of undis~ 
solved salts. 
Large salt deposit. Slightly cloudy extract 
- deposit of undis= 
solved salt.s. 
Snail salt de~it. Clear, slightly yel.lc:w 
solution. 
Large salt deposit. Slightly cloudy extract 
ccnt.aioing deposit of 
undissolved salt.s. 
Large salt deposit. Slightly cloudy extract 
with deposit of 
undissclved salts. 
Small deposi t. Solution dis.:x>loured 
(green) • 
Srrall deposit. 'lb"se di~louratic:n 
than that cbtained in 
extraction XIV. 
Snal.l salt deposit. Clear, slightly yellow 
solution. 
1«) de~it. Clear extract. 
No deposit. Clear extract. 
Very slight salt Clear extract. 
deposit. 
Very slight salt Clear extract. 
deposit. 
Very slight salt Clear extract. 
deposit. 
Small salt deposit. Slightly cloudy extract 
with small deposit of 
umissolved salts. 
large salt depooit. Slightly cloudy extract 
with deposit of 
undissclved salt.s. 
Large salt deposit. Slightly cloudy 
solution with dep:lSit 
of undissolved salts. 
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PE'AKS IN 
BIANK SERlM 
As in Fig. 4.5(b). 
Very large serum peak 
at 3,75 min. extracted. 
Very large peak at 
3,79 min. 
Large serun peak at · 
3,81 min. 
As in Fig. 4.5(b) • 
As in Fig. 4.5(b) • 
Seraa peaks similar 
to those in Fig. 
4.5(b) • 
Serlltl peaks similar 
to tJ-ose in Fig. 
4.5(b) 
Very large serll!\ 
~ak at 3,77 min. 
Very large serlin 
peak at 3,68 min. 
large serun peak at 
3,78 min. 
Very large serm 
peak at 3,78 min. 
Very large serun 
peak at 3,80 min. 
serlin peaks similar 
to those in Fig. 
4.5(b) • 
serlin peaks similar 
to those in Fig. 
4.5 (b}. 
Very ·large serlin 
peak at 3,95 min. 
Serlll1 peaks slightly 
..... ller than those 
in Fig. 4.5 (b) • 
Serum peaks slightly 
smaller than those 
in Fig. 4.5(b). 
Ali in Fig. 4. 5(b) 
As in Fig. 4.5(b) • 
Fairly large sertln 
peak at 3,74 min. 
Large serlJtl peak 
at 3,79 min. 
Very large serum 
peak at 3,68 min. 
Very large serum 
peak at 3,75 min. 
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c. Discussion: 
(il Extraction procedures: 
Proteins and other macromolecules in biological samples 
present the greatest potential problem in liquid chroma= 
tography. If not completely removed prior to injection 
onto the column, these will result in a rapid deterioration 
in column life. During this protein removal step, there 
must not however, be any loss of protein-bound portions of 
a drug. This is particularly important in the case of 
8MZ which is highly protein-bound 33 and the sample preparation 
procedure must hence ensure liberation of the bound moeity. 
In general, acidic drugs bind more strongly than bases 3 8b. 
Numerous methods for protein removal are cited in the 
literature 36a ,36b,91,102 and these have been widely used in 
drug analyses. Water-miscible organic solvents, e.g. 
acetone, acetonitrile, ethanol, isopropanol, can be utilized 
provided that an organic-to-aqueous phase ratio of not less 
than 2:~8a is employed. When added to serum, these solvents 
denature the protein, which is precipitated and can be 
removed by centrifugation. Inorganic salts, when present 
in sufficiently high concentrations, affect the miscibility 
of solvents 36c. Hence, by the addition of salts such as 
sodium chloride, ammonium sulphate, sodium carbonate, etc., 
it is possible to separate even a water-miscible organic 
solvent from the aqueous phase. This so-called salt-
solvent pair approach was utilized during these studies 
since the organic solvent could be removed and subsequently 
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concentrated to enable the detection of low concentrations 
of drugs, especially TMP, present in serum. 
The use of acetonitrile as a deproteinization agent appeared 
to be superior to other water-miscible organic solvents in 
that the precipitated protein formed a "plug" which adhered 
to the bottom wall of the tube to yield a clear supernate 
after mild centrifugation, in contrast with other solvents 
which formed loose precipitates. This was also observed 
by Peng et al.,'09 who employed an acetonitrile deprotein= 
ization procedure for the determination of sulphisoxazole 
in plasma. In addition, when inorganic salts were added 
in an amount sufficient to saturate the aqueous (serum) phase, 
acetonitrile was found to separate readily as an upper layer. 
Upon subsequent evaporation of the acetonitrile layer to 
dryness, very small amounts of salts were observed in the 
dry residue. This facilitated reconstitution in small 
volumes of the appropriate solvent. 
The use of acetonitrile in combination with a neutral salt 
e.g . sodium chloride (extraction I) was found to give 
inadequate recovery of 5MZ. The addition of sodium chloride 
as a final step in the extraction procedure was found to 
yield slightly better recoveries for both drugs as compared 
with those obtained when the salt was added initially 
(extraction VI). This may be due to more thorough mixing 
of the acetonitrile with the serum sample which occurs if 
the salt is not present in the initial stages. Dissociation 
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of protein-bound sulphonamides (as well as other drugs) 
is favoured by dilution of the serum'Z,96. However, 
dilution of the sample resulted in only a very slight 
improvement in the recovery of SMZ (extraction V). 
Improved SMZ recoveries were obtained by variation of the 
inorganic salt utilized in conjunction with acetonitrile. 
The use of ammonium sulphate, which has been employed in 
protein precipitation procedures 3Bb , yielded a slightly 
better recovery (extraction II), while use of anhydrous 
sodium carbonate and sodium sulphate (extractions III and 
IV) resulted in significant increases in recovery figures 
obtained. TMP recovery remained high for all of these 
extraction procedures. However, a very large peak at 3,8 
minutes appeared in the chromatograms of blank sera when 
these salts were utilized for the extractions, although 
this peak did not interfere with the drugs of interest. 
The use of ion-pairing reagents (as utilized in reverse-
phase chromatography '17,11B) may be a possible approach to 
the simultaneous extraction of both a weak acid and a weak 
base. Ion-pair formation between ionized TMP molecules 
and alkyl sulphonate anions would result in the formation 
of an electrically neutral and non-polar complex and this 
would favour extraction into organic solvents. For SMZ, 
which is acidic, a quaternary amine, such as tetrabutyl= 
ammonium phosphate, could be used as the counter-ion at 
the appropriate pH. The use of pentane sUlphonate sodium 
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was investigated (extractions VII and VIII) as a possible 
aid in the extraction of TMP from serum. However, this 
approach was not found advantageous since TMP recovery was 
already adequate. Possibly, the use of ion-pairing 
reagents may be useful to improve SMZ recoveries, but 
these were not investigated here. 
Recoveries obtained when other water-miscible organic 
solvents were utilized as protein-precipitants were also 
assessed. For these extractions, sodium chloride was 
utilized as the inorganic salt to enable separation of the 
organic phase. The use of acetone(extraction XI) did not 
greatly enhance SMZ recovery over that obtained with 
acetonitrile. Although isopropanol and, especially, 
ethanol and acetone-ethanol (1:1) combination 102 
(extractions IX, X and XII) were found to displace the 
protein-bound sulphonamide and to yield good recoveries 
for both drugs, these solvents had a disadvantage in that 
they appeared to dissolve a large quantity of the inorganic 
salt so that a ' large deposit remained in the extract on 
drying. This hindered reconstitution in small volumes of 
solvents. Lower sUlphonamide recoveries obtained when 
using acetonitrile may possibly be due to incomplete displace: 
ment of bound drug as a result of the formation of a "plug" 
of precipitated protein. 
The use of acidic protein precipitants, e.g. trichloroacetic 
acid ' 19-'2', perchloric acid96 ,122 and tungstate followed by 
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sulphuric acid l o " has been described in the literature. 
An acidic pH will encourage the precipitation of protein lo , . 
To facilitate a concentration step, which is required for 
this analysis, the acidified sample, after protein 
precipitation, was extracted using an acetonitrile-
inorganic salt combination. The acetonitrile layer was 
subsequently removed and concentrated. 
Goehl et al . ,I 08 utilized a trichloroacetic acid protein 
precipitation procedure for the determination of Trisulpha= 
pyrimidines in serum and found the reagent to be superior 
to acetonitrile in that it resulted in more complete 
precipitation. Use of trichloroacetic acid for the present 
analysis (extraction XIII) resulted in good recoveries for 
both drugs (88 % for SMZ and 104 % for TMP). These results 
are in fairly good agreement with those obtained by Bury 
and Mashford 9 3 (81 % and 95 % recovery for SMZ and TMP 
respectively) who employed trichloroacetic acid without 
subsequent extraction for the determination of these 
compounds in plasma. However, the large salt deposit 
remaining in the extract after evaporation to dryness, which 
is due, possibly, to solubility of the trichloroacetic acid 
in the acetonitrile, limited the use of this procedure for 
the present determination. 
Precipitation of serum proteins by perchloric acid followed 
by direct HPLC analysis of the acidic supernate was employed 
by Vree et al., 96 who have described a method for the 
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simultaneous determination of TMP and SMZ in biological 
fluids. They reported mean recoveries of 80% and 83 % for 
SMZ and TMP respectively when using undiluted serum (prior 
dilution of the serum improved SMZ recovery). These values 
are fairly consistent with those obtained following the use 
of 2% perchloric acid plus subsequent acetonitrile extraction 
(extraction XIV; 75% recovery for SMZ and 85% for TMP). 
Increasing the perchloric acid concentration to 5% 
(extraction XV) yielded higher SMZ recoveries due, possibly, 
to more complete protein precipitation and hence greater 
displacement of bound drug. However TMP recovery was 
reduced since this drug will be essentially ionized at an 
acidic pH and hence will tend to remain in the aqueous 
phase. Use of perchloric acid, however, resulted in 
discolouration of the reconstituted extract which was 
considered a disadvantage since these pigments may have 
an adverse effect on column life. 
The use of sodium tungstate followed by sulphuric acid and 
then extraction of the acidic sample with acetonitrile 
(extraction XVI) was found to yield good recoveries for 
both drugs without the disadvantages associated with 
trichloroacetic acid and perchloric acid. When using 
this procedure a large peak appeared in the blank extract 
at 3,95 minutes but this did not interfere with the drugs 
of interest. 
Solvent extraction with a chloroform-ethyl acetate (85:15) 
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mixture was previously found to be suitable for the 
extraction of TMP and SMZ from urine (see Section 4.2). 
When this procedure was applied to serum samples, it was 
necessary to saturate the aqueous phase, prior to 
extraction with sodium chloride to enable quantitative 
recovery. The final method utilized (extraction XVII) 
was found to give fairly good recoveries for both drugs. 
In addition, this approach provided a 'clean' extract for 
the analysis since the use of less polar, water-immiscible 
organic solvents results in the extraction of fewer polar 
impurities. 
Since the addition of an alcohol to an organic solvent 
extractant has been found to reduce the likelihoo d o f 
adsorption to glass or to protein 38C , the effect of combining 
a small quantity of methanol with a chloroform-ethyl acetate 
mixture (extraction XVIII) was investigated. This method 
did not, however, yield adequate SMZ recovery. 
Extraction with methylene chloride (dichloromethane) followed 
by addi tion of ethanol' 23 (extr action XXIV,) was found to 
yield good recove ries for both TMP and SMZ. The presence 
of a large salt deposit in the dry residue, however, limited 
the use of this technique for the present analysis. 
It was thought that combinations of ethyl acetate, which 
is commonly utilized as an extractant for SMZ 78 , with 
water-miscible organic protein precipitants may yield a 
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sample preparation system which would result in an adequate 
recovery of both drugs. using sodium chloride as the 
inorganic salt to effect phase separation, good recoveries 
were obtained with acetonitrile-ethyl acetate, isopropanol-
ethyl acetate and ethanol-ethyl acetate combinations 
(extractions XIX, XXII and XXIII respectively). Of these 
combinations, acetonitrile-ethyl acetate was considered most 
suitable since only a very small deposit of salts was present 
in the dry extract. Reconstitution in a small volume of 
solvent produced a clear solution for injection and peaks 
present in the chromatogram of a blank serum sample were 
not excessively large. The use of other inorganic salts, 
i.e. sodium carbonate and sodium sulphate, in conjunction 
with an acetonitrile-ethyl acetate mixture (extractions XX 
and XXI) yielded lower recoveries than those obtained when 
sodium chloride was employed. It was found that similar 
results were obtained whether samples were mixed using a 
vortex mixer or by shaking slowly on a mechanical reciprocating 
shaker. 
Thus it was found that several of the sample preparation 
systems investigated would yield adequate recoveries of 
both TMP and 5MZ from serum. Hence the selection of a 
suitable method depended to a large extent on the appearance 
of the extract before and after reconstitution, the relative 
size and nature of background peaks appearing in the 
chromatogram and the simplicity of the procedure. The 
final method selected for more thorough evaluation with 
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regard to its possible application for the TMP-SMZ analysis 
was that involving extraction with an acetonitrile-ethyl 
acetate (1:1) combination and employing sodium chloride as 
the inorganic salt to enable separation of the organic phase 
(extraction XIX). The procedure was slightly modified when 
applied to the final serum assay in that the extract was 
reconstituted in the mobile phase instead of in methanol. 
The method is relatively simple and rapid; simplicity of 
the extraction procedure tends to enhance its reproducibility. 
An analytically 'clean' extract is produced. When applied 
to blank serum samples, a chromatogram similar to that 
depicted in Figure 4.5(b) was obtained . Background peaks 
eluting between 1,5 and 4,8 minutes were fairly small and 
did not interfere with the analysis . The very small peak 
appearing at 7,9 minutes overlapped, however, with the SMZ 
peak. This peak was found to be present in the blank serum 
irrespective of the extraction methodology utilized or the 
wavelength employed for the detection. Several attempts 
to separate this peak from the other components by altering 
various chromatographic parameters and conditions proved 
unsuccessful. 
Based upon this preliminary study, the percentage recovery 
of both drugs using the selected procedure was adequate . 
It must be borne in mind, however, that the quantities of 
SMZ and TMP incorporated into the 'spiked' serum in this 
instance were lower and higher respectively than those that 
would normally be encountered . These amounts were chosen 
so as to produce peaks of a suitable size at the wavelength 
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used. The recovery of N4-acetyl-SMZ was not evaluated 
during these preliminary studies. 
The selected method, as well as several of the other methods 
investigated, indicate recovery values exceeding 100% for 
TMP. This may be due, possibly, to incomplete partitioning 
of the organic solvent from the aqueous phase. Thus, a 
small portion of the acetonitrile, or other water-miscible 
organic solvent, may remain dissolved in the aqueous layer 
thereby resulting in a lower volume of the organic phase 
than expected. This reduced volume would give rise to an 
ap~arently increased recovery when compared to the standard 
solution. Recoveries exceeding 100 % are not encountered 
when water-immiscib l e organic solvents, such as chloroform-
ethyl acetate (85:15), are utilized. In addition, salts 
which tend to dehydra t e the aqueous layer, e.g. sod ium 
sulphate, do not produce this effect. These observations 
tend to support the above explanation. The same amount of 
internal standard should be present in both extracted samples 
and standard solutions since this was added as a final step. 
However, an inadvertant small l oss of the internal standard 
in the serum samples, due possibly to adsorption to unknown 
constituents in t he extract, could also result in an 
apparently highe·r recovery for TMP when compared to the 
standard solution in methanol . The use of radioisotopically 
labelled compounds would be valuable for the determination 
of over-all r ecovery when developing and applying extraction 
methods. 
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For a quantitative extraction, however, the most important 
factor is the reproducibility of the recoveries at all 
concentration levels. Losses as high as 50%102 can be 
tolerated if reproducibility is good. The higher the 
recovery obtained, however, the more likely it is that 
r eproduc ibility will be suitable. 
(ii) Chromatographic conditions: 
The selection of the mobile phase and other chromatographic 
conditions utilized are discussed in Section 4.3.2. The 
detector wavelengths employed for these preliminary 
investigations were 270 nm and 280 nm. These are not 
i deal in that, at the concentration levels normally 
encountered in serum, they will result in too larg e a 
sulphonamide peak in relation to the TMP peak. These 
wavelengths were, however, not used for the final assay, 
for the above reason. 
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4.3.2 Analysis in Serum: 
A. Experimental: 
(i) Standard solutions: 
Trimethoprim stock solution ; 6,00 mg TMP per 100 ml of 
methanol. 
Sulphamethoxazole stock solution ; 
methanol . 
30,00 mg SMZ per 100 ml 
N4 -acetylsulphamethoxazole stock solution ; 
N4-acetyl-SMZ per 100 ml methanol. 
15,00 mg 
Working internal standard solution. This solution consisted 
of 6 ~g ml -1 sulphafurazole (SFZ) in acetonitrile. 
Internal standard solution for recovery studies . This 
solution contained 15,00 mg sUlphafurazole per 50 ml of the 
mobile phase (1% acetic acid-methanol 80:20) . 
dissolved with the aid of an ultrasonic bath. 
The drug was 
All standard solutions used were freshly prepared. However, 
if stored at 4°C, solutions in methanol and acetonitrile were 
found to be stable for up to two months as determined by 
HPLC. 
(ii) Preparation of "spiked" serum samples: 
The method utilized for fortifying control serum with known 
amounts of pure drugs was carried out in the following 
manner. 
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Suitable aliquots of the TMP, SM2 and N'-acetyl-SM2 stock 
solutions were transferred to a ground-glass stoppered 
flask. The final solution was then evaporated to dryness 
at 50 °C under a gentle stream of nitrogen. Once dry, 
sufficient serum was added so as to yield the required 
concentration levels. The flask was then gently shaken 
for 4-5 hours at room temperature to ensure complete 
dissolution of all drugs in the serum. From this bulk 
serum pool dilutions could be made if required. 
(iii) Chromatographic conditions and quantitation: 
The following chromatographic conditions were utilized: 
Column: C,a reverse-phase (~Bondapak C,a) 
HPLC system: A (see Section 4.1.3.1) 
Detection wavelength: 230 nm 
Sensitivity: 0,020 A.U.F.S. 
Chart speed: 12 inches hr-1 
Flow rate: 1,5 ml min-1 
Pressure: 1250 p.s.i. 
Temperature: 30°C 
Mobile phase: 1% acetic acid - methanol 80:20 (vol/vol). 
Preparation of mobile phase: 
The mobile phase was prepared as described in Section 4.3.1. 
Quantitation: 
Peak height ratios were calculated by dividing the peak 
height corresponding to the drug by the peak height 
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corresponding to the internal standard. These ratios were 
quantitated by comparison with ratios obtained from the 
analysis of s t andards containing known concentrations of 
drugs. 
(iv) Extraction procedure: 
To 1 ml serum in a test tub e (Vacutainer(R)) was added 3 ml 
acetonitrile containing 6 ~g sulphafurazole per ml as internal 
standard. The tube was then stoppered and thoroughly mixed 
on a vortex mixer for 30 seconds. The mixture was allowed 
to stand for 15 minutes to ensure complete protein 
precipitation. Three ml ethyl acetate 
the tube was sea led with Parafilm(R). 
on a vortex mixer set at low speed, to 
reached the Parafilm(R) surface, for 1 
was then added and 
It was then mixed 
ensure that no liquid 
minute. The sample 
was a llowed to stand for 30 minutes and then re-mixed. 
To the mixture was added an excess of sodium chloride (0,4 g) 
in order to saturate the aqueous layer. The tube was re-
sealed with parafilm(R), vortexed briefly and allowed to 
stand for 30 minutes with intermittent mixing, to ensure 
complete solu tion of the sodium chloride. Vigorous mixing 
at this stage may lead to slight emulsification and hence 
must be avoided. The mixture was then centrifuged at 
3000 r.p.m. for 15 minutes. Five ml of the clear upper 
layer was transferred to a finely tapered centrifuge tube 
and evaporated to dryness at 50°C under a gentle stream of 
nitrogen. The sides of the tube were carefully washed 
down with methanol during drying . 
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The dry extract was then reconstituted in 50 ~l of the 
mobile phase and the centrifuge tube sealed as before. 
It was mixed thoroughly on a vortex mixer and placed in an 
ultrasonic bath fo r 1 minute to ensure complete solution of 
the drugs. The sample was then left to stand, with 
occasional mixing, for 15 minutes. Finally, it was 
centrifuged at 3000 r.p.m. for 15 minutes and 1-10 ~l of 
the clear supernatant was injected onto the column. 
(v) Calibration curves: 
Control serum was fortified with pure drugs to yield five 
serum pools containing different concentrations of each 
drug. The range of serum concentrations produced varied 
between 0, 25 and 3,00 ~g ml -1 for TMP, between 5,00 and 
60,00 ~g ml-1 for SMZ and between 2,50 and 30,00 ~g ml-1 
for N'-acetyl-SMZ. Each serum pool was assayed in 
triplicate as described above. Ca~ibration curves were 
then constructed by plotting the ratios of the peak heights 
of each compound to that of the internal standard, SFZ, 
versus their respective concentrations. With all curves, 
a straight-line fit of the data was made by least-squares 
linear regression analysis. 
(vi) Precision: 
The within-run precision was assessed by spiking serum 
with TMP, SMZ and N'-acetyl-SMZ to yield two different 
concentrations of each drug, corresponding approximately 
to the lower and upper limits of the therapeutic ranges 
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expected. six samples at each concentration level were 
than carried through the entire analytical procedure. 
(vii) Extraction Efficiency: 
The analytical recoveries of TMP, SMZ and N4 -acetyl-SMZ were 
evaluated at four different serum concentrations. At each 
concentration level, samples were assayed in triplicate. 
The analytical protocol utilized was as described above 
except that the following modifications were implemented 
for this particular study: 
(a) All glassware was silanized prior to use with a 5% 
solution of dimethyldichlorosilane in toluene. Following 
this treatment, the glassware was rinsed first with toluene, 
then with methanol and was finally dried. 
(b) The internal standard was omitted at the start of the 
extraction procedure; i.e. 3 ml pure acetonitrile was 
added to the serum sample. 
(c) The internal standard was added as a final step prior 
to injection of the sample; i.e. the dry extract was 
reconstituted in 50 ~l of a solution containing 15,00 mg 
SFZ per 50 ml of the mobile phase. 
Aliquots of each sample were then chromatographed and the 
peak height ratios calculated for each component. In order 
to determine the percentage recovery, these ratios were 
compared with those obtained from the injection of standard 
solutions in the mobile phase which were prepared so as to 
contain pure drugs in concentrations corresponding exactly 
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to those expected if 100% recovery were to have occurred 
during the extraction procedure. These standard solutions 
were prepared by addition of the appropriate amounts of 
pure TMP, SMZ and N4-acetyl-SMZ respectively in acetonitrile-
ethyl acetate (1:1) solution to tapered centrifuge tubes in 
order to obtain the required final concentrations. These 
solutions were then evaporated to dryness under nitrogen 
and the residues were reconstituted in 50 ~l of a solution 
containing 15,00 mg SFZ per 50 ml of the mobile phase. 
Thus, the internal standard was present in identical 
quantities in both extracted samples and standard solutions. 
since it was not carried through the extraction procedure, 
the value of the internal standard in this case was to 
account for variations in sample volumes injected. 
Recovery of the internal standard, SFZ, during the 
extraction procedure was also ascertained. Pure samples 
were injected for comparison. In this case, TMP was 
employed as the correction standard by addition of a fixed 
amount (3 ~g) as a final step to all samples. 
B. Results and Discussion: 
Chromatograms obtained following the injection of an extract 
of serum fortified with TMP, SMZ and N4-acetyl-SMZ and of a 
blank serum extract are depicted in Figures 4.6(a) and (b) 
respectively. Under these conditions, the retention times 
were as follows: 
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Fig. 4.6(a). Chromatogram of an extract of serum containing 
1,07 \Jg mIl TMP, 19,48 \Jg mr' SM2 and 20,62 \Jg ml-' N"-acetyl-SM2. 
Chromatographic conditions as in Section 4.3.2. The arrow 
denotes the time of sample injection (5 \Jl injected). 
Peaks: 
2 1 = TMP 
2 = SM2 
3 = internal standard, 
sulphafurazole 
4 = N"-acetyl-SM2 
3 
4 
1 
1 \ 
I I I I 
o 5 10 15 20 
RETENTIGN TIME, min. 
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Fig. 4.6(b). Chromatogram of a blank serum extract. 
Chromatographic conditions as in Section 4.3.2. The arrow 
denotes the time of sample injection (7 ~l inj ected). 
1 
o 5 10 15 20 
RETENTION TIME, min. 
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TMP 5, 7 minutes 
SMZ 7,5 minutes 
Internal standard, SFZ 9,3 minutes 
N4-acetyl-SMZ 16,7 minutes 
All peaks were well resolved and symmetrical. 
When subjected to the analysis, serum samples obtained 
from volunteers after the ingestion of Co-trimoxazole 
tablets (each containing 80 mg TMP and 400 mg SMZ) were 
found to yield chromatograms identical to those produced 
when fortified serum pools were analysed. Thus no 
additional peaks, due perhaps to the other metabolites 
of these drugs, were evident. 
(i) Linearity : 
Calibration curves (see F ig. 4 . 7) for all compounds were 
found to be linear over the entire range of concentrations 
studied. Table 4.4 lists the constants of the respective 
linear regression lines. 
TABLE 4.4: 
LINEAR REGRESSION DATA FOR CALIBRATION CURVES IN SERUMa . 
Drug Concentration Slope . t b Correlation Range, fl9 ml-l. Y-ln ercept Coefficient 
'IMP 0,25 - 3,00 0,9426 -0,0631 0,9935 
SMZ 5,00 - 60,00 0,1149 -0,2466 0,9988 
N4-acetyl-SMZ 2,50 - 30,00 0,0778 -0,1218 0,9904 
a. Analysis using Cia reverse-phase column . 
b. Peak height ratios are plotted on the y-axis and serum 
drug concentrations in fl9 ml -Ion the x-axis . 
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Fig. 4.7. Calibration curves for (a) TMP, (b) SMZ and 
(c) N4-acetyl-SMZ in serum. Peak height ratio: ratio of 
peak height of indicated drug to that of the internal 
standard, sulphafurazole. 
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Drug concentrations normally encountered in the serum 
during therapy fall within the linear range of the 
calibration curves. 
(ii) Precision: 
The results of the within-run precision studies carried out 
on fortified pools of serum are listed in Table 4.5. 
TABLE 4.5: 
WITHIN-RUN PRECISION OF ASSAY IN SERUMa . 
Concentration found, jlg ml-1 
Sample No. TMP SMZ N4-acetyl-SMZ 
1 0,64 1,56 11,86 33,26 5 , 80 16,20 
2 0,58 1,62 11,68 35,81 5,57 15,63 
3 0,59 1,71 12,00 36,70 5,68 16,03 
4 0,60 1,65 10,91 34,46 5,66 15,18 
5 0,57 1,60 11,64 36,78 6,03 16,81 
6 0,61 1,64 11,91 33,66 5,66 15,31 
MEAN 0,60 1,63 11,67 35,11 5,73 15,86 
Standard 0,023 0,046 0,361 1,400 0,149 0,557 Deviation 
Coefficient 
of varia= 3,78 2,83 3,09 3,99 2,60 3,52 
tion, % 
a. Analysis using C 1 S reverse-phase column. 
These results indicate the method to be reproduc ible. 
Coefficients of variation for all drugs at all concentra= 
tion levels s tudied are within the generally accepted limits 
for drug assays. 
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(iii) Extraction Efficiency: 
The analytical recoveries of TMP, SMZ and N4-acetyl-SMZ 
from serum are depicted in Table 4.6. 
TABLE 4.6: 
ANALYTICAL RECOVERY OF DRUGS FROM FORTIFIED POOLS OF SERUMa . 
Serum RecOllery, % 
Drug Concentration, Sample No. Mean Standard 119 ml -1 1 2 3 Deviation 
'IMP 1,23 107,9 100,6 98,3 102,3 4,1 
2,16 100,4 102,6 102,0 101,7 0,9 
3,08 102,8 99,6 94,2 98,9 3,5 
SMZ 5,95 77,6 77,9 - 77 ,8 0,2 
23,79 72,6 71,5 75,8 73,3 1,8 
41,64 76,1 73,4 77,0 75,5 1,5 
59,48 77,4 78,S 79,3 78,4 0,8 
N4-acetyl-SMZ 3,09 78,4 73,8 - 76,1 2,3 
12,35 70,3 68,7 69,6 69,5 0,7 
21,62 69,7 72,0 72,2 71,3 1,1 
30,88 74,6 70,5 71,1 72,1 1,8 
a. Analysis using C 1 B rever se-phase column. 
These results indicate that the recovery of each drug is 
fairly consistent and quantitative at the concentration 
levels studied. Mean values obtained were 101,0%, 76,3% 
and 72,3% recovery for TMP, SMZ and N4-acetyl-SMZ respectively. 
Prior dilution of the serum (by addition of an equal volume of 
distilled water) did not enhance the efficiency of extraction. 
Mean recovery of the internal standard, SFZ, was found to be 
97,9%. 
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Problems of variable and anomalous recoveries were 
experienced during preliminary studies. Unusually high 
values were obtained especially in the case of TMP. 
Apparent recoveries greatly in excess of 100 % were 
recorded for this drug. It appeared that inadvertent 
losses of the internal standard in the extracted samples 
were largely responsible for these high values. Since 
the role of the internal standard for this determination 
was merely to check injection volumes, care must be taken 
to ensure that identical quantities are present in final 
samples of both extracted serum and standard solutions. 
Adherence of the internal standard to unknown compon e nts 
in the final serum extract may represent one possible source 
of loss. The effect was not particularly pronounced if the 
internal standard was dissolved in the mobile phase and added 
to samples prior to injection. However, if the required 
amount of internal standard in methanol solution was added 
to both extracted samples and pure standards, followed by 
ev~poration to dryness and then reconstitution in the mobile 
phase, particularly high and variable recoveries were 
observed. 
Adsorption of drugs onto glass was found to be involved in 
the variability e ncountered during initial assessments of 
extraction efficiency. TMP adsorption has been reported B6 • 
Lanbeck and Lindstrom l " have also suggested that variable 
recoveries of sulphapyridine and sulphamethazine observed 
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when analyzing these drugs in plasma may be due to varying 
adsorption losses caused by the primary amino groups in 
these sulphonamides . It has been found that adsorption 
of drugs by var ious types of glassware 58, I 02,124 and even 
the source of glass tubes used in the extractiod 24 can 
markedly affect the reproducibility and efficiency of the 
extraction. This problem can be overcome by silanization 
of the glass58 ,10 2 . In this case, silanization appeared 
to rectify problems of high and variable recoveries and 
the results depicted in Table 4.6 were obtained. It is 
thus recommended that, for this determination, glassware 
should be inactivated by silanization. 
Losses during the evaporation step may be responsible for 
variability in drug recovery, as suggested by Proelss, et al./ 2 5 
in studies on tricyclic antidepressants. However, since the 
standard solutions were also subjected to an evaporation 
procedure, it was considered unlikely that variable losses 
were occurring at this stage. 
It has been suggested l 4 5 that recoveries of sulphonamides 
(sulphamethoxazole, sulphapyridine and acetylsulphapyridine) 
may be dependent on protein concentration of samples. The 
extent to which this may apply to the present analysis ~s 
not known. 
(iv) Sensitivity and Detection Limit: 
The principal sensitivity problem is associated with TMP since 
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relati ve ly low serum concentration levels of this drug are 
encountered during Co-trimoxazole therapy. Under the 
conditions of this assay, the detection limit for TMP was 
established as 0,10 ~g ml-I serum. This is adequate for 
pharmacokinetic studies involving TMP. In addition, the 
most sensitive of the various analytical methods currently 
available for the determination of TMP in biological fluids 
70,86,92 
also report a minimum detectable quantity of 0, 10 ~g ml - I . 
This lower limit of sensitivity is significantly better than 
tha t obtained by Vree et a1., 96 (0, 75 ~g ml _I) who have 
recently described an HPLC method for the simultaneous 
determination of TMP, SMZ and N4 -acetyl-SMZ in biological 
flui ds. 
The detection limit for both SMZ and its N4 -acetylated 
metabolite under the described conditions was found to be 
1,00 ~g ml -I. This provides adequate sensitivity for the 
determination of levels of these drugs normally encountered 
in the serum during treatment with Co-trimoxazole. 
If very low levels of drugs are expected, it would be 
advantageous to incorporate less internal standard in order 
to retain useful peak height ratios. It may also be possible 
to increase accuracy when measuring very low concentrations 
of drugs, especially TMP, by addition of known amounts of 
the p articular drug to the samples prior to extraction. 
Signal-to-noise ratios would thus be improved. The amount 
of drug present could then be determined by difference. 
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It may be possible to reduce detection limits by increasing 
detector sensitivity specifically for each drug. Fluorescence 
detection is generally more sensitive 91 and, since both TMP72 
and SMZ 126 have been found to exhibit native fluorescence, 
this technique may be useful for the analysis. However, a 
recent HPLC method for the determination of TMP using 
fluorescence detection 92 reported a minimum detectable 
quantity similar to that obtained in the present analysis. 
Increased sensitivity for SMZ and N4-acetyl-SMZ can be gained 
by monitoring these drugs at a higher wavelength (_260 nm) 
which is closer to the absorbance maxima for these compounds. 
Improved detection limits by the use of larger volumes of 
serum or greater concentration of the extracts is not 
feasable since the presence of large amounts of serum 
components would make it difficult to inject the required 
aliquot. In general, however, the proposed method is 
sufficiently sensitive for all clinical applications. 
(v) Background and Interferences : 
When processed by this procedure, blank sera obtained from 
several patients yielded chromatograms showing background 
peaks similar to those depicted in Fig. 4.6(b). The 
relative sizes of these peaks varied slightly among the 
different patients. Serum peaks eluting early in the 
chromatogram did not interfere with the analysis. However 
a small peak appeared at a retention time of 7,3 minutes in 
blank serum and this overlapped with the SMZ peak. The 
elution time of this peak was found to correspond to that 
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of caffeine in serum. Carr, et al. , 58 have also reported 
the presence of a small peak in random plasma samples which 
has a retention time equal to that of caffeine. Caffeine-
containing beverages and preparations should therefore be 
avoided in pharmacokinetic and therapeutic drug monitoring 
where this assay method is being employed for serum samples. 
Several attempts to separate this small peak from the other 
components by altering various chromatographic parameters 
and conditions proved unsuccessful. Possibly analyses 
should be conducted on blank patient sera to ensure that it 
does not constitute a significant interference. 
Solutions of acetylsalicylic acid and salicylic acid were 
also tested for possible interference . Peaks for both 
compounds gave an identical retpntion time of 12,5 minutes 
which did not interfere with any of the compounds of interest. 
(vi) Extraction Procedure: 
The choice of the extraction procedure utilized for this 
determination is discussed in Section 4.3.1. 
Reconstitution of the final dry extracts in the mobile phase 
as opposed to methanol markedly improved resolution and peak 
shape s obtained on injection of the samples. A chromatogram 
produced when a serum extract was dissolved in 50 ~l methanol 
prior to injec tion is depicted in Fig. 4.8. When compared 
to the chromatogram shown in Fig. 4.6(a) which was obtained 
when the mobile phase was utilized for reconstitution, the 
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Fig. 4.8. Chromatogram obtained on reconstitution of the 
final serum ex tract in methanol prior to injection, in place 
of the mobile phase. Drug concentrations and chromatographic 
conditions as in Fig. 4.6(a). The arrow denotes the time of 
sample injection (7 ~l injected). 
Peaks: 
1 = TMP 
2 = SMZ 
3 = internal standard, 
2 sulphafurazole 
4 = N4-acetyl-SMZ 
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improvement is clearly apparent. Identical chromatographic 
conditions were employed for both samples. Reconstitution 
in the mobile phase also avoids the large methanol peak 
occurring initially in the chromatogram. 
Hence, injection band broadening appears to occur when the 
extracts are reconstituted in methanol. This is probably 
due to a large extent to precipitation of components in the 
samples when they come into contact with the mobile phase. 
However, the use of methanol itself as the solvent for 
injected samples is also involved since resolution and peak 
shape obtained with pure drugs in methanol solution was not 
as good as that produced by similar samples in the 
predominantly aqueous mobile phase. The band spreading 
effect may have been enhanced if any area of dead volume 
was present within the injector system. 
It was found that when serum samples were reconstituted in 
the mobile phase a precipitate appeared which had to be 
removed by centrifugation, whereas this did not occur when 
re-dissolving in methanol. Hence, reconstitution in the 
mobile phase is likely to prolong column life by removing 
these components prior to injection. The nature of the 
precipitate formed is not known although it may possibly 
be due to residual protein in the sample. Protein 
precipitation procedures are never 100 % efficient 91 • 
A possible problem associated with the reconstitution of 
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samples in the mobile phase is that the drugs may not 
readily dissolve in this solution. Sonication can be used 
to greatly enhance the rate at which compounds dissolve and 
was utilized for this study to ensure complete solution of 
all drugs. However, results obtained with and without 
sonication were identical. In addition, use of larger 
volumes of the mobile phase for reconstitution of samples 
yielded results identical to those obtained when a volume 
of 50 ~l was employed. Thus, it appeared that all drugs 
were adequately soluble in the small volumes of solvent 
utilized for reconstitution. 
The dry serum extracts before reconstitution were found to 
be stable for up to 5 days when kept at room temperature. 
(vii) Chromatographic Conditions: 
Mobile Phase: 
(a) Reverse-Phase Chromatography: 
Solutions of pure drugs in methanol were initially chromato= 
graphed to select a suitable mobile phase. Binary mixtures 
consisting of various proportions of methanol-water, methanol-
acetate buffer and methanol-dilute acetic acid were tested 
as mobile phases in the preliminary studies. A solvent 
system comprising 1% acetic acid-methanol 70:30 (vol/vol) 
at a flow rate of 1,2 ml min~ was found to yield 
satisfactory retention, resolution and symmetrical peak 
shapes. When applied to the chromatography of biological 
samples, however, it was found that the TMP peak overlapped 
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with peaks of endogenous substances. Adjustment of the 
mobile phase composition to y ield a 1 % acetic acid-methanol 
80:20 (vol/vol) mixture resulted in good separation of TMP 
from these serum peaks. Satisfactory resolution and 
efficiency was obtained with this mobile phase and it was 
selected for the analysis. 
In reverse-phase HPLC the chromatographic behaviour is often 
predictable on the basis of pH of the eluent and the pKa and 
partition coefficient of the eluate 124 • Adjusting the pH 
on the acid side would suppress ionization of the acidic 
SMZ and result in increased retention of this compound on 
the column. This technique is termed ion suppression l17 • 
At this pH, TMP would be present in the predominantly ionic 
form and hence would elute more rapidly . This elution 
sequence is favourable as TMP tended to "tail" when retention 
on the column was prolonged. In addition, since TMP is 
usually present in a far lower concentration than SMZ, the 
sharper peak produced by early elution of this compound 
allows for more accurate quantitation. 
(b) Ion-Pair ChromatograP0Y: 
Weak acids and weak bases can also be simultaneously analysed 
by paired-ion chromatography IlB. Adequate resolution of TMP 
and SMZ was obtained with a mobile phase consisting of 
methanol-water 45:55 (vol/vol) which contained heptane 
sulphonate (5 mmol l~, PIC B-7: Waters Associates ) as the 
counter-ion. The flow rate of the mobile phase (pH = 3,6) 
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was set out 1,6 ml min-I (1400 p.s.i.) and the separation was 
performed at ambient temperature. A chromatogram produced 
under these conditions is depicted in Fig. 4.9. 
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Fig. 4.9. Separation of TMP, 
SMZ and the internal standard, 
sulphaphenazole, on a ~Bondapak 
CIS column using methanol-water 
45:55 containing PIC B-7 (heptane 
sulphonate, 5 mmol 1 -1; Waters 
Associates) as the mobile phase 
at a flow rate of 1,6 ml min - I. 
The ar row denotes the time of 
sample injection. 
Peaks: 
1 = solvent (methanol) 
2 = SMZ 
3 = inte rnal standard, 
sulphaphenazole 
4 = TMP 
Sulphaphenazole could be employed as an internal standard. 
In this case, ion-pair formation between protonated TMP 
molecules and heptane sulphonate anions would result in a 
neutral and non-polar complex which shows increased retention 
on the reverse-phase column. This system could have been 
employed for the present analysis. Its application to 
biological fluids and the retention time of N'-acetyl-SMZ 
were not, however, investigated here . 
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Temperature and Flow Rate: 
The primary reason for using elevated temperatures is to 
reduce the viscosity of the eluting solvent resulting, often, 
in improved resolution. This provides lower operating 
pressures and increased efficiency as a result of the greater 
solute diffusion and faster mass transfer experienced with 
low viscosity eluents. Reverse-phase separations often 
imply that some water is used in the eluting phase . Water 
has a relatively high viscosity. Thus elevated temperatures 
may frequently be advantageous for reverse-phase work. 
At ambient temperature (_20·C), a flow rate of 2,2 ml min~ 
(1950 p.s.i.) was required in order to provide conditions 
of maximum resolution with minimum analysis time for the 
assay of serum samples. Under these conditions, the 
retention time of the final peak in the chromatogram, 
N ~-acetyl-SMZ, was 22,4 minutes. Operation at 30·C enabled 
use of lower flow rates and pressures (1,5 ml min~; 1250 
p.s.i.) and decreased analysis time (retention time of 16,7 
minutes for N~-acetyl-SMZ) whilst improving resolution and 
peak symmetry. Temperatures exceeding 30·C resulted in 
overlap between TMP and serum peaks and hence could not be 
used. 
Use of elevated temperatures also avoids variations 
associated with fluctuations in the ambient temperature . 
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Detection: 
In view of the fact that the mean serum concentration ratio 
of 5MZ to TMP is approximately 20:1, it was necessary to have 
a detection system that is considerably more sensitive for 
TMP in order to obtain responses of a similar magnitude for 
all components. Using a UV detection system, a wavelength 
of 230 nm proved to be optimal for this determination; at 
this wavelength the absorbance of TMP is five times that of 
5MZ on a weight basis (see Fig. 4.10). This enabled use of 
a single internal standard to quantitate both drugs, easy 
measurement of peak heights and a simultaneous analysis 
without the need to selectively attenuate certain peaks. 
When applied to the analysis of serum samples, the slightly 
lower recoveries obtained for 5MZ will, in addition, further 
reduce discrepancies in relative peak heights. 
At 230 nm, the molar response factors relative to the internal 
standard, sulphafurazole, were calculated by analyzing standard 
samples and were found to have the following values: 
TMP 0,27 
5MZ 
N'-acetyl-5MZ 
1,13 
0,69 
A detection wavelength of 225 nm was employed by Vree et al.,96 
for the simultaneous determination of TMP and 5MZ. Use of 
this wavelength will often result in too large a 5MZ peak in 
relation to the TMP peak, making simultaneous determination 
from serum difficult. 
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Fig. 4.10. Ultraviolet absorption spectra of 6 ~ g m14 
TMP and SMZ in 1 % acetic acid-methanol 80:20 (vol/vol) . 
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4.3.3 Analysis in Urine: 
A. Experimental: 
(i) Standard solutions: 
TMP, SMZ and N4 -acetyl- SMZ stock solutions. Each stock 
solution contained 50,00 mg of the relevant drug per 50 ml 
of methanol. 
Working internal standard solution. This solution consisted 
of 75 Ilg ml -I sulphafurazole (SFZ) in acetonitrile. 
Internal standard solution for recovery studies. This 
solution contained 75 mg SFZ per 50 ml of methanol. 
All standard solutions were freshly prepared. 
(ii) Preparation of "spiked" urine samples: 
Th e procedure employed for fortifying control urine with 
known amounts of pure drugs was similar to that described 
for the preparation of "spiked" serum (Section 4.3.2). 
(iii) Chromatographic conditions and quantitation: 
The following chromatographic conditions were utilized: 
Column: C IS reverse-phase (IlBondapak CIS) 
HPLC system: A (see section 4.1.3.1) 
Detection wavelength: 230 nm 
Sensitivity: 0,080 A.U.F.S. 
Chart speed: 12 inches hr-I 
Flow rate: 1,5 ml min-I 
Pressure: 1400 p.s.i. 
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Temperature: Ambient (20 - 24°C) 
Mobile phase: 1 % acetic acid-methanol 80:20 (vol/vol). 
Preparation of mobile phase: 
The mobile phase was prepared as described in Section 4.3.1. 
Quantitation: 
Peak height ratios were used for the quantitation based on 
calibration curves established on the same day. 
(iv) Extraction procedure: 
To a 1 ml urine sample in a test tube (Vacutainer(R» was 
added an equal volume of pH 7,2 Sorensen's phosphate buffer 127. 
Sodium hydroxide solution (0,1 N) was added as required in 
order to adjust the pH of the mixture to 7,2. Two ml 
acetonitrile containing 75 ~g ml ~ SFZ as internal standard 
was then transferred to the tube. After sealing with 
parafilm(R), the tube was thoroughly mixed on a vortex mixer 
for 30 seconds. The solution was left to stand for a period 
of 30 minutes and then re-mixed. Excess sodium chloride 
(1,0 g) was added in order to saturate the aqueous phase. 
The sample was left to stand, with intermittent mi xing, for 
30 minutes to ensure complete solution of the sodium chloride. 
It was subsequently centrifuged at 3000 r.p.m . for 15 minutes. 
One ml of the clear upper layer was transferred to a tapered 
centrifuge tube. It was then evaporated to dryness at 50°C 
under a gentle stream of nitrogen. The sides of the tube 
were carefully washed down with methanol during drying . 
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The dry extract was reconstitu ted in 200 ~l of the mobile 
phase . The tube was sealed as before, mixed thoroughly and 
placed in an ultrasonic bath for 1 minute to ensure complete 
solution of all drugs. The sample was then left to s tand 
with occasional mixing for 15 minutes. Finally it was 
centrifuged at 3000 r.p.m. for 15 minutes and 1-10 ~l was 
injected onto the column. 
(v) Calibration curves and precision: 
Linearity and precision of the method were assessed by 
procedures similar to those employed for the serum analysis 
(Section 4.3.2) . The ranges of urinary drug concentrations 
employed for the calibration curves varied between 20,00 and 
200,00 ~g ml ~ for TMP, between 25,00 and 250 ,00 ~g ml' for 
SMZ and between 40,00 and 400,00 ~g ml' foe N"-acetyl-SMZ. 
(vi) Extraction efficiency: 
The analytical recoveries of TMP, SMZ and N"-acety l-SMZ from 
urine were evaluated at three different concentrations. 
Samples at each concentration level were analysed in tripli~ 
cate. With the exception of the following modifications, the 
ana l yt ical procedure previously described was employed: 
(a) The internal standard was omitted at the start of the 
extrac tion procedure; i.e. 2 ml pure acetonitrile was added 
to the urine sample. 
(b) A fixed aliquot of the internal standard in methanol 
solution was added to all dry samples after ext raction; i.e. 
50 ~l of a solution containing 75 mg SFZ per 50 ml methanol 
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was added. The methanol was subsequently removed by 
evaporation at 50°C. 
After reconstitution of the final samples in the mobile 
phase, aliquots of each were chromatographed. The results 
were compared with the peak height ratios obtained from the 
injection of standard solutions which contained pure drugs 
in concentrations equal to those expected if 100% recovery 
were to have occurred during the extraction. The same 
concentration of internal standard was present in both 
extracted samples and standard solutions. 
B. Results and Discussion: 
Chromatograms obtained following the injection of an extract 
of urine fortified with TMP, 8MZ and N4 -acetyl-8MZ and of a 
blank urine extract are shown in Figures 4.11 (a) and (b) 
respectively. Under these conditions, the retention times 
were as follows: 
TMP 
8MZ 
Internal standard, 8FZ 
N4 -acetyl-8MZ 
6,7 minutes 
8,5 minutes 
10,8 minutes 
20,1 minutes 
Chromatograms of urine samples obtained from normal subjects 
after receiving Co-trimoxazole were identical to those 
obtajned when "spiked" urine samples were assayed. No 
additional peaks or peaks due to other metabolites of these 
drugs were evident. 
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Fig. 4.11(a). Chromatogram of an extract of urine containing 
100,12 ]1g mll TMP, 124,28 ]1g ml -I SMZ and 199,40 ]1g ml-I 
N"-acetyl-SMZ. Chromatographic conditions as in Section 
4.3.3. The arrow denotes the time of sample injection 
(3 ]11 injected). 
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1 = TMP 
2 = SMZ 
3 = in ternal standard, 
sUlphafurazole 
4 = N"-acetyl-SMZ 
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Fig. 4.11(b). Chromatogram of a blank urine extract. 
Chromatographic conditions as in Section 4.3.3. The arrow 
denotes the time of sample injection (10 ~l injected). 
1 
o 5 10 15 20 25 
RETENTION TIME, min . 
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(i) Linearity: 
Figure 4.12 depicts calibration curves obtained for TMP, SMZ 
and N'-acetyl-SMZ in urine. 
Linear regression data fo r the calibration curves (see Table 
4.7) indicated a high degree of linearity for all drugs over 
the entire range of concentrations studied. Levels of these 
drugs normally found in the urine during therapy fall within 
the line~r range of the calibration curvp.s. 
TABLE 4.7: 
LINEAR REGRESSION DATA FOR CALIBRATION CURVES IN URINE a . 
Drug Concentration Slope y-Interceptb Correlation Range, I1g mr""! Coefficient 
'IMP 20,00 - 200,00 0,0302 0,0397 0,9999 
SMZ 25,00 - 250,00 0,0070 0,0091 1,0000 
N'-acetyl-SMZ 40,00 - 400,00 0,0026 -0,0058 0,9997 
a. Analysis using CIS reve rse-pha se column. 
b. Peak height ratios are plotted on the y-axis and urine 
drug concentrations in I1g ml -Ion the x-axis.-
(ii) Precision: 
The results of the within-run precision studies carried out 
on fortified pools of urine are listed in Table 4.8 . 
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Fig. 4.12. Calibration curves for (a) TMP, (b) SMZ and 
(c) N4-acetyl-SMZ in urine. Peak height ratio:ratio of 
peak height of indicated drug to that of the internal 
standard, sulphafurazole. 
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TABLE 4 .8 : 
WITHIN-RUN PRECISION OF ASSAY IN URINEa . 
Concentration Found, jJg ml -, 
Sarrple No . 
N' -acety l-SMZ TMP SMZ 
1 18 ,93 200,51 23,57 247,47 40,88 399,19 
2 19,06 193,96 24,39 243,20 39,23 401,19 
3 19,75 204,25 25,43 250,70 36,88 389,15 
4 19,05 200,82 23, 57 249,01 38,04 382, 29 
5 19,64 205,61 24,64 247,29 39,85 405,62 
6 19,32 194,00 24,20 248,07 38,58 394,04 
Mean 19,29 199,86 24,30 247,62 38,91 395,25 
Standard 0,310 4,525 0,642 2,284 1,282 7,799 Deviation 
Coefficient of 1,60 2,26 2,64 0,92 3,29 1,97 Variation, % 
a. Analysis using C,a reverse-phase column. 
These results indicate the method to be highly reproducible. 
When assessing the precision associated with repeated injections 
of a single sample into the chromatograph, coefficients of 
variation of approximately 1,5% were obtained. This is 
extremely satisfactory since it probably represents var iation 
inherent in the instrumentation utilized and slight inaccuracies 
in the measurem ent of peak heights. The coefficient of variac 
tion for sampling, instrumental and calculation e rror s ha s been 
found by other worker S'19 to be approximately 2 %. 
(iii) Extraction efficiency: 
The recoveries o f TMP, SMZ and N'-acetyl-SMZ from urine a r e 
given in Table 4.9. Th e values obtained were found to be 
fairly consistent and quantitative at all the concentration 
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levels studied, with mean recoveries of 91,0%, 121,5% and 
88,7% for TMP, SMZ and N'-acetyl-SMZ r espectively. Recovery 
of SMZ was found to increase slightly with increasing 
concentrations. This enhanced recovery of drugs as the 
concentration increases has been observed by others l25 • 
Recoveries exceeding 100% were found for SMZ. Failure to 
silanize the glassware in this determination may account for 
the high values obtained. Drug recoveries exceeding 100% 
have also been reported by other workers l 2 3 • 
TABLE 4.9: 
ANALYTICAL RECOVERY OF DRUGS FROM FORTIFIED POOLS 
OF URINE a . 
Urine Recovery, % 
Drug Concentr ation, Sample No. 
].Jg ml-1 Mean 1 2 3 
TMP 20 ,02 91,9 91,3 91,6 91,6 
100,12 90,0 91,8 91,6 91,1 
200,24 87,5 91,9 91,6 90,3 
SMZ 24,86 114,6 119,1 120,0 117,9 
124,28 121,4 121,1 121,2 121, 2 
248 ,55 126,3 126,3 123,7 125,4 
N' - acety I-Sl<lZ 39 ,88 86 ,7 88,5 87,5 87,6 
199,40 88,4b 92,4b 88,5 89,8b 398,80 84,6 87,1 - 85,9 
a. Analysis using CIS reverse-phase column. 
S.D. 
0;2 
0,8 
2,0 
2,4 
0,1 
1,2 
0,7 
1,9b 1,3 
b. For these samples, urine extracts and standards , both 
evaporated to dryness, were kept at room temperature for 6 
days before analysis. Instability was observed after this 
time since peak height ratios, particularly for the standard 
samples, were low and variable. These results were calculated 
by comparing values obtained for urine extracts at this 
concentration level with standards containing known amounts 
of pure drug at a lower concentration level (199,40 ].Jg ml -I). 
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(iv) Sensitivity and detection limit: 
Under the conditions of this assay, the detection limits for 
TMP, SM2 and N4-acetyl-SM2 were established as 0,50; 5,00 
and 10,00 ~g ml -1 respectively. This p rovides adequate 
sensitivity for all clinical applications. 
(v) Background: 
No peaks were evident in the urine control which could interfere 
with the analysis. Peaks due to endogenous urinary components 
elute early in the chromatogram and are well separated from the 
TMP peak. A marked r eduction in the size of these peaks was 
observed if urine samples had been frozen, for storage purposes, 
prior to the analysis. 
(vi) Extraction procedure: 
A simple acetonitrile deproteinization procedure followed by 
separation of the organic phase by the addition of solid sodium 
chloride was found to yield adequate recoveries of all drugs 
from urine. Since sufficiently high drug concentrations are 
encountered in urine, concentration of the extract is not 
essential. However, this procedure was found to be 
advantageous in that (a) the size of background peaks in the 
chromatogram due to urinary constituents was reduced and 
(b) reconstitution of extracts in the mobile phase prior to 
injection resulted in improved peak symmetry and resolution. 
The pH at which the extraction is carried out is important 
since fluctuations are likely to have a significant effect 
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on the extraction efficiency. Possibly, use of a buffer 
with a higher buffer capacity may obviate the need to adjust 
the pH of samples t o the required value by the add ition of 
sodium hydroxide. 
The dry urine extracts before reconstitution were found to 
be stable for up to 5 days when kept at room temperature. 
(vii) Chromatographic cond itions! 
When the optimal chromatographic conditions for the serum 
assay (Section 4.3.2) were applied to urine samples it was 
found that TMP was inadequately resolved from peaks due to 
endogenous urinary constituents. Separation of TMP from 
these background peaks was attained by reducing the operating 
temperature to ambient conditions (20-24°C). This change 
resulted in slight ly longer retention times and somewhat 
broader peaks but this did not affect the quantitative aspects 
of the analysis. 
Care should be taken to avoid variations that may be associated 
with fluctuations in ambient temperature during the course of 
an analysis. It was found that variations produced by changes 
in temperature between 20 and 24°C were insignificant. How= 
ever, temperature increases to 25°C and above resulted in a 
reduction in retention times. Close control over operating 
temperatures is especially important when peak heigh ts are 
being utilized for the quantitation . 
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Detection: 
Although the SMZ:TMP ratio in urine is approximately 1:1, 
detection at 230 nm, as employed for the serum assay, gave 
excellent results for the simultaneous analysis of these 
drugs in urine. Possibly the use of 225 nm would be more 
appropriate in view of the fact that TMP/SMZ responses are 
fairly similar at this wavelength. Background absorbance 
due to the acetic acid in the mobile phase was found, however, 
to be too high at this wavelength. 
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4.3.4 General Discussion of the Method for the Simultaneous 
Determination of TMP, SMZ and N4-acetyl-SMZ in Serum and Urine: 
With the described method, TMP, SMZ and N4-acetyl-SMZ were 
successfully quantitated simultaneously in serum and urine. 
The assay provides adequate sensitivity, specificity and 
precision for monitoring therapeutic steady-state concentrations 
as well as the subtherapeutic concentrations which are encountered 
following the administration of a single solid oral dosage form 
of Co-trimoxazole for bioavailability assessment. It is well 
suited for routine application in the clinical laboratory 
because of the simplicity of the extraction procedure and the 
use of standard HPLC equipment. The final test of the method 
will, of course, be its application in the clinical situation 
and possibly correlation of the results with those obtained by 
conventional assay techniques. 
Chromatographic c ondi tions were chosen so as to provide the 
shortest analysis time with resolution of the drugs to be 
analyzed. Symmetrical and well-resolved peaks were obtained 
for all drugs. Signal-to-noise ratios are high despite use 
of the relatively low wavelength for the detection. Analysis 
time may possibly be reduced by incorporation of a gradient 
elution system to shorten the retention time of N4-acetyl-SMZ. 
This, however, would no doubt result in baseline problems. 
In addition, re-equilibration time may be too long to warrant 
inclusion of a gra0ient system. 
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The proposed method offers considerable advantages over the 
only currently published HPLC method for the simultaneous 
determination of these compounds in biological fluids 9G . 
Detection limits for TMP are substantially lower. The 
incorporation of an internal standard, the advantages of 
which have been well establishe~28,129, represents an 
additional improvement. Despite the lack of chemical 
similarity between the internal standard employed, sulpha= 
furazole, and TMP, the latter compound was successfully and 
accurately quantitated. The published method does not give 
any account of precision. 
Peak heights were utilized for the quantitative determination 
of all compounds. It has been reported l30 that the use of 
peak heights for quantitative analyses gives the same degree 
of precision and accuracy as may be obtained with electron= 
ically measured peak areas. The same report also indicated 
that the precision of the peak height measurement was better 
than that of the product of the peak height and half-height 
width. However, peak height measurements are influenced 
by inadvertant small changes in the mobile phase composition 
and temperature effects and hence, for accurate quantitation, 
close control over these factors is essential. This assay 
technique could potentially be applied to the determination 
of these drugs in other biological fluids and tissues. 
Since TMP has a high volume of distribution (Section 1.4.3) 
its concentration in these tissues is likely to be sufficiently 
high to enable accurate quantitation. SMZ levels are usually 
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readily detectable in most body fluids and tissues. 
Column Stability: 
The C18 reverse-phase column utilized for these studies was 
found to exhibit extremely high stability. A single column 
was employed for several hundred analyses of both biological 
samples and samples obtained during dissolution rate studies, 
without significant loss of resolution and efficiency. 
Retention times were found to be highly reproducible. 
After some time, a slight loss of column efficiency became 
apparent. This was evident since a slight loss of 
resolution and shortened retention times resulted. Column 
back-pressure, however, remained low. Alteration of the 
mobile phase composition to yield a 0,4% acetic acid-methanol 
78:22 (vol/vol) solvent mixture was found to improve 
resolution at this stage and permitted use of the column 
for further analyses. 
After use, the column was rinsed and stored in a methanol-
water 50:50 mixture. Occasionally it was flushed with 
water (150 ml), methanol (150 ml) and then methanol-water 
50:50 in order to remove any accumulated impurities. An 
increase in column back-pressure occurred due to particles 
from injected samples blocking the column inlet filter. 
Filters were cleaned by sonication in a solution of 
concentrated nitric acid for 15 minutes, and also by 
sonication in water and methanol. This solved the problem 
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and operating pressures returned to normal. Rinsing the 
column with methanol was found on a few occasions to remove 
an unknown component which formed a white precipitate on 
contact with water. The nature of this precipitate is not 
known. Possibly it may have been due to impurities 
accumulating in the column as a result of the injection of 
biological samples. Loss of column packing material may 
also be involved although this was considered unlikely since 
resolution and efficiency remained unimpaired . 
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CHAPTER 5 
DISSOLUTION RATE STUDIES ON SOLID ORAL DOSAGE 
FORMS OF CO-TRIMOXAZOLE 
The widespread use of the TMP-SMZ combination (Co-trimoxazole) 
has led to the development of a series of products with 
identical active ingredients. There is increasing 
evidence to indicate that therapeutic equivalence cannot 
necessarily be inferred from equivalence in the chemical 
constitution of different formulations of the same drug4 ,'46. 
Hence, assessment of bioavailability, i.e. measurement of the 
rate and extent to which the active drug ingredient is 
absorbed and becomes available at the site of action '4 7 , 
should, ideally, be carried out on all drug products. How= 
ever, the standardized pharmacokinetic tests needed to 
ascertain bio~equivalence have a number of associated 
disadvantages 146,147. In particular, these tests are very 
costly and time-consuming, requiring sophisticated analytical 
equipment, trained personnel and large numbers of volunteers. 
In vivo testing is an invasive technique since large numbers 
of blood samples are usually required. It is also difficult 
to predict whether pharmacokinetic parameters, such as blood 
levels, urine concentrations, etc. are directly related to 
drug product performance in terms of clinical effect. 
Practical problems concerning the measurement of the drug 
substance in biological fluids and the standardisation of 
the test in order to minimize inter- and intra-individual 
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variation in pharmacokinetics are usually encountered. In 
the case of Co-trimoxazole products, strict control over 
urinary pH and flow would be required since these can 
profoundly influence excretion of the unchanged drugs (see 
Section 1.4.5). Determination of the acetylator status of 
volunteers may also be necessary. 
Comparative bioavailability studies on a few Co-trimoxazole 
preparations have been conducted 31 ,131-13\ The bio= 
availability of TMP from single-component formulations 135 
and from formulations with SMZ 62 has also been reported. 
With the exception of the last mentioned report, none of 
tllese studies made any provision for the control of urinary 
conditions. 
It is important to search for suitable chemical/physical 
test procedures that can extend, supplement or perhaps even 
replace these in vivo bioavailability studies. In this 
regard, emphasis has been placed on determining the 
dissolution rates of active substances. The dissolution 
behaviour represents the speed-determining stage in the 
achievement of an optimal blood level, particularly in the 
case of therapeutically important active substances which 
are difficult to dissolve. Medical preparations with which 
such ahsorption problems can occur, and have been demonstrated, 
include SMZ tablets 136 • 
Dissolution rate studies have been developed as indicators 
..... - 150 -/ 
- 150 -
of bioavailability l'7. However, well defined in vi ~ro-in 
vivo correlations must be established before dissolution 
data can be accepted in lieu of in vivo bioequivalence 
data. Dissolution testing is extremely useful as a 
quality control parameter and as a tool for dosage form 
design. Moreover, it can be used to establish whether . 
subsequent batches of a product will perform comparably to 
the batch on which bioavailability studies were originally 
conducted l ' 7 . 
An extensive comparative trial on 15 Co-trimoxazole 
preparations was carried out by Steinigen and Bruene l36 
by examinating their dissolution behaviour. They found 
that when artificial gastric juice was used as the dissolution 
medium, the TMP dissolved considerably more quickly than the 
SM2. Thus, it was considered that measurement of the SM2 
only , wou l d give an adequate comparison. Simultaneous 
measurement of the comparative dissolution rates of TMP 
from these dosage forms was not carried out. Ghanem et 
al.,l37 have recently reported studies on the dissolution 
rates of different Co-trimoxgzole dosage forms. They found 
release of the drugs to be pH-dependent. 
At the time of this investigation, a total of eleven Co-
trimoxazole preparations were commercially available in 
South Africa l3 ". Since no extensive comparative dissolution 
rate data were available for these products, it was considered 
important to conduct a study on these preparations. HPLC 
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was utilized for the simultaneous determination of TMP and 
SMZ in the dissolution samples. (Difficulty was experienced 
in obtaining one of the products, Ultrasept (R) and hence it 
was omitted from the study.) 
5.1 MATERIALS AND APPARATUS: 
5.1. 1 Reagents: 
SMZ (Lot no. 3262) and TMP (Lot no. 3156) were supplied by 
Wellcome (Pty) Ltd., S.A. Sulphadiazine (Lot no. RFA 2298) 
was obtained from Maybaker (Pty) Ltd., S.A. 
complied with BP specifications. 
All drugs 
All other solvents and reagents utilized were of analytical 
r eagent grade and a l l were purchased from E. Merck, Darmstadt, 
with the exception of chloroform (Hopkin and Williams) and 
ammonium sulphamate (BDH Chemicals, Ltd., England). The 
water used was deionized and then glass-distilled. 
5.1.2 Co- trimoxazole Products: 
The names and batch numbers of the Co-trimoxazole preparations 
utilized in this study are given in Table 5.1. Six of the 
products studied contained 400 mg SMZ and 80 mg TMP per dose 
unit; these will be referred to as "standard" tablets or 
capsules. The remaining four preparations are "double-
strength" tablets, i.e. they contain 800 mg SMZ and 160 mg 
TMP per dose unit. All dosage forms were compressed 
uncoated tablets with the exception of CO-Trim(R) which 
was a capsule. 
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The individual samples were obtained either through a 
pharmacy or directly from the manufacturer. All the 
products were relatively fresh, none having been manufactured 
more than two years previously. 
5 . 1.3 Apparatus: 
(i) Beckman Model 25 U.V.-visible spectrophotometer. 
(ii) Beckman Acta M VI U.V.-visible spectrophotometer. 
(iii) Multiple spindle drive dissolution apparatus, Model 
QC72R-230B, Hanson Research Corp., Northridge, 
California, U.S.A. 
(iv) HPLC system A (see Section 4.1.3.1) 
(v) Pipetman(R)p and Finnpipette(R) continuously adjustable 
digital pipettes. 
(vi) Wang 2200, Basic desk-top mini-computer. 
5.2 EXPERIMENTAL: 
A. Active Substance Content: 
Each of the preparations studied was assayed according to 
the method specified in the British Pharmacopoeia 1973 7d . 
Analyses were performed using 20 tablets or the contents 
of 20 capsules of each product. 
in triplicate . 
Each sample was assayed 
The procedure for the determination of TMP content involved 
extraction of the active substance from alkaline solution 
with chloroform, re-extraction from the organic phase with 
dilute acetic acid, and subsequent measurement of the U.V . 
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absorption at 271 nm. A Beckman Acta MVI spectrophotometer 
was utilized for the absorbance measurements. The TMP 
content was calculated by comparison with a standard solution 
containing a known amount of pure drug. 
A colorimetric procedure was employed for the assay of SMZ, 
which remains in the alkaline aqueous phase after chloroform 
extraction. The method involved diazotization with nitrous 
acid followed by coupling with N-(l-naphthyl)-ethylenediamine 
hydrochloride to form a coloured azo complex. The 
absorbance of the final solution was then measured at 538 nm 
using a Beckman Mode l 25 spectrophotometer. A standard 
solution containing a known quantity of SMZ was employed for 
comparison. 
B. Dissolution Rates: 
(i) Standard solutions: 
Internal Standard Solutions. Sulphadiazine, SDZ, was 
utilized as the internal standard for these determinations. 
It was incorporated into the dissolution medium, which was 
O,lN HCl (pH 1,1). The following stock solutions of SDZ 
were prepared:-
(a) 1,5000 9 SDZ per 5000 ml O,lN HC1. 100 ml aliquots of 
this stock solution were diluted to 1000 ml with O, lN HC1. 
The final solutions, which contained 30,0 mg 1 -1 SDZ in 
O,lN HC1, were employed as the dissolution fluids for the 
standard tab l ets and capsules. 
(b) 3,0000 9 SDZ per 5000 ml 0,1 N HCL . 100 ml aliquots of 
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this stock solution were diluted to 1000 ml with O,lN BC1. 
The resulting solutions, which contained 60,0 mg l~ SDZ in 
O,lN BCl were utilized as the dissolution fluids for the 
double-strength tablets. 
Some difficulty was experienced in dissolving the SDZ but 
this was aided by application of gentle heat « 40°C) and 
prolonged shaking. Use of an ultrasonic bath would greatly 
enhance solution of this compound. 
TMP and SMZ Stock Solutions. Two stock solutions containing 
both TMP and SMZ were prepared as follows: 
(a) 40,00 mg SMZ and 8,00 mg TMP were dissolved in 100 ml of 
the dissolution fluid utilized for standard tablets and 
capsules, i.e. O,lN BCl containing 30,00 mg 1 -1 SDZ; 
(b) 80,00 mg SMZ and 16,00 mg TMP were disso l ved, with the 
a i d of gentle heat, in 100 ml of the dissolution fluid 
employed for double-strength tablets, i.e. O,lN BCl 
containing 60,00 mg 1 -1 SDZ. 
By dilution of these stock solutions with the appropriate 
dissolution fluid, a series of calibration curve standards 
were prepared so as to cover the entire range of concentrations 
expected during the dissolution studies. 
(ii) Chromatographic conditions: 
Except for an alteration in the sensitivity setting, identical 
chromatographic conditions were utilized for all analyses. 
The following conditions were employ,ed: 
Column: ].lBondapak C,a (see Section 4.1.3.2) 
BPLC System: A (see Section 4.1.3.1) 
Detection Wavelength: 230 nm 
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Sensitivity: 
(a) For standard tablets, capsules and the appropriate 
calibration standards, the sensitivity setting was 0,020 
A.U.F.S. 
(b) For double-strength tablets and the appropriate calibration 
standards, a sensitivity of 0,040 A.U.F.S. was employed . 
Char t Speed: 12 inches hr-I 
Flow Rate: 1,5 ml min-I 
Pressure: 2000 p. s. i. (Pressure was high during these 
de terminations due to partial blockage of the column inlet 
filter caused by particles from previously analyzed biological 
samples. ) 
Temperature: 30°C 
Mobile Phase: 1 % acetic acid-methanol 80:20 (vol/vol). 
Preparation of mobile phase: 
The mobile phase was prepared as described in Section 4.3.1. 
(iii) Dissolution methodology: 
The dissolution rates of the Co-trimoxazole p reparations 
were determined utilizing the U.S.P. XIX rotating basket 
method l39 • The test was conducted under the conditions 
indicated in Table 5.2, Six dosage unit s of each o f the 
products studied were subjected to the test. The following 
methodology was applied to all dosage forms: 
A single tablet or capsule was placed into each wire-mesh 
dissolution basket. The basket was then immersed in the 
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TABLE 5.2: 
CONDITIONS UTILIZED FOR DISSOLUTION 
RATE STUDIES 
Standard Tablets Double-Strength 
and Capsules Tablets 
Dissolution medium O,lN HCl containing O,lN HCl containing 
30 mg 1 -1 SDZ 60 mg 1-1 SDZ 
Volume 1000 ml 1000 ml 
Stirring rate 100 r.p.m. 100 r.p.m. 
Temperature 37°C 37°C 
No. of dosage units 
per test 1 1 
dissolution fluid and stirring commenced immediately. One 
hundred microlitre samples of the dissolution medium were 
then withdrawn from a distance of 22 mm below 
the surface at 0,5; 1; 1,5; 2,5; 5; 10; 20; 30; 40; 
60; and 90 minutes after immersion of the basket. These 
samples were removed using digital micro-pipettes equipped 
with disposable plastic tips. The tips were employed for 
a single sample only and were subsequently discarded. There 
was no replacement of the dissolution medium. 
Once each sample had been withdrawn, it was placed into a 
clean, dry 1 ml amber ampoule. The neck of each ampoule 
had been shortened to facilitate delivery of the samples 
into the body of the ampoule. The ampoules were 
immediately sealed and kept in a cool place until analysis . 
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Six determinations could be conducted concurrently in the 
dissolution apparatus by appropriate staggering of the 
starting times. 
(iv) Analysis of dissolution samples: 
A 2 ~l aliquot of each sample was injected onto the column 
under the specified HPLC conditions. If necessary, i.e. 
for samples removed during the initial stages of dissolution 
where drug concentrations were low, the injected volume was 
increased to 10 ~l in order to more easily visualize the 
peak s. 
It was found that a few samples had evaporated to dryness 
owing to improper sealing of the ampoules. These were 
reconstituted by add ition of 100 ~l of the mobile phase before 
injection. 
(v) Calculation of results: 
Calibration curves were constructed to cover the expected 
concentration ranges of TMP and SMZ in the dissolution media. 
In order to cover the range anticipated during the dissolution 
of standard tablets and capsules, standard solutions were 
prepared so as to contain five different concentrations of 
each drug varying between 80,00 and 400,00 mg 1 ~ for SMZ 
and between 16,00 and 80,00 mg 1-1 for TMP. The appropriate 
dissolution fluid, i.e. O,lN HCl containing 30 mg 1-1 SDZ, 
was employed as the solvent for these standard solutions. 
Aliquots (2-10 ~l) were then injected onto the column under 
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the conditions specified for standard preparations. Each 
sample was assayed in triplicate and the mean value obtained. 
Calibration curves were then constructed by plotting the 
ratios of the peak heights of each drug to that of the 
internal standard, sulphadiazine, versus their respective 
concentrations. Concentrations were expressed as a 
percentage of the labelled content of the particular drug. 
Calibrat ion curves to cover the concentration range for 
double-strength tablets were constructed in a similar manner. 
Solutions of pure drugs were prepared in O,lN HCL containing 
60 mg 1 -1 SDZ, and comprised concentration ranges of 160,00 -
800,00 mg 1-1 SMZ and 32,00 - 160,00 mg 1-1 TMP. These were 
analyzed under the sensiti vity settings employed for double-
strength tablets. 
The ratios of the peak heights of TMP and SMZ to that of the 
internal standard, SDZ, were determined for each dissolution 
sample. Drug concentrations could thus be calculated by 
referring to the relevant calibration curve data. 
5.3 RESULTS: 
A. Active Substance Content: 
The results of the assays conducted on the Co-trimoxazole 
preparations are indicated in Table 5.1. All products 
complied with the requirements of the British Pharmacopoeia 
1973, i.e. they contained 92,5-107,5 % of the stated amount 
of both TMP and SMZ. 
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TABLE 5.1: 
ASSAY OF CO-TRIMOXAZOLE PRODUCTS 
Labelled Content, 
NAME OF PREPARATION BATCH 
mg per dose unit 
NUMBER 
TMP SMZ 
Septran(R) CBP/I00/625 80 400 
Bactrim(R) B/N8 80 400 
Thoxapr im (R) 110678 80 400 
purbac(R) SW 1241 80 400 
Nezenol (R) 432127 80 400 
CO-Trim(R) 060978 80 400 
Bactrim Double Strength(R) J002A82P 160 800 
Bactrim ~ouble Strength 
Quiksolv R) JOOIA82E 160 800 
Septran Double Strength(R) - 160 800 
Mezenol Double Strength(R) - 160 800 
--_.-
- - --
a. Me an of 3 determinations. 
Assay, 
TMP 
MEAN a 
102,91 
100,21 
101,00 
99,08 
102,18 
103,19 
99,75 
101,88 
103,31 
101,31 
% of Labell ed Content 
SMZ 
S. D. MEAN a S. D. 
2,21 100,37 1,21 
0,93 101,71 0,10 
1,90 99,22 1,32 
0,89 101,11 0,94 
0,49 102,22 0,91 
0,38 101,06 0,32 
0,15 99,00 0,73 
0,16 104,49 1,83 
2,64 101,19 0,65 
0,15 99,41 0,32 
"-I 
o 
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B. Dissolution Rates: 
(i) HPLC Analysis: 
A typical chromatogram obtained from the HPLC assay of a 
dissolution medium sample is depicted in Figure 5.1. All 
peaks were well-resolved and symmetrical. Under these 
conditions, the retention times were as follows: 
SDZ 3,1 minutes 
TMP 4,B minutes 
SMZ 6,5 minutes 
Calibration curves were linear over the entire range of 
concentrations tested. Table 5.3 lists the constants of 
the respective linear regression lines. Coefficients of 
correlation were 0,9999 in all cases. A single reference 
solution of known concentration could thus be used for 
quantitative determinations. 
TABLE 5.3: 
LINEAR REGRESSION DATA FOR CALIBRATION CURVES IN DISSOLUTION 
MEDIA. 
Concentration Slope c Correlation Drug Range, mg 1-1 Y-Intercept Coefficient 
'!MFa 16,00 - BO,OO 0,037B 0,0070 0,9999 
SMZa 80,00 -400 , 00 0,0359 0,0086 0,9999 
'!MFb 32,00 -160,00 0,0373 0,0136 0,9999 
SMZb 160,00 -BOO,OO 0,0354 0,0130 0,9999 
a·· Cal ibration curve for standard tablets and capsules. 
b· Calibration curve for double-strength tablets. 
c· Pea k height ratios are plotted on the y-axis and drug 
concentrations as a percentage of the labelled content on 
the x-axis. 
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Fig. 5.1. Chromatogram of a sample of 
the dissolution medium obtained during 
the dissolution of a s tandard Co-
trimoxazole tablet. Drug concentrations 
are 81,4 mg 1-1 and 327,6 mg 1-1 for TMP 
and SMZ respectively. Chromatographic 
conditions as in section 5.2. The arrow 
denotes the time of sample injection 
(2 \11 injected). 
Peaks: 
10 
1 = internal standard, 
sulphadiazine 
2 = TMP 
3 = SMZ 
RETENTION TIME, min . 
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(ii) Dissolution data: 
The rates of dissolution of TMP and SM2 from the Co-trimoxazole 
formulations studied are depicted in Figures 5.2 - 5.5. 
These results represent the means of six individual deter-
minations. 
The N.F. XIV monograph on "sulphamethoxazole tablets"l O 
specifies that at least 50,0% of the active substance must 
be dissolved within 20 minutes . For this measurement the 
rotating wire basket is specified, rotating at a speed of 
100 r.p.m. in dilute hydrochloric acid medium. This 
specification was used by Steinigen and Bruene 1 36 as the 
standard for assessment of the dissolution time of SMZ in 
Co-trimoxazole tablets (standard strength). When applied 
to the present determinations, it was found that all standard 
tablets and capsules complied with the N.F. XIV specification 
as regards dissolution time of SMZ. The double-strength 
tablets, with the exception of Bactrim Double-Strength(R) 
(46,94% SM2 .dissolved within 20 minutes) also met the N.F. 
requirements. However, the significance of this specification 
in the case of Co-trimoxazole formulations, especially double-
strength preparations which have a high 8M2 content, is not 
known. 
No dissolution rate specifications are currently given in 
official Pharmacopoeias for either TMP or Co-trimoxazole 
tablets . 
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Fig. 5.2. Rate of dissolution of trimethoprim from standard 
Co trimoxazole preparations. Each point represents the mean 
of 6 individual determinations. 
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Fig. 5.3. Rate of dissolution of sulphamethoxazole from 
s tandard Co-trimoxazole preparations. Each point represents 
the mean of 6 individual determinations. Readi ngs for 0,5 
minute samples not depicted. 90 
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Fig. 5.4. Rate of dissolution of trimethoprim from double-
strength Co-trimoxazole preparations. Each point represents 
the mean of 6 individual determinations. Readings for 0,5 
minute samples not depicted. 
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Fig. 5.5. Rate of dissolution of sulphamethoxazole from 
double-strength Co-trimoxazole preparations. Each point 
represents the mean of 6 individual determinations. Readings 
for 0,5 minute samples not depicted. 
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Statistical Analysis of Dissolution Data: 
Statistical methods were employed in order to ascertain 
whether significant differences existed between any of the 
products as regards their dissolution behaviour. Application 
of these methods would hence provide standardized parameters 
for comparison of the different products. 
The percentages of TMP and SMZ dissolved from each dosage 
unit of (a) standard tablets and capsules and (b) double-
strength tablets were compared at each sampling time. One-
way analysis of variance was found most suitable for the 
analysis of this data. Whereas this technique takes into 
account variations in the values between individual tablets 
as well as variations among the means of the different products, 
it only considers variation within the group as a whole and 
does not, however, discriminate between individual products. 
One-way analysis of variance of the data indicated statistically 
significant (p < O,Ola) differences among the products with 
respect to both TMP and SMZ at all time intervals with the 
exception of (a) the 0,5 minute samples and (b) samples 
obtained between 20 and 90 minutes with respect to the TMP 
component of standard tablets only. 
a p = probability. p < 0,01 implies that results are 
significant at the 1% level, i.e. the probability of a result 
not falling within the range is less than 1% . 
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Further analysis of the data at those time inter vals 
showing significant differences was required in order to 
distinguish the differing products. For this purpose, 
Scheffe's test was employed. This test was applied to the 
data in order to establish a range of values at each time 
interval within which variation between individual product 
means is not significantly different. Thus, the difference 
between the mean percentages of TMP and SMZ dissolved at each 
time was calculated for all possible pairs of products. If 
this d ifference was within the range determined using Scheffe's 
test, the product pair compared were not s ignificantly 
different. A value outside the calculated range implied 
a statistically significant difference between the products 
compared at the particular time interval. The results 
obtained using Scheffe's test are summarized in Tables 5.4 
and 5.5. (Full details of these results are listed in the 
Appendix.) The results indicate the time intervals at which 
a statistically significant (p < 0,01) difference between the 
relevant product pair was obser ved. However, they do not 
indicate for which product the higher value was obtained. 
This information can be obtained by inspection of the 
comparative dissolution profiles depicted in Fi g ures 5.2 -
5.5. In some cases, one product may have been superior at 
certain time intervals while at other times the position was 
reversed. 
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TABLE 5.4: 
STATISTICAL ANALYSIS OF DISSOLUTION DATA FOR STANDARD TABLETS 
AND CAPSULES 
Time Intervals (Minutes) at which Differences 
Between Products were Significant (p < 0,01) 
PRODUCTS CCMPARED 
'IMP SMZ 
Bactrim (R)/septran (R) 1; 1,5 1 
Bactrim(R)/Mezenol(R) 1; 1,5; 2,5 1; 10; 20; 30; 
40; 60 
Bactrirn(R) /ThOKaprim(R) Nil 1; 1,5; 2,5 
Bactrirn(R)/purbac(R) 1 Nil 
Bactrim (R)/Co-Trim (R) 1; 1,5; 2;5 1; 1,5; 5; 10; 
20 
septran(R)/Mezeno1(R) 1; 1,5; 2;5 10; 20; 30 
Septran (R)/ThOKaprim (R) 1 1; 1,5; 2,5; 60; 
90 
Septran(R)/purbac(R) Nil Nil 
septran(R)/Co-Trim(R) 1; 1,5; 2,5; 5 5; 10 
Mezeno1(R)/ThOKaprirn(R) 1; 1,5; 2,5 1; 1,5; 2,5; 10; 
20; 30; 40; 60; 90 
Mezenol(R)/purbac(R) 1; 1,5; 2,5 10; 20; 30; 40; 60 
Mezeno1(R)/Co-Trim(R) 1,5; 2,5 30; 40; 60 
ThOKaprirn(R)/Purbac(R) 1 1; 1,5; 2,5 
ThOKaprim(R)/co-Trim(R) 1; 1,5; 2,5 1; 1,5; 2,5; 20 
purbac(R)/CO-Trim(R) 1; 1,5; 2,5 1; 1,5; 5; 10 
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TABLE 5.5: 
STATISTICAL ANALYSIS OF DISSOLUTION DATA FOR DOUBLE-STRENGTH TABLETS 
Time Intervals (Minutes) at which Differences 
PRODUCTS COTYIPARED a 
Between Products were Significant (p < 0,01) 
TMP SMZ 
Bactrim D.S. (R)/Bactrim D.S. Quiksolv(R) 1, 1,5, 2,5, 5, 10, 2,5, 5, 10 
20, 30, 40, 60, 90 
Bactrim D.S. (R)/septran D.S. (R) 1, 1,5 10, 40 
Bactrim D.S. (R)/TYIezenol D.S. (R) 1, 1,5, 2,5 2,5, 5, 10, 20, 30, 
40, 60 
Bactrim D.S. QuiksOlv(R)/septran D.S. (R) 5, 10, 20, 30, 40, 1,5, 2,5, 5, 60; 90 
60; 90 
Bactrim D.S. QuikSOlv(R)/TYIezenol D.S. (R) 5, 10; 20, 30; 40; 60; 30, 40; 60, 90 
90 
Septran D.S. (R)/Mezenol D.S. (R) Nil 2,5, 5 
-~ ---
a D.S.: Double-strength. 
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5.4 DISCUSSION: 
(i) Analytical procedure: 
HPLC was utilized for the simultaneous analysis of TMP and 
SMZ in samples of dissolution media obtained during the 
dissolution of various Co-trimoxazole formulations. 
The chromatographic condi tions employed were similar to 
those selected for the assay of these drugs in serum 
(Section 4.3.2). Detection at 230 nm yielded responses 
of a s imilar magnitude for SMZ and TMP when these compounds 
were present in a 5 :1 ratio by weight. Since this 
represents the ratio found in pharmaceutical preparatio ns, 
the wavelength used is optimal for the analysis. The HPLC 
method was found to be specific, accurate and rapid. 
Calibration curves were highly reproducible which can be 
attributed to the stability of the column and the simplicity 
of the procedures. 
Several advantages were associated with the use of HPLC for 
the analysis of dissolution samples. Firstly, since the 
volume of sample required for HP'LC assay was very small, it 
was possible to remove 100 ~l portions of the dissolution 
medium for analysis. Hence, the volume of medium removed 
during the entire dissolution procedure was 1,1 ml. This 
is a negligable quantity in a total volume of 1 litre. 
Replacement of the dissolution medium after each sampli ng 
was, thus, unnecessary and there was no need to adjust 
calculations to compensate for samples already removed. 
This methodology facilitated more frequent and rapid sampling 
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of the dissolution fluid. 
Samples were removed from a distance of 22 mm below the 
surface of the dissolution medium. This was an arbitrary 
value utilized since it represented the maximum depth at 
which samples could be withdrawn using digital micro-
pipettes. The latter dev ices made sampling simple and 
rapid. Representative samples appeared to be obtained in 
this manner since drug concentrations, in most cases, 
reached expected values, indicating complete dissolution 
of the active substances. 
The use of HPLC also allowed for the direct analysis of 
dissolution medium samples without any pre-treatment. 
Despite the fact that the pH of the medium was low (pH 1,1) 
this direct injection had no apparent effect on column 
efficiency. At least 800 samples were in)ected with no 
adverse effects. Samples were of small volume and hence 
would be diluted to a l evel where column damage was highly 
unlikely. There was no evidence of any particulate matter 
or undissolved tablet material in the dissolution samples 
which could cause problems when injected. No increase in 
column back-pressure occur red . Calibration standards were 
injected throughout the procedure and these results indicated 
no change in column efficiency or separating ability. 
Sulphadiazine was utilized as the internal standard for 
these determinations because of its favourable elution time . 
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Incorporation of the internal standard into the dissolution 
medium had several advantages. Accuracy of the procedure 
was enhanced because the use of large volumes of internal 
standard solutions minimized errors. The same stock 
internal standard solutions were utilized for the preparation 
of all dissolution fluids for standard and double-strength 
tablets respectively. The internal standard compensated for 
sample volume changes that could occur as a result of 
temperature differences. It also accounted for inadvertant 
small losses in sample volume that may occur before or during 
sealing of the ampoules or due to improperly sealed ampou l es. 
Inaccuracies associated with failure to remove precise sample 
volumes were avoided by inclusion of the internal standard 
into the dissolution fluid. In addition, this allowed for 
more rapid analysis since addition of the internal standard 
as a final step to the dissolution samples was unnecessary. 
Inclusion of the internal standard into the dissolution 
medium did not interfere with the dissolution process. 
Preliminary tests were carried out on Co-trimoxazole 
preparations (Bactrim(R) and 5eptran(R)) where 0,1 N RCl 
without additives was utilized as the dissolution fluid. 
The internal standard was then added to all samples and to 
standards prior to analysis. Dissolution profiles for 5MZ 
obtained in this way (see Fig. 5.6) were identical to those 
obtained when the internal standard was included in the acid 
medium. TMP was found to be completely dissolved within 
2,5 minutes for both products . This is also in agreement 
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Fig. 5.6. Dissolution profiles of SMZ from standard 
Co-trimoxazole tablets obtained when the internal standard 
was not included in the dissolution medium but was added to 
samples prior to HPLC analysis. Each point represents the 
value obtained for a single tablet. 
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with results obtained when the internal standard was 
incorporated into the dissolution fluid. In this case, 
2,5 minutes represented the initial sampling time. Readings 
were found, however, to be less precise and occasional 
deviations from the dissolution curves were noticed. 
It is likely that the HPLC method utilized during these 
studies for the analysis of dissolution samples could be 
adapted to enable the simultaneous determination of TMP and 
SMZ in combination in pharmaceuticals. The active substances 
could be extracted from the required aliquot of finely powdered 
tablets by shaking in the mobile phase or in methanol, with the 
possible use of sonication to ensure complete solution. SDZ 
could be added as internal standard. However, this application 
was not investigated during these studies. Methods for the 
simultaneous HPLC determination of TMP and SMZ in solid 
pharmaceutical dosage forms have, however, been reported in 
the literature 9 9 , 1 40. In the former method, the separation 
was achieved on a reverse-phase column (LiChrosorb(R) RP-8,5 ~m; 
E. Merck) at a temperature of 40°C, utilizing acetonitrile-
0,05 M phosphoric acid (1:3) as the mobile phase and with 
spectrophotometric detection at 230 nm. The active 
ingredients were extracted into the mobile phase before 
injection. Quantitative determinations were carried out 
using external standardization. The latter method involved 
the use of an alkylnitrile bonded phase column (Micropak(R) 
CN-IO; Varian Associates). In this case, the mobile phase 
consisted of diethylamine-ethyl acetate-methanol-heptane 
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(1:8:16:75) and a wavelength of 254 nm was utilized for the 
detection. The extraction solvent was 0,1 N HCl in methanol. 
SUlphanilylsulphanilamide was employed as an internal standard. 
Stability of Samples: 
Samples of the dissolution medium could be kept at room 
temperature and protected from light (amber ampoules) for 
twenty days before HPLC analysis without any evidence of 
degradation. However, in samples stored for longer periods, 
a slight "shoulder" was observed on the leading edge of the 
SMZ peak although this did not appear to significantly affect 
the measured peak height. 
SMZ will hydrolyze partially in acidic or basic solutions"'. 
In acidic solvents appearance of a white precipitate (5-
methyl isoxazole ring), indicating hydrolysis of SMZ, has 
been reported"'. Sulphanilamide would thus be formed at 
the same time and would remain in solution. Sulphanilic 
acid has also been reported to be a sUlphonamide degradation 
product"o. Analysis of samples by HPLC thus offers the 
additional advantage that sample decomposition would probably 
be clearly indicated in the chromatogram, i.e. the assay is 
"stability indicating". 
(ii) Dissolution data: 
Innumerable factors influence the dissolution characteristics 
of any drug or drug combination. Features of the production 
technique and the excipients employed are involved, as well 
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as physicochemical properti es of the drug itself, e.g. 
particle size, surface area, solubility, polymorphism, 
differences in salt or ester form, etc . In addition, the 
apparatus '36 and conditionsl~l utilized for the dissolution 
rate determination can have a profound effect on the results 
obtained. It cannot be assumed that in vitro dissolution 
rates are predictive of in vivo bioavailability. In vitro 
tests must be correlated on a quantitative basis with in vivo 
studies in order to establish a meaningful relationship. 
When comparing the dissolution profiles obtained during this 
study, it was apparent that the TMP component of all prepara= 
tions dissolved considerably more rapidly than the SMZ 
component. This feature is consistent with the solubility 
of the drugs in the dissolution fluid (0,1 N HCl). Complete 
dissolution of the TMP component occurred within 10 minutes 
for all products, with the exception of Bactrim Double-Strength 
Quiksolv(R) which appeared to yield a maximum of 85% of the 
labelled content of TMP. In the case of SMZ, however, 90 
minutes was required for complete solution of the active 
ingredi e nt in the majority of standard preparations. 
Double-strength tablets yielded only 65 - 77% of the total 
SMZ content within the same time interval. This may have 
been due to the limited solubility of the SMZ in the acidic 
medium and hence use of large r volumes of fluid or alteration 
of pH may provide more suitable conditions. 
Discrepancies in the relative rates of release of SMZ and TMP 
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were observed when comparing different formulations. For 
example, Bactrim(R) was found to release TMP more rapidly 
than Mezenol(R), but SMZ dissolved at a slower rate from 
the former pr eparation as compared with the latter. This 
feature did not, however, apply to all preparations s tudied. 
In addition, comparison of the percentage of activp 
ingredient dissolved on completion of the dissolution process 
(i.e. the 90 minute sample) did not indicate relative 
differences among the products as regards the total amount 
of SMZ and TMP released. 
Reasons for the discrepancies in the relative release rates 
of SMZ and TMP from Co-trimoxazole dosage forms are not known. 
Possibly this may be related to differences in the physico= 
chemical attributes of the particular drug or to formulation 
variables. The dissolution medium, which has been shown to 
markedly affect the dissolution behaviour of drugs l41 , may 
not have been ideal. Selection of a single dissolution 
fluid to accommodate these drugs which have diverse characters 
and solubility properties may pose a problem. Possibly, 
comparison of results obtained using media of higher pH values 
may indicate whether this factor is involved. Ghanem et al. ,137 
have reported an unexpected pH effect for SMZ when conducting 
dis solution rate studies on Co-trimoxazole formulations. 
Slow release profiles could also be accounted for by the fact 
that very small tablet particles, including perhaps undissolved 
SMZ, may pass thro ugh the mesh of the wire basket and fall to 
the bottom of the vessel where they largely escape the stirring 
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action of the rotating basket 136 • 
Statistical Analysis: 
Analysis of the dissolution data using statistical methods 
was essential in order to provide a basis for comparison of 
the different Co-trimoxazole preparations. Application of 
these methods to the data obtained for both standard tablets 
and capsules and double-strength tablets indicated large 
differences between several of the products. 
In the case of standard preparations, significan t differenc e s 
between TMP dissolution profiles were encountered only at early 
time intervals. In view of this fact, it is probable that the 
products would not be considered different as regards dissolu= 
tion of the TMP component under these conditions. SMZ 
dissolution curves for Mezenol(R) and Thoxaprim(R) were found 
to differ significantly at most time intervals. However, the 
latter product was superior during the initial stages whereas 
the former yielded better results at later time intervals. 
Mezenol(R) was also found to be significantly better than 
Bactrim(R) and purbac(R) at several time intervals as regards 
dissolution of SMZ, although release rates of TMP from these 
preparations yielded contradictory results. For most other 
standard preparations dissolution profiles of SMZ were 
generally similar although significant differences were 
encountered at certain time intervals. 
When comparing the double-strength tablets, it was found that 
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Bactrim double-strength Quiksolv(R) yielded a significantly 
lower percentage of the TMP component than the other products 
(viz. Bactrim double-strength(R), Mezenol double-strength(R) 
and Sept ran double-strength(R)). Differences in SMZ 
dissolution profiles were less marked and at early sampling 
times Bactrim double-strength Quiksolv(R) often yielded more 
favourable results. However, this product was found to yield 
a significantly lower amount of SMZ than either Septran double-
strength(R) or Mezenol double-strength(R) when comparing 
samples removed at the end of the dissolution process (i.e . 
60 and 90 minute samples). Significant differences in the 
percentage of SMZ released from Bactrim double-strength(R) 
and Mezenol double-strength(R) tablets were also observed 
at most time intervals. Discrepancies in the relative rates 
of release of TMP and SMZ from these products were, however, 
observed. 
Thus, significant differences at several time intervals were 
encountered between the products studied. Often, however, 
evaluation of preparations was difficult since relative 
release rates of TMP and SMZ yielded contradictory results. 
In several instances, one product was found to yield better 
results than another during certain time intervals, whilst 
at other times the position was reversed. Under the 
conditions utilized, a meaningful comparison could not be 
obtained on the basis of either TMP or SMZ dissolution rates 
alone. 
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Care should be taken in the use of arbitrary values, e.g. 
amount dissolved within 20 minutes, as these may not provide 
meaningful assessments of relative product performance. 
The data obtained after application of the various statistical 
analyses may facilitate selection of more suitable parameters 
for comparison of Co-trimoxazole products and, especially, may 
aid establishment of appropriate in vivo-in vitro correlations. 
Comparison of results at more frequent time intervals may 
provide more information concerning the dissolution process 
as a whole. It is therefore essential to optimize both 
apparatus and dissolution conditions in order to make a valid 
comparison and perhaps to attempt to establish further 
parameters which may be useful for comparative purposes to 
differentiate between generic products . 
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CHAPTER 6 
HIGH PRESSURE LIQUID CHROMATOGRAPHY 
OF SOME SULPHONAMIDES 
Although they have largely been superceded by antibiotics 
in the treatment of infections, the sUlphonamides continue 
to constitute a therapeutically important group of anti= 
microbial agents. Combinations of these drugs with TMP 
are becoming increasingly popular, particularly for the 
treatment of respiratory and urinary tract infections. 
Several studies have been conducted on methods of separation 
and quantitative evaluation of sulphonamides using 
HPLC 96 ,103-106,140. 
During the present investigation, a number of sulphonamides 
were injected under varying chromatographic conditions. 
The chromatographic data are listed below. 
6.1 REAGENTS: 
All drugs utilized complied with BP standards. Solvents 
were of analytical reagent grade and were obtained from 
E. Merck, Darmstadt. The water used was deionized and 
then glass-distilled. 
Predominantly aqueous mobile phases were filtered before 
use through a Millipore type HA (0,45 ~m) membrane filter 
(Millipore Corp., Bedford, Mass . ) while solutions that were 
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mainly organic solvents were filtered through a type FH 
(0,5 ].lm) filter. 
6.2 EXPERIMENTAL: 
Solutions of pure sulphonamides were prepared in methanol so 
as to yield final concentrations of approximately 20 ].lg ml -). 
Ten ].ll aliquots of each solution were then injected into the 
liquid chromatograph under the appropriate conditions. TMP 
and other compounds were analysed in a similar manner. The 
following chromatographic systems were employed. 
I. Column: Micropak(R) NH, - 10; 10].lm (see Section 4.1.3.2) 
HPLC system: C (see Section 4.1.3.1) 
Detection wavelength: 290 nm 
Sensitivity: Vari-chrom O,lA 
CDS III 4 
Recorder input 5 mV 
Flow rate: 50 ml hr-) 
Pressure: 1000 p.s.i. 
Temperature: Ambient (_20°C) 
Mobile phase: Acetonitrile-methanol 80:20 (vol/vol). 
The results of sUlphonamide analyses conducted under these 
conditions are listed in Table 6.1 . 
II. Column: ].lBondapak C) 8; 10].lm (see Section 4.1. 3. 2) 
HPLC system: B (see Section 4.1.3.1) 
Detection wavelength: 270 nm 
Sensitivity: 0,040 A.U.F.S. 
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Flow rate: 1·,6 ml min-1 
Pressure: 1430 p.s.i. 
Temperature: Ambient (~20°C) 
Mobile phase: 1% Acetic acid-methanol 70:30 (vol/vol). 
Retention times recorded for various sUlphonamides and 
trimethoprim under these conditions are listed in Table 6.2. 
III. Column: \lBondapak C's; 10 \lm (see Section 4.1.3.2) 
HPLC system: B (see Section 4.1.3.1) 
Detection wavelength: 270 nm 
Sensitivity: 0,040 A.U.F.S. 
Flow rate: 1 ml min-1 
Pressure: 890 p.s.i. 
Temperature: Ambient (~200C) 
Mobile Phase: Methanol-water 50:50 with PIC reagent B-7 
(heptane sulphonate, 5 rnrnol 1 -1, Waters Assoc.) 
Table 6.3 lists the retention times obtained for several 
sulphonamides as well as TMP and pyrimethamine. 
IV. Column: Spherisorb ODS: 5 \lm (Spectra-Physics) 
HPLC system: B (see Section 4.1.3.1) 
Detection wavelength: 270 nm 
Sensitivity: 0,040 A.U.F.S. 
Flow rate: 0,8 ml min-1 
Pressure: 3400 p.s.i. 
Temperature: Ambient ( ~20°C ) 
Mobile phases: 
(i) Sodium acetate 0,05 M - methanol 50:50 (vol/vol) . 
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Sufficient glacial acetic acid was added to adjust the pH to 
4,1. 
(ii) Sodium acetate 0,05 M - methanol 55:45 (vol/vol). 
Sufficient glacial acetic acid was added to adjust the pH to 
4,4. 
(iii) Sodium acetate 0,05 M - methanol 55:45 (vol/vol). 
Sufficient glacial acetic acid was added to adjust the pH to 
4,1. 
Retention times obtained for several sUlphonamides and other 
compounds under these conditions are listed in Table 6.4. 
6.3 RESULTS AND DISCUSSION: 
The majority of the sulphonamides investigated were found to 
elute fairly rapidly under all chromatographic conditions 
utilized. In general, no correlation was observed between 
pKa values and retention times. A number of factors, 
including partition coefficients, are also involved in 
determining the elution sequence. Sulphaguanidine and 
sulphanilamide, however, which have very high pKa values, 
appeared to elute early in the chromatograms. This was 
consistent for a number of the chromatographic systems 
investigated. 
It was found that elution sequence could not necessarily be 
predicted by the nature of the stationary phase . When 
similar chromatographic conditions (chromatographic system 
IV, mobile phase (i)) were applied to two octadecylsilane 
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TABLE 6.1: 
RETENTION DATA FOR A RANGE OF SULPHONAMIDES AND TRIMETHOPRIMa . 
COMPOUND 
Sulphanilamide 
Su1phaguanidine 
Tr imethopr im 
Su1phadimidine 
Su1phamethoxydiazine 
Su1phamerazine 
Su1phamoxo1e 
Su1phadimethoxine 
Su1phamethoxypyridazine 
Su1phadiazine 
Sulphamethoxazo1e 
Sulphasomidine 
Sulphathiazo1e 
Su1phacetamide 
Su1phafurazole 
RETENTION 
TIME, MINUTES 
1,4 
1,4 
2,5 
2,5 
4,6 
5,8 
7,0 
7,1 
7,7 
8,8 
15,4 
18,0 
18,0 
23,1 
a. Chromatographic system I (Section 6.2). 
b . Data from Francke!4 2 and Merck Index!4'. 
c. Eluted in void volume. 
. . . .. - 187 - / 
10,4 
12,0 
7,2 
7,4 
6,8 
6,9 
7,4 
6,7 
7,0 
6,4 
5,8 
7,5 
7,2 
1,8 
5,1 
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TABLE 6.2: 
RETENTION DATA FOR A RANGE OF SULPHONAMIDES AND TRIMETHOPRIMa . 
COMPOUND RETENTION pKa b TIME, MINUTES 
Sulphaguanidine 1,7c 12,0 
Sulphanilamide 1,9c 10,4 
Sulphasomidine 2,4 7,5 
Sulphadiazine 2,6 6,4 
Sulphacetamide 2,6 1,8 
Sulphathiazole 2,7 7,2 
Sulphapyridine 3,1 8,6 
Sulphamerazine 3,3 6,8 
Sulphamoxole 3,6 7,4 
Trimethoprim 3,7 7,2 
Sulphadimidine 4,4 7,4 
Sulphamethoxydiazine 4,6 6,8 
Sulphamethoxypyridazine 4,7 6,7 
Sulphamethoxazole 5,8 5,7 
Sulphafurazole 7,0 4,8 
Sulphaphenazole 10,8 5,9 
Sulphadimethoxine 15,5 6,0 
a . Chromatographic system II (Section 6.2). 
b. Data from Francke'42 and Merck Index'43. 
c. Eluted in void volume. 
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TABLE 6.3: 
RETENTION DATA FOR SEVERAL SULPHONAMIDES, TRIMETHOPRIM AND 
PYRIMETHAMINEa . 
COMPOUND RETENTION pKa b TIME, MINUTES 
Sulphag uani di ne 2,9 c 12,0 
Sulphathiazole 3 2c , 7,2 
Sulphadiazine 3,4 d 6,4 
Sulphasomidine 3,5 7 , 5 
Sulphamoxole 3,6 7,4 
Sulphamethoxydiazine 3,7 6,8 
Sulphamethoxazole 4,1 5,8 
Sulphaphenazole 4,8 6,5 
Sulphadimethoxine 5,9 6,7 
Trimethoprim 6,6 7,2 
pyrimethamine 18,0 7,2 
a. Chromatographic system III (Section 6.2). 
b. Data from Francke '42 and Merck Index ' 43 • 
c. Eluted in void volume. 
d. Not resolved from solvent (methanol) peak. 
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TABLE 6.4: 
RETENTION DATA FOR SEVERAL SULPHONAMIDES AND OTHER COMPOUNDS a . 
MOBILE COMPOUND RETENTION pKa b PHASE a TIME, MINUTES 
( i ) Sulphapyridine 2,lc 8,4 
Dapsone 2,lc 1,0 
Sulphamethoxydiazine 2,2 6,8 
Sulphamethoxazole 2,3 5,8 
Sulphadimidine 2,3 7,4 
Salicylic acid 2,8 3,0 
Tr imethopr im 5,4 7,2 
(ii ) Sulphamethoxazole 2,5 5,8 
Sulphafurazole 2,6 5,1 
Sulphaphenazole 3,3 6,5 
Trimethoprim 7,4 7,2 
Pyrimethamine 19,3 7,2 
(iii ) Sulphamethoxazole 2,4 5,8 
Sulphosalicylic acid 2,6 -
Sulphadimethoxine 3,6 6,7 
Trimethoprim 6,7 7,2 
a. Chromatographic system IV (Section 6.2). 
b. Dat a from Francke l42 and Merck Indexl4 ' . 
c. Not resolved from solvent (methanol) peak. 
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reverse-phase columns, i.e. a ~Bondapak C,a column (10 ~m 
particle size) and a Spherisorb ODS column (5 ~m pa rticle 
size), the observed elution order for TMP and SMZ differed. 
Whereas retention times under these conditions were 3,7 and 
4,1 minutes for TMP and SMZ respectively using the former 
column, the values obtained using the latter column were 5,4 
and 2,3 minutes respectively. Differences in column packing 
or particle s ize may account for these results. Thus, it 
cannot be assumed that columns obtained from different 
manufacturers will necessarily yield similar results despite 
having identical surface functionality. 
The chromatographic data obtained in this study may possibly 
aid the development of suitable methods for the assay of 
single sulphonamides or sulphonamide mixtures, if adequate 
resolution can be attained. This data should also enable 
selection of a suitable internal s tandard. Recent interest 
in the clinical monitoring of sulphapyridine concentrations 
in inflammatory bowel disease patients receiving sulphasalazine 
has led to the development of HPLC methods for the analysis of 
this drugl~~,145. Possibly, a suitable system for the assay 
of sulphapyridine may be developed from data obtained in this 
study (system II). In addition, the chromatographic systems 
could be applied, possibly with slight modifications, to the 
assay of TMP-sulphonamide combinations, e.g. TMP-sulphadiazine 
(system II) and TMP-sulphamoxole (system III). A number of 
alternative systems for analysis of TMP-SMZ were also obtained . 
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Reproducibility of retention times obtained using the amino-
bonded column cannot, however, be assured since this column 
was found to be rather unstable dur ing the present studies 
(Section 4.2). 
. .... - 192 -/ 
- 192 -
CHAPTER 7 
SAMPLE INJECTORS - PROBLEMS OF DEAD VOLUME 
The design of all parts of the chromatographic system from 
the injector, through the column and the detector must aim 
to reduce to an absolute minimum the void space within the 
components. It is also important to avoid badly flushed 
regions where sample molecules could be trapped and held 
back relative to the ma in sample plug. The presence of 
dead volume with in the system will lead t o a considerable 
broadening of the sample bands with an associated l oss of 
resolution '48 . 
A number of different modes of sample introduction are utilized 
in HPLC'48 ,1 49. These include both stop-flow and continuous-
flow injectors. Diffusion in liquids is so small that the 
flow of the mobile phase can be stopped, the sample injected, 
and flow restarted without detriment to resolution. Sample 
introduction techniques may be divided into two main types: 
(i) Direct injection with a microsyringe either onto the 
head of the column or into the liquid stream immediately 
ahead of the column. Samples can be injected through a 
septum with or without interruption of solvent flow. A 
septumless, stop-flow in jector can also be employed. 
(ii) A microsampling valve can be utilized for sample 
introduction. Small fixed-volume (four-port) valves or 
external-loop (six-port) valves are available. The sample 
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is introduced either into a cavity within the valve shaft or 
into an external sample loop. When the valve is actuated, 
the sample is diverted into the mobile phase stream immediately 
ahead of the column. 
Problems associated with dead volume within the injector 
system were encountered during this study . 
discussed below. 
These are 
A. Faulty Sample Loop in External-Loop Valve : 
Chromatographic conditions: 
Column: ~Bondapak CIB (see Section 4.1 . 3.2) 
HPLC system: B (see Section 4.1 . 3.1) 
Detection wavelength: 270 nm (Schoeffel detector) 
Sensitivity: 0,040 A.U.F.S. 
Chart speed: 5 mm min-I 
Flow rate: 1,6 ml min-I 
Pressure: 1430 p.s.i. 
Temperature: Ambient (_20°C) 
Mobile phase: 1% acetic acid-methanol 70:30 (voljvol)~ 
A Valco CV-6-UHPa sample injection valve equipped with a 
10 ~l loop w~s utilized for sample introduction. The 
basic design and mode of operation of this injector is 
depicted in Fig. 7.1. 
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Fig. 7.1. Operation of external-loop valve. 
,. LOAD SAMPLE INJECT SAMPLE 
INJECTp05ilion 
Samples injected consisted of pure drugs in methanol solution; 
approximate concentrations were 10 mg per 100 ml and 2 mg per 
100 ml for TMP and SMZ respectively. When the loop was 
completely filled with the solution to be injected (volumes 
in excess of 10 ~l were loaded to ensure total filling), a 
considerable spreading of the sample bands with a resultant 
loss of resolution were observed . (see Figures 7.2(a) and (b)). 
This did not occur if volumes of les s than 10 ~l were loaded 
into the sample loop. Chromatograms obtained when the loop 
was partially filled are depicted in Figures 7.2(c) and (d). 
Peaks in this case were sharp and well-resolved. At all 
times, the loop was rinsed with methanol between injections. 
The defective sample loop was detached from the valve and 
was rep laced with a second 10 ~l loop. The valve itself 
was not changed. Chromatograms obtained using the new loop 
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Fig. 7.2. Chromatograms obtained using faulty samp l e loop. 
Chromatograms (a) and (b) were produced when the loop was 
completely filled with the sample solutions; (c) and (d) 
were obtained when the loop was partially filled. Peaks: 
1 = TMP, 2 = SMZ. The arrows denote times of sample injection. 
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were identical to those depicted in Figures 7.2(c) and (d) . 
The same results were observed whether the loop was completely 
or partially filled. Comparison of results obtained with the 
two sample loops also indicated that the volume of the 
defective loop was actually slightly in excess of 10 ~l~ 
The injector valve itself was not involved in the band 
spreading effects observed. Attachment of the faulty loop 
to a second valve did not alter results obtained, i.e. 
considerable broadening of sample bands continued to occur 
when this loop was completely filled with the sample solution. 
In addition, overloading of the column was not responsible for 
the effects seen. Sample volumes in excess of 10 ~l were 
injected onto the column without resultant peak broadening 
when HP LC system A (Section 4.1.3.1) was utilized. The latter 
system was equipped with a Rheodyne Model 70-10 sample 
injection valve containing a 20 ~l loop. 
Thus, excessive dead volume may have been pr esent within the 
sample loop which only became apparent when it was completely 
filled. Possibly badly flushed regions may have existed 
within the capillary tubing into which part of the sample 
could have been swept. 
Examination of the loop indicated that the int~rnal diameter 
was larger at one end of the tubing than at the other. 
However, no alteration in the chromatogram occurred when the 
positions of attachment of the loop to the valve were reversed . 
. . . .. - 197 -/ 
- 197 -
The discrepancy in the internal capillary diameter may have 
been due to manufacturing errors, which could contribute to 
the adverse effects observed. 
B. Dead Volume in Stop-Flow, Septumless Injector: 
Serum samples spiked with TMP and SMZ were assayed according 
to the method described in Section 4.3 . 2 with the exception 
that chromatographic analysis was performed using HPLC 
system C (Section 4.1.3.1). A stop-flow, septumless injector 
was thus utilized in place of an external-loop valve for sample 
introduction. Chromatogoams obtained under these conditions, 
however, depicted "split" peaks for all components (see Figure 
7.3(a». This effect did not occur when the same samples 
were analyzed using the HPLC system previously employed for 
serum assays (HPLC system A; see Figure 4.6(a). 
Splitting of the sample bands was also observed when the 
drugs were extracted from aqueous solutions using a procedure 
similar to that applied to serum samples (Figure 7.3(b». The 
effect here, however, was less marked. In addi ti on, 
chromatograms obtained on injection of pure drugs in the 
mobile phase depicted slight "shoulders" on all peaks produced 
(Figure 7 . 3(c». When methanol was employed as the solvent 
for injected samples, these effects did not occur (Figure 7.3(d». 
The observed splitting of peaks was not due to the syringe 
utilized for sample injection. Several syringes were tested 
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Fig. 7.3. Chromatograms obtained using stop-flow septumless 
injector. Samples injected were (a) drugs extracted from 
serum, (b) drugs extracted from an aqueous solution, (c) pure 
drugs in the mobile phase (1% acetic acid-methanol 80:20) and 
(d) pure drugs in methanol solution. 
Peaks: 1 = TMP; 2 = SMZ; 3 = internal standard, sulphafurazole; 
4 = N4-acetyl-SMZ. 
The arrows denote times of sample injection. 
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without any effect on the resultant chromatogram. 
It thus appeared that areas of dead volume or poorly flushed 
regions may have existed within the injector system, which 
resulted in failure to introduce samples as a single plug. 
Samples were not injected directly onto the head of the 
column although a zero dead-volume fitting was utilized to 
connect the injector to t he column. Figure 7 . 4(a) depicts 
the type of fitting employed in order to connect the column 
to the stop-flow septumless injector. This special adaptor 
was required to attach the ~Bondapak Cla column (and any 
other standard columns) t o the stop- flow septumless 
injector block of the Varian 8500 liquid chromatograph which 
is specially designed to only accommodate the unusual left-
hand thread of Varian Micropak (R)columns . Hence, the fitting 
differed from that empl oyed when the external loop valve was 
utilized for sample introduction (see Figure 7.4(b)). In 
the latter case the peak splitting effect was not observed. 
Thus the fitting utilized to connec t the injector to the 
column may have contributed t owards the adverse effects seen. 
With the stop-flow septumless injector system, it may be 
advantageous to inject samples directly onto the column 
packing to minimize injection band broadening caused by 
diffusion. Splitting of the sample bands was influenced 
by the nature of the sample and the solvent employed, since 
the effect was particularly marked when serum extracts were 
injected but was not observed when pure drugs in methanol 
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solution were analyzed. The reason for this, as well as 
a complete explanation for the observed effects, is not, 
however, known. 
Fig. 7.4. Zero dead-volume fittings utilized to connect 
the ~Bondapak C's column to (a) the stop-flow septumless 
injector (Varian 8500 Liquid Chromatograph) and (b) the 
external-loop valve (Rheodyne Model 70-10). 
from injector from injector 
(a) (b) 
1 
to column to column 
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TABLE I. 
ANALYSIS GF DISSOLUTION DATA FOR THE SMZ COMPONENT OF STANDARD TABLETS AND CAPSULES a . 
Difference Between Mean Percent Dissolved at Each Time Interval 
PRODUCTS COMPARED 
1 Ii 2i 5 10 20 30 40 60 90 
Bactrim(R)/septran(R) 10,46* 6,77 2,30 1,34 5,00 4,63 5,21 8,86 6,12 4,54 
Bactrim(R) /Mezenol(R) 11,50* 8,09 0,34 10,44 21,04* 20,04* 18,08* 17,2* 12,09* 4,68 
Bactrim(R)/Thoxaprim(R) 28,49* 28,36* 26,62* 15,84 7,05 0,36 1,98 0,83 4,73 5,93 
Bactrim(R)/purbac(R) 4,15 1,09 6,91 0,25 0,79 3,18 2,16 3,22 1,35 1,09 
Bactrim(R)/Co-Trim(R) 15,70 * 16,43* 7,23 18,74 * 19,76* 11,75* 5,39 2,65 1,88 2,61 
septran(R)/ Mezenol(R) 1,04 1,32 1,96 9,10 16,04* 15,41* 12,87* 8,34 5,97 0,14 
septran(R)/ Thoxaprim(R) 38,95* 35,13* 24,32* 14,50 2,05 4,99 7,19 9,69 10,85* 10,47* 
septran(R) /purbac(R) 6,31 7,86 4,61 1,59 4,21 1,45 3,05 5,64 4,77 5,63 
Septran(R)/co~Trim(R) 5,24 9,66 9,53 17,40 * 14,76* 7,12 0,18 6,21 8,00 7,15 
Mezenol(R)/Thoxaprim(R) 39,99* 36,45* 26,28* 5,40 13,99* 20,40* 20,06* 18,03* 16,82* 10,61* 
Mezenol(R)/purbac(R) 7,35 9,18 6,57 10,69 20,25* 16,86* 15,92* 13,98 * 10,74* 5,77 
Mezenol(R)/co~Trim(R) 4,20 8,34 7,57 8,30 1,28 8,29 12,69* 14,55* 13,97* 7,29 
Thoxaprim(R)/purbac(R) 36,64* 27,27* 19,71* 16,09 6,26 3,54 4,14 4,05 6,08 4,84 
Thoxaprim(R)/co-Trim(R) 44,19* 44,79* 33,85* 2,90 12,71 12,11* 7,37 3,48 2,85 3,32 
Purbac(R) /Co-Trim(R) 11,55* 17,52* 14,14 18,99* 18,97* 8,57 3,23 0,57 3,23 1,52 
RANGE ± 7,36 9,82 13,16 13,64 9,98 7,99 7,22 7,06 6,27 6,07 
-
a. Scheffe's test. 
*Statistically significant (p < 0,01) difference. 
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TABLE II. 
ANALYSIS OF DISSOLUTION DATA FOR THE TMP COMPONENT OF 
STANDARD TABLETS AND CAPSULES a . 
Difference Between Mean Percent 
Dissolved at Each Time Interval 
PRODUCTS COMPARED 
1 I! 2! 5 10 
Bactrim(R)/septran(R) 55,88* 22,01* 1,59 2,42 2,18 
Bactrim(R)/Mezenol(R) 87,56* 76,25* 57,77* 14,48 5,89 
Bactrim(R)/Thoxaprim(R) 5,58 2,72 4,29 2,85 1,46 
Bactrim(R)/purbac(R) 45,77* 18,40 10,56 6,55 3,13 
Bactrim(R)/co-Trim(R) 100,04* -,-00,76* 85,87* 21,00 0,55 
septran(R)/Mezenol(R) 31,68* 54,24* 59,36* 16,90 3,71 
septran(R) / Thoxaprim(R) 50,30* 19,29 5,88 5,27 3,64 
septran(R) / purbac(R) 10,11 3,61 12,15 8,97 5,31 
septran(R)/co-Trim(R) 44,16* 78,75* 87,46* 23,42* 2,73 
Mezenol(R)/Thoxaprim(R) 81,98 * 73,53 * 53,48* 11,63 7,35 
Mezenol(R)/purbac(R) 41,79* 57,85* 47,21* 7,93 9,02 
Mezenol(R)/co-Trim(R) 12,48 24,51* 28,10* 6,52 6,44 
Thoxaprim(R)/purbac(R) 40,19* 15,68 6,27 3,70 1,67 
Thoxaprim(R) /CO-Trim(R) 94,46* 98,04* 81,58* 18,15 0,91 
purbac(R)/CO-Trim(R) 54,27* 82,36* 75,31* 14,45 2,58 
RANGE ± 22,64 17,97 18,58 20,96 5,98 
a. Scheffe's test. 
*Statistically significant (p < 0,01) difference . 
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TABLE III. 
ANALYSIS OF DISSOLUTICN DATA FUR THE SMZ CCMPONENI' OF DOUBLE-STREN:mI TABLETSa • 
PRODUCTS COMPAREDb 
Difference Between Mean Percent Dissolved at Each Time Interval~ 
1 1~ 2~ 5 10 20 30 40 60 90 
Bactrim D.S. (R)/Bactrim D.S. Quiksolv(R) 0,98 10,98 21,94* 19 ,16* 10·,83* 7,11 2,05 1,92 2,08 5,67 
Bactrim D.S. (R)/septran D.S. (R) 7,82 7,80 1,34 5,83 9,89* 8,80 6,48 8,50* 5,03 5,36 
Bact~im D.S. (R)/Mezenol D.S. (R) 2,16 0,22 12,51* 20,70* 15,09* 12,31* 11,07* 10,24* 8,20* 5,37 
Bactrim D.S. Quiksolv(R)/septran D.S. (R) 8,80 18,78* 23,28* 13,33* 0,94 1,69 4,43 6,58 7,11* 11,03* 
Bactrim D.S. QuikSOlv(R)/Mezenol D.S. (R) 3,14 11,20 9,43 1,54 4,26 5,20 9,02* 8,32* 10,28* 11,04* 
Septran D.S. (R) /Mezenol D.S. (R) 5,66 7,58 13,85* 14,87* 5,20 3,51 4,59 1,74 3,17 0,01 
RANGE ± 7,67 10,27 7,17 8,30 4,33 4,11 4,38 5,63 3,62 3,71 
---
a. Scheffe!s test. 
b . D. S.: double-strength. 
*Statistically significant (p < 0,01) difference. 
N 
a 
LV 
IV 
o 
U1 
~ 
TABLE IV. 
ANALYSIS OF DISSOWTION DATA FOR THE 1MP CCMPONENl' OF IXlUBLE-STRENGTH TABLETSa • 
PRODUCTS CCMPAREDb 
Difference B€tween Mean Percent Dissolved at Each Time Interval 
1 1! 2 ! 5 10 20 30 40 60 90 
Bactrim D.S. (R)/Bactri m D.S . Quiksolv(R) 44,85* 27,97* 21,65* 18,62* 19,17* 18,57* 20,06* 18,64* 17,86* 20 ,60* 
Bactrim D.S. (R)/septran D.S. (R) 39,85* 40,62* 16,92 2,35 1,82 1,36 0,57 2,21 1,69 0,41 
Bactrim D.S. (R)/Mezenol D.S . (R) 41,59* 44,91* 30,08* 2,97 1,70 1,46 1,53 0,13 0,12 2,57 
Bactrim D.S. ,QuikSOlv(R)/septran D.S. (R) 5,00 12,65 4,73 20,97* 20,99* 19,93* 20,63* 20,85* 19,55* 21,01* 
Bactrim D.S. Quiksolv(R)/Mezenol D.S. (R) 3 ,26 16,94 8,43 15,65* 20,87* 20,03* 21,59* 18,77* 17,98* 18,03* 
Septran D.S. (R) /Mezenol D.S. (R) 1, 74 4,29 13,16 5,32 0,12 0,10 0,96 2,08 1,57 2,98 
RANGE ± 25,42 23,45 15,06 6,28 3,13 2,94 3,84 3,72 3,99 5,41 
-, 
a. Scheffe' s test. 
b . D.S.: double-strength. 
*Statistically significant (p < 0,01) difference. 
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